

(19) World Intellectual Property  
Organization  
International Bureau




(43) International Publication Date  
21 April 2005 (21.04.2005)

PCT

(10) International Publication Number  
**WO 2005/034841 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K**
- (21) International Application Number:  
PCT/US2004/014971
- (22) International Filing Date: 13 May 2004 (13.05.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/470,563 14 May 2003 (14.05.2003) US
- (74) Common Representative: **MERCK & CO., INC.**; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (71) Applicant (*for all designated States except US*): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **HEPLER, Robert** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **JANSEN, Kathrin** [DE/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **KELLY, Rosemarie** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **KURTZ, Myra** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **LOSADA, Maria, C.** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). **SCHULTZ, Loren** [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US).
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ANTHRAX VACCINE



(57) **Abstract:** This invention provides DNA sequences that encode Bacillus anthracis Protective Antigen (PA) proteins that can be used for prophylactic immunization against anthrax infections. The codon usage in the sequence is optimized for expression in the yeast, including strains of *Saccharomyces cerevisiae*, a known safe fermentation source for vaccine products. The invention also includes vaccines and methods of vaccination against *B. anthracis*.

WO 2005/034841 A2

## TITLE OF THE INVENTION

## ANTHRAX VACCINE

## CROSS-REFERENCE TO RELATED APPLICATIONS

- 5 This application claims the benefits of U.S. Provisional Applications Serial Number 60/470563 filed May 14, 2003.

## FIELD OF THE INVENTION

The invention relates to the field of vaccination.

10

## BACKGROUND

- Anthrax infection, a disease caused by the spore-forming bacterium Bacillus anthracis, is highly lethal in the pulmonary or inhalation form (For general reviews see Friedlander, 2000; Little and  
15 Ivins, 1999; Mock and Fouet, 2001). With an increased awareness of the potential of this pathogen as a weapon, the need for a readily available, safe and effective vaccine for wide public use has grown (*See, e.g., Ibrahim et al.*, 1999). Current vaccine preparations for human use are typically attenuated live spores or cell-free secretion products of B. anthracis adsorbed to alum (AVA). The former preparation was reportedly used in the Soviet Union and had a number of toxicities and production issues. In the US,  
20 AVA is reported to be used exclusively. Neither vaccine has the characteristics preferred for broad distribution in the event of an emergency or for general public prophylaxis, *i.e.*, long term protection, high level efficacy with limited number of immunizations, low reactogenicity, and reliable, safe production. Thus, there is a need for new vaccines that provide a better fit to these criteria.

- The cytotoxicity of germinating anthrax spores is mediated by two toxins, lethal factor and  
25 edema factor. Lethal factor (LF) is a 90-kD protein with catalytic activity which combines with an activated form of protective antigen, PA, an 83-kD protein, to produce an active toxin in macrophages. Edema factor is of similar molecular weight (89 kD) and combines in a separate complex with activated PA to enter its target cell, the neutrophil. Each of the three components are non-toxic individually.

- Recent studies have shown that during infection, PA83 is cleaved by mammalian cells at amino  
30 acid position 167 of the mature peptide to yield a 63-kD component that binds to either lethal factor (LF) or edema factor (EF). Mutated PA83 that can not be cleaved is not functional for the production of toxin because it fails to form the heptameric pore that facilitates LF or EF to enter mammalian cells (Leppla, 2000). Under fermentation conditions and presumably during infection, B. anthracis synthesizes PA83 with a leader sequence that is responsible for its secretion into the medium and into tissues.

- 35 Although there are limited data in humans correlating protection against B. anthracis infection to specific immune responses, the available evidence suggests that neutralizing antibodies against the 83-

kD uncleaved protective antigen (PA83) is a surrogate marker for protective immunity (Baillie, 2001; Turnbull *et al.*, 1988). The data are more extensive in animal protection models using guinea pigs, rabbits, mice and rhesus monkeys (Fellows *et al.*, 2001; Ivins *et al.*, 1998). Immunization with purified PA or recombinant PA reportedly confers protection against challenge in rhesus macaques (Ivins *et al.*, 5 1998). Passive protection was also reportedly demonstrated with anti-PA antibodies. It is believed that there is a rough correlation between anti-PA titer and protection against lethal challenge with B. anthracis spores. Reuveny *et al.* reported a more quantitative correlate with neutralization of *in vitro* macrophage killing for the guinea pig model (Reuveny *et al.*, 2001). The cumulative evidence supports the concept that PA, whether obtained from B. anthracis or as a recombinant protein, can be an effective 10 immunogen for anthrax prophylaxis. Published data also purport to show that the reactive epitopes are found within the cleaved, activated 63-kD form of PA (Flick-Smith *et al.*, 2002; Little and Ivins, 1999; Singh *et al.*, 1991).

One of the current anthrax vaccines is produced from a culture filtrate of germinating B. anthracis spores (Puziss, 1962; Puziss, 1963). The major component of this formulation is PA83 with 15 some LF and EF. No further enrichment or purification of the protective component is reportedly performed. Minor, but highly potent reactogenic substances could also be present. Trace amounts of LF and EF purified from the B. anthracis fermentation could theoretically combine with PA cleaved after administration to yield toxins.

A variety of alternative preparations designed to address the toxicity issues raised above have 20 been reported in the literature. These range from the use of attenuated B. anthracis strains with enhanced PA production, to acellular recombinant protein products to naked DNA preparations. A summary of these approaches are listed below:

Replicating vector strategies:

Bacillus anthracis – An attenuated, non-capsular strain has been reported that produces 25 recombinant PA constitutively from a replicating vector. The heterologous constitutive promoter from  $\alpha$ -amylase expressed as much as 10-fold higher titers of rPA than the native pagA promoter. The spores from the recombinant strains were stated to have elicited good anti-PA antibody titers and protected guinea pigs in a lethal challenge model (Cohen *et al.*, 2000). Appropriate containment for production of a live, attenuated spore vaccine is an important consideration for large-scale production.

Bacillus subtilis – This related non-pathogenic, sporulating bacillus is a good vehicle for 30 expressing secreted proteins. It has been under investigation as a substitute production vehicle for production of PA for decades (Ivins and Welkos, 1986). The limitations of this system are safety concerns that require the development of non-sporulating strains and more importantly, degradation of PA by B. subtilis proteases (Baillie *et al.*, 1998a; Baillie *et al.*, 1998b). The maximal reported yield 35 using this system was 2 mg/L. The introduction of mutations affecting catabolite repression and growth

phase regulation reportedly resulted in an increase in the yield of PA but a multiply protease-negative background to improve PA yield is still needed (Baillie *et al.*, 1998a).

Salmonella typhimurium – The PA gene was cloned into S. typhimurium with the aim of using the ability of this non-pathogenic (for humans) bacterium as a vector to introduce the PA antigen. A high copy plasmid with the *placd* promoter was used. The resultant strain was stated to have the ability to colonize the host and it was necessary to passage to regain colonization ability. The plasmid in the colonizing strain had lower copy number, suggesting that less PA antigen may be produced. This strain was reported to afford some protection against lethal challenge in mice (Coulson *et al.*, 1994).

Vaccinia virus – PA was cloned into vaccinia virus to use a replicating vector as an immunization strategy. Some protection was reported when using particular vector constructs (60% and 50% of mice and guinea pigs respectively), but anti-PA titers were produced only in mice (Iacono-Connors *et al.*, 1990). The relevance for humans is not known.

Lactobacillus casei – Lactobacilli are commensals of the gut and are generally regarded as safe (Zegers *et al.*, 1999). L. casei strains expressing PA internally have been reported with the aim of developing a live oral vaccine with a high level of mucosal immunity, an unproven strategy. Acellular antigen production:

Baculovirus – The PA gene was cloned into baculovirus for the production of PA (Iacono-Connors *et al.*, 1990). The material produced was larger (86 kD vs. 83.5 kD) than authentic PA83 because it still had a secretory leader sequence. The preparations were reported to have produced high titer anti-PA responses in mice and to have protected mice and guinea pigs from lethal challenge when administered with an adjuvant. Production by baculovirus requires tissue culture growth – a costly protocol for large-scale production.

Escherichia coli – Several laboratories have reported production of recombinant wild-type PA in E. coli and have made mutated PA in this organism. One potential limitation of bacterially produced material is the requirement to purify the antigen from the lipopolysaccharide component of E. coli, an extremely potent pyrogen. Using the E. coli signal sequence on PA causes the material to accumulate in the periplasmic space (yield - 500 µg/L) (Sharma *et al.*, 1996). A his-tagged fusion accumulated as inclusion bodies and was denatured in urea and refolded (Gupta *et al.*, 1999). This change improved the yield to 2 mg/L. Until very recently, yields from inducible vectors were relatively low but constitutive overexpression has been reported to give yields of biologically active material at 125 mg/L (Chauhan *et al.*, 2001). Metal chelate chromatography was used for purification.

DNA plasmid – A DNA plasmid encoding PA63 was reported to have elicited a humoral immune response in mice. Mice immunized with the PA DNA vaccine were said to have been protected against lethal challenge with a combination of anthrax PA plus LF (Gu *et al.*, 1999).

Saccharomyces cerevisiae – Baker's yeast is generally recognized as safe for the production of heterologous protein. This yeast has been shown to be easily and rapidly cultivated under minimal

containment conditions and to lack toxic secreted or intracellular materials. Antigens isolated from yeast fermentations have good safety profiles. Small peptides and large proteins have been produced successfully. It has been proven to be a safe and commercially viable production vehicle for recombinant DNA derived hepatitis B vaccine. However, the current state of understanding of protein production in yeast does not allow one to predict which proteins will be made in sufficient quantities for commercial production. Variables that are not yet foreseeable or controllable are the degree of glycosylation, either O or N, the extent of protein degradation, and correct polypeptide folding. Potential glycosylation sites can be determined by sequence analysis, but the presence of such a consensus site does not guarantee that it will be glycosylated. Furthermore, addition of a yeast leader sequence does not by itself guarantee that a given protein will be secreted. Neither can one predict whether a protein will be toxic for the producing yeast cells. The parameters that are understood and can be controlled include the presence or absence of yeast non-translated leader sequences, mutations that reduce, but do not eliminate N-glycosylation, mutations that reduce protein degradation, promoter sequences that permit tightly regulated control of synthesis, plasmid copy number, and strain to strain variations. For any given protein, the outcome depends on the correct combination of sequence, expression vector, host strain, fermentation conditions and the intrinsic nature of the protein to be expressed, none of which can be predicted or guaranteed in the absence of empirical results. Thus, it is not possible to predict whether the sequence of a gene of interest will be translated into the desired functional protein in yeast or, if it is produced, whether it will be made in quantities sufficient for commercial application.

One report of a B. anthracis gene expressed in S. cerevisiae is a study designed to identify the substrates of the LF component via the yeast two-hybrid system (Vitale *et al.*, 1999). The experiment employed an inactive mutated LF as bait. This approach reportedly led to the identification of the MAP kinase kinases (MAPKKs) Mek1 and Mek2 as proteins capable of specific interaction with LF.

## SUMMARY OF THE INVENTION

This invention relates to polynucleotides encoding a Bacillus anthracis Protective Antigen (also referred to herein as "PA") protein wherein the coding sequence of the polynucleotide has been codon-optimized for efficient expression in a yeast host cell. Preferably, the polynucleotides are DNA. In one preferred embodiment, the polynucleotide encodes a protein which retains its wild-type amino acid sequence. In one preferred embodiment the polynucleotide encodes a 63-kD form of the PA protein, referred to as PA63.

In another preferred embodiment, the polynucleotide encodes an 83-kD form of PA, referred to as PA83. In an alternate embodiment, the polynucleotides encode a mutated form of a PA protein which has reduced protein function as compared to wild-type protein, but which retains the immunogenicity of the wild-type protein such as the chymotrypsin processing site. A preferred mutated

form of the PA protein is a PA83 which has been mutated to prevent processing of the protein to the PA63 form of PA. This invention also relates to the PA proteins produced using the polynucleotides.

Another aspect of this invention is a vector carrying the polynucleotides encoding a codon-optimized PA protein. Yet another aspect of this invention are host cells containing these vectors.

5 In a preferred embodiment, the vector is a plasmid vector. In a particularly preferred embodiment, the vector is a plasmid vector comprising an insert wherein the insert comprises an expression cassette comprising:

a) a polynucleotide encoding a codon-optimized PA protein for expression in a yeast host cell; and

10 b) a promoter operably linked to the polynucleotide.

Another type of vector which is envisioned by this invention is a shuttle plasmid vector comprising a yeast origin of replication, a bacterial origin of replication and a polynucleotide insert, wherein the insert comprises an expression cassette comprising:

a) a polynucleotide encoding a codon-optimized PA protein for expression in a yeast host cell; and

b) a promoter which functions in yeast operably linked to the polynucleotide; and

c) a yeast-active transcriptional terminator.

An aspect of this invention is a yeast host cell carrying a polynucleotide of this invention. In a preferred embodiment, the polynucleotide is carried on a plasmid vector. In alternative 20 embodiments, the polynucleotide is integrated into the chromosomal DNA of the yeast host cell. In a preferred embodiment, the synthetic PA gene is under the control of a promoter from the yeast galactose gene cluster (a GAL promoter) and the yeast host cell has been genetically engineered for controlled induction of genes regulated by GAL promoters. In alternative embodiments, the controlled induction is high level, mid level or low level induction of genes regulated by GAL promoters.

25 This invention also relates to a method of making a PA protein comprising expressing in a yeast host cell a polynucleotide encoding a PA protein, or mutated form of a PA protein which has reduced protein function as compared to wild-type protein, but which maintains immunogenicity, the sequence of the polynucleotide encoding PA comprising codons optimized for expression in a yeast host. In a preferred embodiment, the synthetic PA gene is under the control of a GAL promoter and the yeast 30 host cell has been genetically engineered for controlled induction of genes regulated by GAL promoters. In a preferred method, the PA protein is produced as an intracellular product. In another preferred method, the PA protein is produced as a product secreted from the yeast host cell.

An aspect of this invention provides a vaccine against disease, cellular toxicity or death caused by B. anthracis. A vaccine of this invention includes an effective amount of a PA protein that was

expressed in yeast through the use of a polynucleotide of this invention. A vaccine of this invention also includes pharmaceutically acceptable excipients.

An aspect of this invention is a method of vaccinating a patient against disease, toxicity or death caused by B. anthracis. A vaccine of this invention is administered to a patient in a manner appropriate for the induction in the patient of an immune response against the PA protein of B. anthracis.

An aspect of this invention provides a method for purification of the PA protein expressed in yeast. In the method a homogenate of yeast cells is formed. Yeast proteases are inactivated in the homogenate by addition of a series of protease inhibiting compounds, and the PA protein is separated from yeast cellular proteins by a series of chromatographic separations.

An aspect of this invention is a process of isolating the 63 kilodalton form of Protective Antigen from a culture of yeast cells expressing a recombinant polynucleotide. In particular embodiments, the polynucleotide is carried on an expression vector in the cells, for example, a plasmid or artificial chromosome. The expression of the polynucleotide can be regulated by an inducible promoter. After expression of the polynucleotide, the yeast cells are disrupted to create a suspension which is subsequently clarified. The cells can be disrupted using methods known in the art including a press, homogenizer or microfluidizer. Clarification is commonly performed by low speed centrifugation. The clarified solution is mixed with a denaturant. In preferred embodiments the denaturant is a non-ionic denaturant, e.g., 6M urea. Thereafter the PA63 is purified from the solution by chromatography on cation exchange resin followed by chromatography on an anion exchange resin, in a denaturing buffer. In preferred embodiments, the PA63 is eluted from each column using a linear gradient of NaCl and 6M urea. The fractions containing the PA63 are then dialyzed against an appropriate buffer and, optionally, concentrated.

A polynucleotide according to this invention comprises a sequence encoding a B. anthracis PA protein, such coding sequence having been "codon optimized" for expression in yeast by substituting wild-type codons with codons that are preferred by a yeast host. Because the coding sequences used in this invention are not found in nature, we sometimes refer to polynucleotides having such codon optimized sequences as "synthetic" polynucleotides, as having a "synthetic" sequence encoding a PA protein, or simply as having a "synthetic" PA gene. In each case, the use herein of the term "synthetic" means that the gene has been modified so that it contains codons which are preferred for expression in a non-native host, e.g., a yeast or other eukaryote. In many cases, the amino acids encoded by the synthetic PA gene remain the same as the wild-type. In some embodiments, the synthetic gene may encode a modified protein.

The term "promoter" as used herein refers to a recognition site on a DNA strand to which the RNA polymerase binds. The promoter forms an initiation complex with RNA polymerase to initiate

and drive transcriptional activity. The complex can be modified by activating sequences termed "enhancers" or inhibiting sequences termed "silencers."

The term "cassette" refers to the sequence of the present invention which contains the nucleic acid sequence which is to be expressed and may also include regulatory sequences. Each cassette will have its own sequence. Thus by interchanging the cassette the vector will express a different sequence. Because of the restriction sites at the 5' and 3' ends, the cassette can be easily inserted, removed or replaced with another cassette.

The term "vector" refers to some means by which DNA fragments can be introduced into and maintained in a host organism or host tissue. Various types of vectors are known in the art including plasmid, virus (including adenovirus), bacteriophages, artificial chromosomes, linear DNA and cosmids. Vectors can replicate autonomously or integrate into the host cell genome.

The term "effective amount" means sufficient vaccine composition is administered to a patient so that an immune response results. One skilled in the art recognizes that this level may vary.

In reference to a nucleic acid or protein sequence, the term "native" means that the sequence is the same as it is found occurring in nature. It is also referred to as a "wild type" sequence.

The term "patient" means a mammal, particularly domesticated livestock including but not limited to dogs, cats, cows, bulls, steers, pigs, horses, sheep, goats, mules, donkeys, etc. Most preferably, a patient is a human.

## BRIEF DESCRIPTIONS OF THE DRAWINGS

FIGS. 1A&B. FIG. 1A. Diagram of B. anthracis PA gene. FIG. 1B. DNA sequence (SEQ ID NO:47) and amino acid translation product (SEQ ID NO:48) of portion of B. anthracis PA83 gene corresponding to PA63.

FIGS. 2A&B. Yeast codon-optimized DNA sequence (SEQ ID NO:49) and amino acid translation product (SEQ ID NO:50) of synthetic B. anthracis PA63 gene.

FIGS. 3A&B. FIG. 3A. Yeast secretion vector pHK4 $\alpha$ 2 used for expression of secreted PA63. FIG. 3B. pAGT1 – pHK4 $\alpha$ 2 with PA63.

FIG. 4. Yeast expression vector pGAL110 used for internal expression of PA63 (PA63pGAL10#2).

FIG. 5. Time course of intracellular PA63 expression from transformant L-1 in S. cerevisiae strain 1849. Equal volumes of cell lysate were loaded on the gel. A and B indicate duplicate fermentations of transformant L-1 and vector control transformant K-1. Samples of L-1A and L-1B are shown for 0, 48, and 72 h in lanes 3-5 and 6-8, respectively. A 72 h sample of K-1A alone is shown in lane 2. A 48 h sample of K-1A and a 72 h sample of K-1B mixed with 10 ng PA63 standard are shown in lanes 1 and 9, respectively. Molecular size standards are also shown.



FIG. 6. An exemplary Western blot used for quantitation of internally expressed PA63 by transformant 8-3 (*S. cerevisiae* host strain 1260). Samples are from two independent experiments: lanes 12-15 are samples of cell lysates of 8-3 from one experiment, and lanes 4-7 and 8-11 represent duplicate sample preparations of cell lysates of 8-3 from another experiment. Replicate fermentations of 8-3 within the same experiment are represented by 4,5; 6,7; 8,9; 10,11; 12,13; 14,15. Odd and even-numbered lanes contain 0.25 and 0.5 µg total protein of 8-3 loaded, respectively. For the samples of the vector control transformant, 0.5 µg total protein was loaded. Lane 1 is a sample of vector control transformant 7-1A alone. Lanes 2, 3 and 16, 17 contain samples from vector control transformant 7-1A and -B mixed with 10 and 20 ng PA83, respectively. Molecular size standards are also shown.

FIG. 7. Time course for induction of secreted PA63 by strain 14A (*S. cerevisiae* host strain 1849). Equal volumes of supernatants were loaded in each lane. T0, T24, T48, and T72 are shown for 14A in lanes 1, 3, 5, and 7, respectively. T48 and T72 are shown for vector control transformant 12B alone in lanes 4 and 6. 10 ng PA63 standard is shown alone in lane 9 and mixed with vector control 12B from 24 h in lane 2. Lane 8 contains a supernatant from an independent 72 h fermentation of strain 14A. Molecular size standards are shown.

FIGS. 8A&8B. FIG. 8A. DNA sequence (SEQ ID NO:53) and FIG. 8B. Amino acid translation product (SEQ ID NO: 54) of native bacterial PA83 gene without its leader sequence.

FIG. 9. DNA sequence (SEQ ID NO: 51) and amino acid translation product (SEQ ID NO: 52) of yeast codon-optimized domain 4 of *B. anthracis* PA gene.

FIGS. 10A&B. FIG. 10A. DNA sequence (SEQ ID NO: 55) and FIG. 10B. Amino acid translation product (SEQ ID NO: 56) of yeast codon-optimized *B. anthracis* PA83 gene.

FIGS. 11A&B. FIG. 11A. FIG. 11A DNA sequence (SEQ ID NO: 57) and FIG. 11B. Amino acid translation product (SEQ ID NO: 58) of yeast codon-optimized *B. anthracis* PA83 with a mutation at the furin cleavage site.

FIG. 12. Exemplary Western blot comparing production of codon-optimized and native PA63 from transformants fermented for 72 h in complex YEHDG medium. Lane 1, MW size standards mixed with 100 ng cell-lysate protein from yeast transformant 8-3 which produces PA63 intracellularly (see Example 2). Lane 2, 20 ng purified *E. coli*-produced rPA83. Lanes 3-7 and 13 contain 25 µL medium supernatant from yeast transformants: lane 3, vector control transformant 12B; lanes 4 and 5 "native" PA63 transformants b-2 and b-3, respectively; lanes 6 and 7, "rebuilt" PA63 transformants 14A and 14C, respectively; lane 13, transformant 14A fermented in a previous experiment. Lanes 8-12 contain 500 ng protein cell lysate from yeast transformants: lane 8, 12B (vector control); lane 9, b-2; lane 10, b-3; lane 11, 14A; lane 12, 14C. Positions of molecular weight markers are indicated.

FIG. 13. Western blot depicting intracellular expression of uncleavable PA83 (lacking Furin cleavage site) from *S. cerevisiae* transformant Q-3 (yeast host 1558) and uncleavable PA83 from transformants 9-1 through 9-8 of yeast host strain 1260. Lanes 1-8 contain 4 µg cell lysate protein from transformants 9-1

through 9-8 and lane 9 contains 4 µg cell lysate protein from transformant Q-3. Lane 10 contains 1 µg of recombinant PA83 purified from *E. coli*.

FIG. 14. Western blot depicting intracellular expression of uncleavable PA83, from *S. cerevisiae* transformant 9-1, and cleavable PA83 from *S. cerevisiae* strain 5-C: lane 1, 200 ng *E. coli*-purified

5 recombinant PA83; lanes 2-8 contain 250 ng of cell lysate protein; lane 2, vector control transformant fermented in shake flask; lanes 3 and 4, strain 9-1 (uncleavable PA83) fermented in shake flask; lanes 5 and 6, strain 5C (cleavable PA83) fermented in shake flask; lanes 7 and 8, strain 5C (cleavable PA83) fermented in culture tube.

FIG. 15. Western blot depicting intracellular expression of PA63 from large-scale fermentation of strain

10 8-3. Lanes 1 and 11: 10 ng PA63 mixed with 500 ng protein cell lysate of vector transformant 7-1. Lanes 2 and 12: 20 ng PA63 mixed with 500 ng protein cell lysate of vector transformant 7-1. Lanes 3 and 9: 10 ng PA83 mixed with 500 ng protein cell lysate from vector transformant 7-1. Lanes 4 and 10: 20 ng PA83 mixed with 500 ng protein cell lysate from vector transformant 7-1. Lanes 5 and 6, 250 and 500 ng protein of cell lysate, respectively from large-scale fermentation of 8-3. Lanes 7 and 8, 250 and 500 ng  
15 protein of cell lysate, respectively from tube fermentation of 8-3.

FIG. 16. Flow chart of a process for purification of PA63 protein from a yeast cell homogenate.

FIG. 17. SDS-PAGE gel analysis and Western blot of purified PA63 product and process retains. (A).

20 SDS-PAGE analysis of 50HS chromatography; lane 1, load to 50HS column; lane 2, non-retained pool; lane 3, gradient fractions 12-21 (load to source Q); lane 4, gradient fractions 22-30; lane 5, high salt wash. (B). SDS-PAGE analysis of source Q chromatography. Lane 1, gradient fractions 17-18 (product); lane 2, gradient fractions 31-32; lane 3, gradient fractions 52-53.

#### DETAILED DESCRIPTION OF THE INVENTION

25 The present invention provides a synthetic polynucleotide sequence that encodes for a PA protein of *Bacillus anthracis*. The invention also provides a synthetic polynucleotide sequence that encodes for an 83-kD form of the PA protein that is identical to the mature 83-kD PA protein of *Bacillus anthracis* or a 63-kD form of the PA protein. The invention also relates to synthetic sequences that  
30 encode mutated or truncated versions of PA63 or PA83 which, upon introduction into a patient, elicit antibodies that are protective against disease, cellular toxicity, debilitation or death due to anthrax infections or ameliorate such symptoms. These mutations include alterations that prevent the formation of activated PA63, such as alterations in the furin cleavage site.

The codon usage in the sequences for PA proteins have been optimized for expression in the yeast *Saccharomyces cerevisiae*, a known safe fermentation source for vaccine products. The invention  
35 also provides plasmids that are suitable for expression in yeast of the desired product intracellularly and

plasmids that are suitable for production in yeast of extracellular protein using a S. cerevisiae secretory leader sequence, an example of which is the alpha factor-based pre-pro-leader sequence. The invention also provides the 63-kD protein, PA63, the 83-kD protein PA83, and mutant proteins produced by expressing the synthetic DNA sequence in S. cerevisiae. The invention also includes methods of inducible and constitutive production of yeast produced PA.

The present invention provides a method for generating a polynucleotide sequence of B. anthracis PA that has been optimized for expression in yeast cells. In particular preferred embodiments, use of the polynucleotides results in the expression of authentic 63-kD PA as a secreted protein or as protein that accumulates within the yeast cell. It is readily apparent to those skilled in the art that portions of polynucleotide sequence can be used to generate larger PA proteins including polypeptides such as PA83 or smaller PA proteins that display domains of PA that induce an immunoprotective response in a patient. The polynucleotide sequence can also be used to create plasmids that will express PA in bacteria such as E. coli as native protein, or peptides derived from PA63. The bacterially expressed proteins can also be tagged proteins with groups such as 6X his, HA or GST, to facilitate purification. The present invention also provides a method for producing PA in recombinant yeast host strains which are genetically deficient in their ability to glycosylate proteins and/or carry a mutation in the *prb1* and or *pep4* protease genes.

The wild-type sequence containing the coding region of PA63 (BACPAG) is known. FIGs. 1 A and B. PA63 is a post-translational protein cleavage product of full-length PA83. In accordance with this invention, PA63 segments were converted to sequences having identical translated amino acid sequences, but with alternative codon usage as defined by Lathe (Lathe, 1985) and selected for yeast codons for highly expressed genes (Sharp and Cowe, 1991). The methodology may be summarized as follows:

1. Identify placement of codons for proper open reading frame.
2. Compare wild-type codon for observed frequency of use by yeast genes.
3. If codon is not one of those commonly employed by yeast, replace it with an optimal codon for high expression in yeast cells.
4. Repeat this procedure until the entire gene segment has been replaced.
5. Inspect new gene sequence for undesired sequences generated by these codon replacements (e.g. unwanted restriction enzyme sites, splice sites, promoters, undesirable palindrome or repeat sequences, etc.) and substitute codons that eliminate these sequences. See FIG. 2.

6. Assemble synthetic gene segments and test for expression in yeast cells.

Once the desired sequence is designed, the gene fragment encoding PA63 can be prepared by annealing and extension of oligomers designed to encode the final desired sequence.

Using the present invention, one can produce an immunogenic PA protein in a yeast host cell. It should be understood that the PA protein need not retain the functional activity of a wild-type

PA63 protein as produced by B. anthracis. The key concept is that the yeast produced protein is immunogenic and, when used as a vaccine, can stimulate an immune response that is fully or partially protective against the disease, debilitation, cellular toxicity or death caused by infection with B. anthracis. Therefore, because when making a PA protein of this invention, one is only concerned with retaining the immunogenic properties of the protein, and not the functional properties, one is free to modify the protein. Modified proteins can lack some or all of the functional characteristics of the wild-type PA63 protein and be equivalent, immunologically, to the wild-type protein. It can be useful to modify the protein in the process of designing yeast codon optimized versions of the protein, *i.e.*, changed amino acids, full length uncleavable PA83, or to produce PA63 protein that is less than full length.

It is known that epitopes within Domain 4 can stimulate antibodies against the PA63 protein that can protect against the disease, cellular toxicity, debilitation or death caused by anthrax infection. Therefore, when designing mutant forms of the PA protein, it is most preferred that one attempt to maintain the wild-type sequence of domain 4. Changes can be introduced in other areas of the PA protein, especially in the N-terminal domain between the N-terminus and the cleavage site for processing PA83 to the PA63 form of PA. In general, it can be useful to modify the PA protein sequence to prevent cleavage of the protein by proteases and/or protein processing enzymes in yeast and/or mammals. For example, one may choose to alter the amino acid sequence of the cleavage site located at the furin cleavage site, amino acids 163-167. This change is useful to prevent potential cleavage of the PA protein by the yeast Kex2 protease. Another example of a change is to alter the amino acid sequence of the chymotrypsin cleavage site located at amino acids 312-313.

#### Vectors

In accordance with this invention, a synthetic polynucleotide sequence encoding a PA protein can be inserted into a vector. The vector is preferably a plasmid, although other vectors including linear DNA linked to a promoter, integrative vectors, Yeast Artificial Chromosomes, phages or cosmid vectors may also be used. For convenience in manipulating the vector, the vector may be in a shuttle plasmid form, that is, may contain origins of replication for both yeast and bacterial hosts.

An expression cassette can be used. An expression cassette includes a synthetic sequence encoding a PA protein operably linked to a promoter and, optionally, other regulatory sequences such as an enhancer or a terminator. The regulatory sequences are from yeast genes, are from non-yeast genes or are hybrid regulatory sequences derived by assembling regulatory elements from different organisms. In the latter two cases, the regulatory sequences are recognized by the protein and genetic expression systems of yeast.

It is preferred that the vector contain one or more promoters that are active in yeast or other host cells. For example, the vector could contain only a promoter active in yeast or, if expression is desired in another host, also or alternatively contain a promoter active in such host. Alternatively, a promoter could be used that is active in both yeast and an alternate host. In a preferred embodiment where expression is desired in yeast, the plasmid would contain a promoter that is active in yeast. Yeast promoters such as the ADH1, GAL1, GAL10, GAL7, PGK or GAP(TDH) promoters are commonly used in the art. However, numerous other promoters including other yeast promoters, eukaryotic promoters that are active in yeast and even hybrid promoters made from portions of promoters from two different organisms are known, and will become known. So long as the promoter is active in yeast, such promoters can be used interchangeably for expressing a synthetic PA gene in yeast. It is preferred that the synthetic codon-optimized sequence encoding the PA protein is operably linked to such a promoter.

In preferred embodiments, there are restriction sites flanking the expression cassette portion of the plasmid so that the cassette can easily be removed or replaced. The shuttle plasmid may be replicated in prokaryotic cells or eukaryotic cells.

Standard techniques of molecular biology for preparing and purifying DNA constructs enable the preparation of the plasmids, phages, shuttle plasmids and other recombinant nucleic acid molecules of this invention.

#### Expression of Synthetic PA Protein

A vector carrying a synthetic PA gene is introduced into a yeast host cell. Preferred yeast hosts include strains of Saccharomyces cerevisiae, Saccharomyces carlsbergensis and Kluyveromyces lactis. Other yeasts, including but not limited to Pichia pastoris, Hansenula sp., Schizosaccharomyces pombe and Candidia sp. may also be useful. The cell is used to establish a yeast cell culture using standard techniques known in the art. To produce PA protein, the culture is incubated and allowed to ferment in an appropriate manner as known in the art. The synthetic PA gene can be expressed throughout the period of incubation or, preferably, the expression of the gene is induced at a particular time during the incubation. In the latter case, the time of induction can be chosen taking into consideration the age, cell density, metabolic state, growth phase or other measures or combinations of measures of the cell culture as deemed appropriate by the skilled artisan or as known and practiced in the art.

Production of PA using a synthetic DNA sequence can be strain-dependent and is expected to vary with culture conditions. Other known sources of variation in production are known to arise from mechanical conditions, local water and air. Therefore, one of skill in the art will be aware that when production of PA is performed using strains or culture conditions other than those exemplified

herein, one should perform routine testing and optimization of production conditions for the equipment and conditions employed.

The present methods can produce PA as an intracellular product or as a secreted product. Of the exemplified constructs, the constructs designed to produce secreted PA do not produce yields as large as the constructs designed to produce internal PA. However, it is believed that a secreted product will serve better in a production scale process because of ease of harvest and purification.

Recombinant Protective Antigen has been purified from various sources (*E. coli*, *B. subtilis*) in the 83-kilodalton form using both native and denaturing purification processes. We are not aware of literature reports on the purification of the 63-kilodalton form of protective antigen.

Once the synthetic PA gene has been expressed for an appropriate period of time the PA protein can be harvested from the culture using standard methods of protein isolation and purification known and practiced in the art. If the PA was expressed in a fashion that produced secreted PA protein, the protein is isolated from the culture fluid. If all or a portion of the protein exists in refractile or inclusion bodies within yeast cells, the protein can be isolated, denatured and refolded using standard techniques.

If recombinant protein is produced and retained in an intracellular compartment of the host yeast cell, a cell pellet can be isolated from the culture medium by centrifugation, washed, and lysed by a variety of known physical or chemical methods. The crude lysate can be further clarified to remove cellular debris components. Purification of recombinant protein is undertaken from either the supernatant liquid or the pellet, depending on the solubility of the expressed protein. A variety of known techniques including, but not limited to, membrane filtration, centrifugation, chromatography, and differential extraction may be employed to purify the recombinant protein from host cell contaminants. In the case of poorly soluble or aggregated proteins, a variety of known techniques may be employed to improve solubilization, including, but not limited to, detergent extraction, solvent extraction, and use of denaturants and refolding techniques.

#### Formulations

The vaccine of the present invention can be formulated according to methods known and used in the art. Guidelines for pharmaceutical administration in general are provided in, for example, *Modern Vaccinology*, Ed. Kurstak, Plenum Med. Co. 1994; *Remington's Pharmaceutical Sciences* 18th Edition, Ed. Gennaro, Mack Publishing, 1990; and *Modern Pharmaceutics* 2nd Edition, Eds. Banker and Rhodes, Marcel Dekker, Inc., 1990.

PA protein of the present invention can be prepared as acidic or basic salts. Pharmaceutically acceptable salts (in the form of water- or oil-soluble or dispersible products) include conventional non-toxic salts or the quaternary ammonium salts that are formed, e.g., from inorganic or organic acids or

bases. Examples of such salts include acid addition salts such as acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate; and base salts such as ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine and lysine.

It is preferred that the adjuvant is chosen as appropriate for use with the particular protein used as well as the ionic composition of the final formulation. Consideration should also be given to whether the PA protein alone will be formulated into a vaccine or whether the protein will be formulated into a combination vaccine. In the latter instance one should consider the buffers, adjuvants and other formulation components that will be present in the final combination vaccine.

Aluminum based adjuvants are commonly used in the art and include aluminum phosphate, aluminum hydroxide, aluminum hydroxy-phosphate and aluminum hydroxy-sulfate-phosphate. Trade names of adjuvants in common use include ADJUPHOS, MERCK ALUM and ALHYDROGEL. The conjugate can be bound to or co-precipitated with the adjuvant as desired and as appropriate for the particular adjuvant used.

Non-aluminum adjuvants can also be used if approved for use in the expected patient population. Non-aluminum adjuvants include QS21, Lipid-A and derivatives or variants thereof, Freund's complete or incomplete adjuvant, neutral liposomes, liposomes containing vaccine, microparticles and cytokines or chemokines.

It is preferred that the vaccine be formulated with an aluminum adjuvant. In other preferred embodiments, the vaccine is formulated with both an aluminum adjuvant and QS21.

It is preferable, in certain embodiments, to formulate the PA protein with immunogens from Haemophilus influenza, hepatitis viruses A, B, or C, human papilloma virus, measles, mumps, rubella, varicella, influenza virus, polio virus, smallpox, rotavirus, Streptococcus pneumoniae and Staphylococcus aureus. Combination vaccines have the advantages of increased patient comfort and lower costs of administration due to the fewer inoculations required.

When formulating combination vaccines one should be mindful of the various buffers and adjuvants used with the other immunogens. Some buffers may be appropriate for some immunogen-adjuvant pairs and not appropriate for others. In particular, one should assess the effects of phosphate levels on the various immunogen-adjuvant pairs to assure compatibility in the final formulation.

## Vaccination

The vaccine of the present invention can be administered to a patient by different routes such as intravenous, intraperitoneal, subcutaneous, intranasal or intramuscular. A preferred route is intramuscular. Suitable dosing regimens are preferably determined taking into account factors well known in the art including age, weight, sex and medical condition of the subject; the route of administration; the desired effect; and the particular PA protein and formulation employed. The vaccine can be used in multi-dose vaccination formats. It is expected that a dose would consist of the range of 1  $\mu$ g to 1.0 mg total protein. In an embodiment of the present invention the range is 0.1 mg to 1.0 mg. However, one may prefer to adjust dosage based on the amount of protein delivered. In either case these ranges are guidelines. More precise dosages should be determined by assessing the immunogenicity of the PA protein produced so that an immunologically effective dose is delivered. An immunologically effective dose is one that stimulates the immune system of the patient to establish a level immunological memory sufficient to provide long term protection against disease, cellular toxicity, debilitation or death caused by infection with B. anthracis. The PA protein is preferably formulated with an adjuvant.

The timing of doses depend upon factors well known in the art. After the initial administration one or more booster doses may subsequently be administered to maintain antibody titers. An example of a dosing regime would be day 1, 1 month, a third dose at either 4, 6 or 12 months, and additional booster doses at distant times as needed.

A patient or subject, as used herein, is a mammal, particularly domesticated livestock and animals including but not limited to dogs, cats, cows, bulls, steers, pigs, horses, sheep, goats, mules, donkeys, etc. Most preferably a patient is a human. A patient can be of any age at which the patient is able to respond to inoculation with the present vaccine by generating an immune response. The immune response so generated can be completely or partially protective against disease, cellular toxicity, debilitation or death caused by infection with B. anthracis.

The following examples are offered by way of illustration and are not intended to limit the invention in any manner.

### EXAMPLE 1:

#### Design and Synthesis of a Synthetic PA Sequence

The wild-type sequence for the PA gene encoding PA63 as part of PA83 (BACPAG) is known (See FIGs. 1A and B). In accordance with this invention, PA63 segments were converted to sequences having identical translated amino acid sequences, but with alternative codon usage as using the methodology described above. The yeast codon-optimized sequence is shown in FIGs. 2A and B.

The gene fragment encoding PA63 was prepared by the annealing and extension of 24 oligomers (91-110 bp in length) designed to encode the final desired sequence.



5'GACGTCGACGGTGTAACCTTCGACTTCCAAGGAGTCTGGAATACCGTCGTTGTCTCTGTCTGGAACAG  
TTGGACCAGCGGAGGTGGA (SEQ ID NO:1)

5 5'CCTTGGAAGTCGAAGGTTACACCGTCGACGTCAAGAACAAGAGAACCTTCTTGTCTCCATGGATCTCC  
AACATTACGAAAAGAAGGGTTTGACCAAG (SEQ ID NO:2)

5'CGGTGACCTTTTCGAAGTCGGAGTATGGGTCGGAAGCAGTAGACCACTTTTCTGGGGAAGACTTGTAC  
TTGGTCAAACCCTTCTTTTCGTGAATGTTGGAG (SEQ ID NO:3)

10

5'CCGACCCATACTCCGACTTCGAAAAGGTCACCGGTAGAATCGACAAGAACGTCTCCCCAGAAGCTAGA  
CACCCATTGGTTGCTGCTTACCCAATTGTCCACGT (SEQ ID NO:4)

15

5'CTGGTTTCGGAGTCCGTGTTTTGGGTGGATTGGTCTTCGTTCTTGGACAAAATGATGTTTTCCATGTC  
AACGTGGACAATTGGGTAAGCAGCAACCAATGG (SEQ ID NO:5)

5'ATCCACCCAAAACACGGACTCCGAAACCAGAACTATCTCTAAGAACACCTCCACTTCTAGAACCCACA  
CTTCCGAAGTCCACGGTAACGCTGAAGTTCACGC (SEQ ID NO:6)

20

5'CGATAGCGACGGTGGAGGAGTTGGAGTTGGAGAAACCAGCAGAGACGGAACCACCAATGTCTGAAGAAA  
GAAGCGTGAACCTCAGCGTTACCGTGGACTTCG (SEQ ID NO:7)

5'CTCCAACTCCAACTCCTCCACCGTCGCTATCGACCACTCTTTGTCCTTGGCTGGTGAAAGAACTTGGG  
CTGAAACCATGGGTTTGAACACTGCTGACACCGC (SEQ ID NO:8)

25

5'GGAGGTGGTTGGCAAGACGTTGTAGATTGGAGCGGTACCAGTGTTGACGTATCTAATGTTAGCGTTCA  
ATCTAGCGGTGTCAGCAGTGTTCAAACCCATGG (SEQ ID NO:9)

30

5'CTCCAATCTACAACGTCTTGCCAACCACCTCCTTGGTCTTGGGTAAAGAACCAAACCTTGGCTACTATC  
AAGGCTAAGGAAAACCAATTGTCCCAAATCTTGGC (SEQ ID NO:10)

5'GGAGAAAGTCGTCTTGAGCGTTCAAAGCGATTGGAGCCAAGTTCTTGGATGGGTAGTAGTTGTTTGGAG  
CCAAGATTGGGACAATTGGTTTTCTTAGCC (SEQ ID NO:11)

35

5'CCAATCGCTTTGAACGCTCAAGACGACTTCTCCTCTACTCCAATCACCATGAACCTACAACCAATTCTT  
GGAATTGGAAAAGACTAAGCAATTGCGTTTGGACACC (SEQ ID NO:12)

5 ' CCGGTGTCGACTCTGACTCTACCGTTTTTCGAAGTTGTAAGTAGCAATGTTACCGTAAACTTGGTCGGT  
GTCCAAACGCAATTGCTTAGTCTTTTCCAATT (SEQ ID NO:13)

5 5 ' CTTGAAAACGGTAGAGTCAGAGTCGACACCGGTTCCAACCTGGTCTGAAGTCTTGCCACAAATCCAAG  
AAACCACCGCTAGAATCATCTTCAACGGTAAGGACTTG (SEQ ID NO:14)

5 ' GTCTGGCTTGGTGGTTTCCAATGGGTCGGATGGGTTGACAGCAGCAATTCTTCTTTCAACCAAGTTCA  
AGTCCTTACCGTTGAAGATGATTCTAGCGGTGG (SEQ ID NO:15)

10

5 ' CCGACCCATTGGAAACCACCAAGCCAGACATGACCTTGAAGGAAGCTTTGAAGATCGCTTTCGGTTTC  
AACGAACCAAACGGTAACTTGCAATACCAAGGTAAGG (SEQ ID NO:16)

15

5 ' GCCAATTGGTTCTTGATGTTTTGAGAGGTTTGGTGGTCGAAGTTGAAGTCGAATTCGGTGATGTCCTT  
ACCTTGGTATTGCAAGTTACCGTTTGGTTCG (SEQ ID NO:17)

5 ' CCAACAAACCTCTCAAAACATCAAGAACCAATTGGCTGAATTGAACGCTACCAACATTTACACTGTTT  
TGGACAAGATCAAGTTGAACGCCAAGATGAACATCTTGATCAGAGAC (SEQ ID NO:18)

20

5 ' GGGCTTCCTTGACAACGGATTCGTCAGCACCGACAGCAATGTTGTTTCTGTCGTAGTGGAATCTCTTG  
TCTCTGATCAAGATGTTTCATCTTGGCGTTCAACTTG (SEQ ID NO:19)

5 ' GCTGACGAATCCGTTGTCAAGGAAGCCACAGAGAAGTCATCAACTCCTCCACCGAAGGTTTGTGTT  
GAACATCGACAAGGACATCAGAAAGATCTTGTCGGG (SEQ ID NO:20)

25

5 ' GAGGAAATGTTCAACATGTCGTATCTGTCGTTGATGACTTCCTTCAAACCTTCGGTGTCTTCAATTTC  
GACGATGTAACCGGACAAGATCTTCTGATGTCCTTGTCGATG (SEQ ID NO:21)

30

5 ' GTCATCAACGACAGATACGACATGTTGAACATTTCTCTTTGAGACAAGACGGTAAGACCTTCATCGA  
CTTCAAGAAGTACAACGACAAGTTGCC (SEQ ID NO:22)

5 ' GGGTTGATGATGGTGTTCCTTAGTGACAGCGTAAACGTTGACCTTGTAGTTTGGGTTGGAAATGTA  
CAATGGCAACTTGTCGTTGTACTTCTTGAAGTCGATGAAGG (SEQ ID NO:23)

35

5 ' CGCTGTCACTAAGGAAAACACCATCATCAACCCATCCGAAAACGGTGACACTTCCACCAACGGTATCA  
AGAAGATTTTGATCTTCTCTAAGAAGGGTTACGAAATTGGT (SEQ ID NO:24)

The oligomers were alternating, overlapping sense and antisense sequences that spanned the entire length of the optimized PA63 coding sequence. Each oligomer had a complementary overlap of 28-38 bp with the adjoining oligomer (duplex had a  $T_m$  of 72-78  $^{\circ}\text{C}$  as calculated by VECTOR NTI program, version 7 INFORMAX, Bethesda, MD).

Six separate extension reactions were performed using four adjoining overlapping oligomers and sense and antisense PCR primers (28-32 nt in length with duplex  $T_m$ =62-68  $^{\circ}\text{C}$ ). Appropriate conditions for PCR are those described in International Publication number WO 01/14416A2. As a result of these PCR reactions, 6 colinear fragments of the gene were created (referred to herein for convenience as C+, D, E, F, G, H).

The fragments were gel-separated on agarose and the appropriately-sized products excised were purified using the GENE CLEAN Spin Column method (QBIogene, Carlsbad, CA) as recommended by the manufacturer. Colinear fragments C+, D, and E and colinear fragments F, G, and H were combined in subsequent PCR reactions with the appropriate primers to yield fragments II+ and III, respectively. The complete gene for PA63 was then assembled by an additional PCR reaction in which fragments II+ and III were combined using distal sense and antisense primers which incorporated *Bam*HI sites to allow cloning of the final product into a yeast vector. The sense primer incorporated additional upstream sequences to permit in frame cloning with a yeast secretion leader including its cleavage site via the Kex2 protease. The resulting 1.7-kb product (designated PA63 +L) was gel-isolated and cloned into pCR-Blunt II-TOPO (INVITROGEN, Carlsbad, CA) as recommended by the manufacturer. The sequence was obtained and errors identified. The gene was subcloned into pGEM3zf+ (PROMEGA, Madison, WI) and the errors sequentially corrected by site-directed mutagenesis using the QUIK-CHANGE Site-directed Mutagenesis Kit (STRATAGENE, La Jolla, CA) using the manufacturer's recommendations. A final PCR reaction with HIGH FIDELITY PCR Supermix (INVITROGEN, Carlsbad, CA) using an antisense primer

(5'CGCGGATCCTTAACCAATTTTCGTAACCCTTCTTAGAGAA) (SEQ ID NO: 25)

which incorporated a stop codon upstream of the *Bam*HI site and a sense primer which contained a *Bam*HI site as listed below (SEQ ID NO:26) plus a convenient portion of the gene sequence amplified the corrected sequence. The reaction product was subcloned into a TA cloning vector (INVITROGEN, Carlsbad, CA) using the manufacturer's protocol.

The DNA was purified from the final clone and the *Bam*HI fragment subcloned in the proper orientation into a yeast secretion vector (pHK4 $\alpha$ 2, FIG. 3) to construct pAGT1. The sequence of the insert was verified by DNA sequencing.

It is readily apparent to those skilled in the art that this invention extends to the use of DNA sequence data and its deduced amino acid sequence from naturally occurring modifications of the PA protein and from recombinant sequences that confer improved properties such as increased

5

10

15

## 20

## 20

25

25

30

liter of distilled water: agar, 20 g; sorbitol, 182 g; and SD medium minus leucine, 27.4 g (QBIogene #4811-015) (Carlsbad, CA). Clonal Leu<sup>+</sup> isolates were obtained by serial growth on Leu<sup>-</sup> plates.

Five-ml seed cultures were grown at 30° C in 5X minus leucine medium containing 4.0 % glucose and 0.1 M sorbitol medium for 18-24 h to OD<sub>600</sub> of 1.5-3.0/ml. 5X minus leucine medium contains the following components per liter: Yeast Nitrogen Base without added amino acids or ammonium sulfate, 8.5 g; adenine, 0.40 g; L-tyrosine, 0.25 g; uracil, 0.20 g, succinic acid, 10.0 g, ammonium sulfate, 5.0 g and 50 ml of Leucine-Minus Solution #3. Leucine-Minus Solution #3 contains per liter of distilled water, L-arginine, 2 g; L-histidine, 1.0 g; L-isoleucine, 6 g; L-lysine 4.0 g; L-methionine, 1.0 g; L-phenylalanine, 6.0 g; L-tryptophan, 4.0 g. A 0.3 ml aliquot was transferred to either 5.0 ml of 5X minus leucine medium containing 2 % glucose, 4 % galactose or YEHDG medium for 72 h to a final OD<sub>600</sub> of 5-16.0/ml. YEHDG medium contains per liter: L-Hy-Soy peptone-Sheffield, 10 g; Yeast extract, 20 g; L-dextrose, 16 g; D(+) galactose, 40 g.

After harvesting a total of 10 ODs per sample, the cell pellets were broken with glass beads in 0.3 mL lysis buffer (0.1 M sodium phosphate buffer, pH 7.2, 0.5 M NaCl, 1 mM PMSF). The lysate was recovered by centrifugation, the unbroken cells/beads were washed with 0.3 mL of lysis buffer and the clarified supernatants were combined. The clarified lysate was assayed for protein by the BIO-RAD Protein Assay Dye Reagent system (cat#500-0006) (BIORAD, Hercules, CA) according to the manufacturer's instructions. The cell lysates were analyzed for the expression of PA63 by immunoblot analysis after electrophoresis on either 4-15 % gradient Tris-HCl gels (BIORAD #161-1158) or 10-20% gradient Tris-HCl Criterion gels (BIORAD # 345-0043) in 1X Tris glycine SDS buffer (cat#161-0732) (BIORAD, Hercules, CA) under reducing and denaturing conditions. When equal amounts of protein lysate were subjected to electrophoresis, the samples contained 0.25-0.5 µg of total cellular protein. Sometimes equal volumes of cell lysate were analyzed and in this case, 0.05-1.0 µg total protein were loaded on the gels. The gels were electroblotted onto 0.2 micron PVDF membrane filters. To estimate protein size, prestained standards between 10 and 250 kDa were run in parallel with the lysates (cat # 161-0372) (BIORAD, Hercules, CA).

Recombinant PA83 prepared from *E. coli* BL21 as described by Roberts, J.E. et al. (Roberts *et al.*, 1998) was used as size standard. PA63 was derived from PA83 by treatment with trypsin as described by Miller et al. (Miller *et al.*, 1999) using Trypsin, type XI (SIGMA # T1005) (SIGMA CHEMICAL CO., St. Louis, MO) and Trypsin soybean inhibitor (SIGMA #T9003) (SIGMA CHEMICAL CO., St. Louis, MO). Either PA63 or PA83 were run as standards on every gel. For both qualitative and quantitative purposes, PA63 and PA83 standard were mixed with cell lysates prepared from a vector control transformant. Proteins were immunodetected using a monoclonal antibody to PA83 obtained from BIODESIGN (Clone C3 #C86613M) (BIODESIGN INTERNATIONAL, Saco, ME) as primary antibody and goat anti-mouse IgG (H+L) horseradish peroxidase-linked whole antibody (ZYMEX #81-6520) (ZYMED LABORATORIES, South San Francisco, CA, City, State) as the

secondary antibody. The filters were processed using the "WESTERN LIGHTNING<sup>TM</sup> Chemiluminescence Reagent Plus kit (PERKIN ELMER, Wellesley, MA).

A time course of induction of PA63 by transformant L-1 (strain 1849) fermented in duplicate, A and B, in complex YEHDG medium showed a major protein band that had the same mobility as the PA63 standard (FIG. 5). No expression was detected with a vector control transformant, K-1A (lane 2). Optimal expression was obtained at 48 hours (lanes 4 and 7). Production of internal PA63 was greater in complex medium than in a defined medium. Isolate 8-3 was chosen as the best producer of internally-produced PA63 in yeast strain 1260 based on Western analysis using PA63 and PA83 as standards and ELISAs using PA83 as standard.

### EXAMPLE 3:

#### Quantitation of Internal Yields

To estimate the yield of PA per culture volume, 5 mL culture of strain 8-3 which produces PA63 intracellularly, and vector control transformant 7-1 (both transformants of strain 1260) were processed either for quantitative ELISAs or for semi-quantitative Westerns. Two independent fermentation experiments designated one and two, were conducted with duplicate fermentations, A and B, for each transformant. For each experiment, the samples were analyzed by both techniques using authentic recombinant PA83 from *E. coli* as standard. ELISA and Westerns were performed using standard techniques. The antibodies used to capture and detect PA63 in the ELISA were monoclonal antibodies to PA83 (clone BAP0103, #C86301M,) and (clone C3, #C86613M,), respectively, (BIODESIGN INTERNATIONAL, Saco, ME). The antibody used in the Western blots was clone C3. A typical Western blot for quantitation is shown in FIG. 6. The results from ELISA determinations and semi-quantitative Westerns from the two independent experiments with culture 8-3 are shown in Table 1. These yields are within the range of the best yields reported for PA production from *B. anthracis* (Leppla, 1988) and recombinant PA production in *E. coli* (Chauhan *et al.*, 2001) without the potential of contamination with toxic bacterial components.

Table 1       $\mu\text{g PA/mL culture (tube)}$   
-transformants of 1260

Analysis Method	Isolate 8- 3 <sup>a</sup> titer( $\mu\text{g PA/mL}$ )
Experiment 1	
ELISA-1 <sup>b</sup>	71
ELISA-2 <sup>b</sup>	58
Western-1	47
Western-3	52
Experiment 2	
ELISA-3 <sup>b</sup>	144
Western-2	99
Western-3	82
Average <sup>c</sup>	79

<sup>a</sup> Avg. of duplicate fermentations-Avg. variation, 1.4 and 1.2-fold for ELISA and Western, respectively

<sup>b</sup> Underestimate due to inhibition of PA detection by cell lysate

5    <sup>c</sup> Average of all values from both experiments

#### EXAMPLE 4:

##### Expression of Secreted PA63 in Yeast Strain 1849

10            The synthetic DNA encoding the PA63 protein and with codons optimized for yeast expression was purified from the clone described in Example 1 and the *Bam*HI fragment subcloned in the proper orientation into a yeast secretion vector (pHK4 $\alpha$ 2, FIG. 3) to construct pAGT1. The sequence of the insert was verified by DNA sequencing. For secretion, the vector of choice is pKH4 $\alpha$ 2, which utilizes the yeast *GAL10* promoter and contains a unique *Bam*HI site for fusion (in-frame) of the ORF of interest to

15    the yeast alpha factor (MF $\alpha$ 1) pre-pro secretory leader. The 5'-end of the synthetic PA63 was modified to add the last 7 amino acids of the pro-leader including the cloning site and Lys-Arg cleavage site for the

yeast Kex2 protease by using PCR amplification with appropriate primers. The 5'-region is shown below:

BamHI

KEX2 site

5'-GTCACGG ATC CTG TCT TTG GAT AAG AGA (SEQ ID NO:26)

5 Ile Leu Ser Leu Asp Lys Arg (SEQ ID NO:30)

Plasmid pAGT1 was used to transform *S. cerevisiae* strains #1260 (MATa, leu2-2,112 mnn9, ura3Δ, can1, his3Δ::GAL10p-GAL4-URA3, prb1Δ::HIS3, cir<sup>o</sup>), #1558 (MATa, leu2-04, prb1Δ::HIS3, mnn9::ura3, ade1, his3::URA3, cir<sup>o</sup>) and #1849 (MATa, leu2-04, prb1Δ::HIS3, mnn9::ura3, ade1, his3::GAL10p-GAL4-URA3, cir<sup>o</sup>) to leucine prototrophy (Leu<sup>+</sup>) by using a spheroplast transformation protocol (Hinnen et al., 1978). Transformants were selected on synthetic agar medium lacking leucine and containing 1 M sorbitol. The synthetic medium contained per liter of distilled water: agar, 20 g; sorbitol, 182 g; and SD medium minus leucine, 27.4 g (QBIogene #4811-015)(Q BIO, Carlsbad, CA). Clonal Leu<sup>+</sup> isolates were obtained by serial growth on Leu<sup>-</sup> plates.

Five-ml seed cultures were grown at 30° C in 5X minus leucine medium containing 4.0 % glucose and 0.1 M sorbitol medium for 18-24 h to OD<sub>600</sub> of 1.5-3.0/mL. 5X minus leucine medium contains the following components per liter: Yeast Nitrogen Base w/o amino acids or ammonium sulfate, 8.5 g; adenine, 0.40 g; L-tyrosine, 0.25 g; uracil, 0.20 g, succinic acid, 10.0 g, ammonium sulfate, 5.0 g and 50 ml of Leucine-Minus Solution #3. Leucine-Minus Solution #3 contains per liter of distilled water, L-arginine, 2 g; L-histidine, 1.0 g; L-isoleucine, 6 g; L-lysine 4.0 g; L-methionine, 1.0 g; L-phenylalanine, 6.0 g; L-tryptophan, 4.0 g. A 0.3 mL aliquot was transferred to either 5.0 mL of 5X minus leucine medium containing 2 % glucose, 4 % galactose or YEHDG medium for 72 h to a final OD<sub>600</sub> of 5-16.0/ml. YEHDG medium contains per liter: L-Hy-Soy peptone-Sheffield, 10 g; Yeast extract, 20 g; L-dextrose, 16 g; D(+) galactose, 40 g.

The yeast cells were removed and the supernatants were directly analyzed for the expression of PA63 by immunoblot analysis. Twenty-five microliter samples were subjected to electrophoresis on 4-15 % gradient Tris-HCl gels (cat #161-1158)(BIORAD, Hercules, CA) in 1X Tris glycine SDS buffer (cat #161-0732) (BIORAD, Hercules, CA) under reducing and denaturing conditions. The gels were electroblotted onto 0.2 micron PVDF membrane filters. To estimate protein size, prestained standards between 10 and 250 kDa were run in parallel with the samples (cat # 161-0372) (BIORAD, Hercules, CA). Recombinant PA83 from *E. coli* BL21 as described by Roberts, J.E. et al. (Roberts *et al.*, 1998) was used as size standard. PA63 was derived from PA83 by treatment with trypsin as described by Miller et al. (Miller *et al.*, 1999) using Trypsin, type XI (cat # T1005)(SIGMA CHEMICAL CO., St. Louis, MO) and Trypsin soybean inhibitor (cat #T9003) (SIGMA CHEMICAL CO., St Louis, MO). Either PA63 or PA83 were run as standards on every gel. For both qualitative and quantitative purposes, PA63 and PA83 standard were mixed with cell lysates prepared from a vector control transformant.



Proteins were immunodetected using a monoclonal antibody to PA83 obtained from BIODESIGN INTERNATIONAL, Saco, ME (Clone C3 #C86613M) as primary antibody and goat anti-mouse IgG (H+L) horseradish peroxidase-linked whole antibody (Zymed #81-6520) (ZYMED LABORATORIES, South San Francisco, CA) as the secondary antibody. The filters were processed using the "WESTERN LIGHTNING<sup>™</sup> Chemiluminescence Reagent Plus kit (PERKIN ELMER, Wellesley, MA).

Multiple isolates were screened using small scale shake flask fermentations or roller tube fermentations. Culture 14A in strain 1849 was determined to yield the most secreted PA63 as determined by semi-quantitative Western blots. A time course of production of secreted PA from strain 14A is shown in FIG.7. A protein band of ~75 kDa was detected minutely at 24 h, increased at 48 h, and was maximally produced at 72 h (see lanes 3, 5 and 7, respectively). No protein was detected in the supernatant of a transformant containing the vector control alone, 12B, shown at 48 and 72 h as shown in lanes, 4 and 6, respectively. There were some smaller proteins that could be degradation products. These proteins appear as early as 24 h and appear to get smaller with time. The ~75-kDa protein is larger than the PA63 control. There are several possibilities for the altered mobility of the secreted protein including N- or O-linked core glycosylation and uncleaved leader sequence. A protein band of ~75 kDa was detected in all three of the transformed *S. cerevisiae* strains tested. Production of secreted PA was greater in complex medium than in a defined medium. Assays on cellular lysates indicated that some PA63 was retained intracellularly.

PA63 secretion was not improved in 2 different *pep4* mutants (deficient in vacuolar proteases) incubated for various times.

#### EXAMPLE 5:

##### Domain 4 Construct

Native PA63 has a cellular receptor binding site within domain 4 that has been implicated in vaccine-induced immunity. Domain 4, a 140-amino acid protein corresponding to bacterial amino acids 596-735 of SEQ ID NO: 54, is capable of inducing antibodies that protect mice from infection with *B. anthracis* (Flick-Smith *et al.*, 2002). Further evidence that domain 4 has a key role was shown by neutralization of toxin with affinity-enhanced recombinant antibodies directed to an epitope within domain 4. Thus, it can be readily seen that expression of recombinant domain 4 in yeast would yield a small protein in a safe expression host. It is expected that this domain and other appropriate immunogenic domains of PA expressed in yeast would offer the advantage of increased immunogenicity, easier purification and higher yields than the entire protein.

The wild-type sequence for the gene encoding the uncleaved PA83 (BACPAG) is known (See FIG. 8). In accordance with this invention, domain 4 sequence without the bacterial signal sequence having identical translated amino acid sequences, but with alternative codon usage as defined by Lathe (Lathe, 1985) and selected for yeast codons for highly expressed genes (Sharp and Cowe, 1991) was

amplified by PCR from a plasmid containing PA63 DNA sequence optimized for yeast codon usage. The 5' primer (GTCACGGATCCTGTCTTTGGATAAGAGATTCCACTACGACAGAAA CAACATT) (SEQ ID NO: 31)

contained the desired yeast leader sequence for secretion and the 3' primer

5 (CGCGGATCCTTAACCAATTTCGTAACCCTTCTTAGAGAA) (SEQ ID NO: 32)

contained a *Bam*HI restriction site and TAA as a stop codon. The PCR fragment was digested with *Bam*HI and cloned into secretory vector. The yeast codon optimized domain 4 sequence without the leader is shown in Figure 9A and its translation in 9B.

#### 10 EXAMPLE 6:

##### PA83 Construct and Expression

The wild-type sequence for the gene encoding the uncleaved PA83 (BACPAG) is known (See FIG.8). In accordance with this invention, PA83 segments without the bacterial signal sequence were converted to sequences having identical translated amino acid sequences, but with alternative codon  
15 usage as defined by Lathe (Lathe, 1985) and selected for yeast codons for highly expressed genes (Sharp and Cowe, 1991). See FIG. 11. The methodology was the same as for Example 1.

Native, mature PA83 binds to cellular receptors and requires activation by endoproteolytic cleavage to interact with either LF and EF to form active toxin (Reviewed by Mock and Fouet, 2001). A mutated form of PA83 that has the amino acid sequence RKKK (SEQ ID NO: 33)  
20 instead of the wild-type RKKR (SEQ ID NO: 34) sequence within the furin cleavage site at amino acids 164-167 does not form active toxins with EF and LF (Beauregard et al, 2000). Proteolytic cleavage is rate-limiting for internalization of the protein and the mutated protein remains on the surface. Yet this mutated protein still contains the immunoprotective domains implicated in vaccine-induced immunity such as domain 4 (Flick-Smith *et al.*, 2002). This mutant form of PA83 and other appropriate  
25 immunogenic domains of PA expressed in yeast can offer the advantages of increased immunogenicity, easier purification and higher yields.

The gene fragment encoding PA83 with a mutation of R to K at amino acid 167 to alter the furin and potential Kex2p cleavage site was prepared by the annealing and extension of 31 oligomers (91-110 bp in length) designed to encode the final desired sequence. The oligomers were alternating,  
30 overlapping sense and antisense sequences that spanned the entire length of the optimized PA83 coding sequence. Each oligomer had a complementary overlap of 28-38 bp with the adjoining oligomer (duplex had a Tm of 72-78 C° as calculated by Vector NTI program, version 7, INFORMAX, Bethesda, MD). Eight separate extension reactions were performed using four adjoining overlapping oligomers and sense and antisense PCR primers (28-32 nt in length with duplex Tm=62-68 C°). The actual conditions of PCR  
35 were similar to those described in International Publication number WO 01/14416A2.

The oligomers and resulting fragments D,E,F,G, and representing the PA63 portion of the molecule are the same as in Example 1. The N-terminal portion were created from the following oligomers which were used to create fragments A, B and C. The 12 oligomers for A, B, and C are the following:

5 ' GAAGTTAAGCAAGAAAACAGATTGTTGAACGAATCTGAATCCTCTTCCCAAGGTTTGT'TGGGTTA  
CTACTTCTCCGACTTGAAC'TTCCAAGCTCCAATGGTCGTCACC-3 ' (SEQ ID NO: 35)

5 ' CGGATGGGATGTTCTCTAATTCGGAGGATGGGATGGACAAGTC  
ACCGGTAGTAGAGGAGGTGACGACCATTGGAGCTTGGAAAGTTCAAGTCGG-3 ' (SEQ ID NO: 36)

5 ' TCCCATCCTCCGAATTAGAGAACATCCCATCCGAAAACCAATACTTCCAATCCGCTATCTGGTCC  
GGCTTCATCAAGGTCAAGAAGTCCGACG-3 ' (SEQ ID NO: 37)

5 ' GGAAGCCTTGTTGATGACTTCTTGGTCGTCGACCCACATAGTAACGTGGTTGTCAGCGGAGGTAG  
CGAAAGTGTATTCGTCGGACTTCTTGACCTTGATGAAGCCGG-3 ' (SEQ ID NO: 38)

5 ' GGGTCGACGACCAAGAAGTCATCAACAAGGCTTCCAAC'TCCAACAAGATCAGATTGGAAAAGGGT  
AGATTGTACCAAATTAAGATCCAATACCAAAGAGAAAACCCAACCG-3 ' (SEQ ID NO: 39)

5 ' GAGATGACTTCTTCTTGT'TTTGGGAGTCGGTCCAGTACAAC'TGAAGTCCAAACCTT'TTCGGT  
TGGGTTTCTCTTTGGTATTGGATCTTAATTTGG-3 ' (SEQ ID NO: 40)

5 ' GGACCGACTCCCAAAACAAGAAGGAAGTCATCTCYTCTGACAACTTGCAATTGCCAGAAATTGAAG  
CAAAAGTCYTCCAAC'TCCAGAAAGAAGAAGTCCACCTCCGCTGG (SEQ ID NO: 41)

5 ' GACGTCGACGGTGTAACCTTCGACTTCCAAGGAGTCTGGAATACCGTCGTTGTCTCTGTCTGGAA  
CAGTTGGACCAGCGGAGGTGGACtctCTTCTTTCTGGAGTTGG-3 ' (SEQ ID NO: 42)

5 ' CCTTGGAAGTCGAAGGTTACACCGTCGACGTCGAAGAACAAGAGAACCTTCTTGTCTCCAATGGATC  
TCCAACATTCACGAAAAGAAGGGTTTGACCAAG-3 ' (SEQ ID NO: 43)

5 ' CGGTGACCTTTTCGAAGTCGGAGTATGGGTCGGAAGCAGTAGACCACTTTTCTGGGGAAAGACTTG  
TACTTGGTCAAACCTTCTTTTCGTGAATGTTGGAG-3 ' (SEQ ID NO: 44)

5 ' CCGACCCATACTCCGACTTCGAAAAGGTCACCGGTAGAATCGACAAGAACGTCTCCCCAGAAGCT  
AGACACCCATTGGTTGCTGCTTACCCAATTGTCCACGT-3 ' (SEQ ID NO: 45)

5 ' CTGGTTTCGGAGTCCGTGTTT'TGGGTGGATTGGTCTTCGTTCTTGGACAAAATGATGTT'TTCCAT  
GTCAACGTGGACAATTGGGTAAGCAGCAACCAATGG-3 ' (SEQ ID NO: 46)

5 As a result of these PCR reactions, the following 8 fragments of the gene were created: A, B, C, D, E, F,G, H. Fragment C contains the mutation which results in a lysine in place of the arginine at amino acid 167.

10 The fragments were gel separated on agarose with the appropriately-sized products excised and purified using the Gene Clean Spin Column method (QBIOSGENE, Carlsbad, CA) as recommended by the manufacturer. Fragments A and B, fragments C, D, and E, and fragments F, G, and H were combined in a subsequent PCR reaction with the appropriate primers to yield the fragments I, II and III, respectively. The complete gene for PA83 was then assembled by an additional PCR reaction in which

fragments I, II and III were combined using distal sense and antisense primers which incorporated *Bam*HI sites to allow cloning of the final product into a yeast vector. The sense primer incorporated additional upstream sequences that permit in-frame cloning with a yeast secretion leader and its Kex2 protease cleavage site as in Example 1. The resulting 2.2-kb product (designated PA83 U +L) was gel isolated and cloned into pCR-Blunt II-TOPO (INVITROGEN, Carlsbad, CA) as recommended by the manufacturer. The sequence was obtained and errors identified. The final DNA sequence and encoded protein sequence are shown in Figure 11. The gene was subcloned into pGEM3zf+ (PROMEGA, Madison, WI) and the errors sequentially corrected by site-directed mutagenesis using the Quik-Change Site-directed Mutagenesis Kit (STRATAGENE, La Jolla, CA) using the manufacturer's recommendations. It can be readily seen by those skilled in the art that the sequence of the PA83 can be changed to produce wild-type and altered forms of PA83 in response to mutated versions made by man or naturally occurring modifications.

#### EXAMPLE 7:

##### Preparation of Immunogenic Compositions

Purified PA63 is formulated according to known methods, such as by the admixture of pharmaceutically acceptable carriers, stabilizers, or a vaccine adjuvant. The immunogenic PA63 of the present invention may be prepared for vaccine use by combining with a physiologically acceptable composition such as, e.g. PBS, saline or distilled water. The immunogenic PA63 are administered in a dosage range of about 0.1 to 100 mcg, preferably about 1 to about 20 mcg, in order to obtain the desired immunogenic effect. The amount of PA63 per formulation may vary according to a variety of factors, including but not limited to the individual's condition, weight, age and sex. Administration of the PA63 formulation may be by a variety of routes, including but not limited to oral, subcutaneous, topical, mucosal and intramuscular.

An antimicrobial preservative, e.g. thimerosal, optionally may be present. The immunogenic antigens of the present invention may be employed, if desired, in combination with vaccine stabilizers and vaccine adjuvants. Typical stabilizers are specific compounds, e.g. polyanions such as heparin, inositol hexasulfate, sulfated beta- cyclodextrin, less specific excipients, e.g. amino acids, sorbitol, mannitol, xylitol, glycerol, sucrose, dextrose, trehalose, and variations in solution conditions, e.g. neutral pH, high ionic strength (ca. 0.5-2.0M salts), divalent cations ( $\text{Ca}^{2+}$ ,  $\text{Mg}^{2+}$ ). Examples of adjuvants are  $\text{Al}(\text{OH})_3$ ,  $\text{Al}(\text{OH})_x(\text{SO}_4)_y(\text{PO}_4)_z$  and  $\text{Al}(\text{PO}_4)$ . The vaccine of the present invention may be stored under refrigeration or in lyophilized form.

#### EXAMPLE 8:

S. cerevisiae codon usage required for optimal production of PA63 in yeast

To determine whether the alteration of codons used in Examples 1-4 provided for optimal production in yeast, the authentic bacterial sequence of PA63, which is the 1.7-kb furin cleavage product of authentic native PA83, was amplified by PCR from authentic native bacterial PA83 isolated from B. anthracis. The authentic native bacterial PA83 had been cloned and the sequence subsequently corrected so that the amino acid sequence matched that of codon-optimized PA83. The native PA63 sequence as inserted into the same yeast secretory expression vector as the codon-optimized sequence (see Example 4). The amount of secreted and internal PA63 was determined by semi-quantitative Western analysis.

DNA from B. anthracis ATCC strain 14578 was obtained from a 5.0-mL culture. The culture was inactivated and total DNA was purified by the addition of 0.5 mL 20 % SDS, 5.0 mL of phenol-chloroform and 0.75 mL 5.0 M NaCl. The DNA was purified by standard procedures and resuspended in TE for use in PCR.

The full-length PA83 (2.2 kb) was amplified with *Bam*HI restriction enzyme sites by PCR using the following primers (*Bam*HI sites underlined): 83 sense,

5'CGCGGATCCGAAGTTAAACAGGAGAACCG3' (SEQ ID NO: 59), 83 antisense -

5'CGCGGATCCTTATCCTATCTCATAGCCTT 3'(SEQ ID NO: 60).

Two rounds of PCR were used to amplify the desired regions. The first round used PFU turbo DNA polymerase, genomic DNA according to the manufacturer's recommendations and the following PCR conditions: 1 min 95 °C, 1 X; 95 °C 45 sec, 55 °C 45 sec, 72 °C 2.5 min 30X; 72 °C 10 min, 1 X; 4 °C hold. The second round was performed with 1 µL of product from the first round, and PCR SUPERMIX HIGH FIDELITY (cat # 10790-020)(INVITROGEN, Carlsbad, CA) according to the manufacturer's recommendations. The PCR conditions were as follows: 30 sec 94° C, 1 X; 94° C 30 sec, 55° C, 30 sec, 68° C, 2.5 min, 25X; 68° C, 7 min, 1X; 4° C hold. The PCR product was purified and concentrated on a Gene Clean Spin column according to the manufacturer's recommendation (QBIOSGENE, Carlsbad, CA). The PCR products were cut with *Bam*HI, purified by Gene Clean Spin columns and ligated to the vector pKH4alpha2 that had been digested with *Bam*HI and treated with alkaline phosphatase to prevent self-ligation. The orientation of the insert was confirmed by restriction digest and the DNA sequence of plasmid pba83PAG#11 analyzed. Four bp that differed from the published sequence, used to construct the yeast codon-optimized version, were found.

To facilitate correction of the sequence, the *Bam*HI fragment of pba83PAG#11 was gel isolated and concentrated on a Gene Clean Spin column according to the manufacturer's recommendation (QBIOSGENE, Carlsbad, CA). The *Bam*HI fragment was ligated to pGEM3zf that had been digested with *Bam*HI and treated with alkaline phosphatase to construct pba83#13. The sequence was corrected using QUICK CHANGE MULTI-SITE-DIRECTED mutagenesis kit (STRATAGENE, La Jolla, CA) according to the manufacturer's instructions and the DNA sequence of the resultant plasmid, pba83multi#5, was verified.

In order to clone the 1.7-kb furin cleavage product of authentic native PA83, and to facilitate cloning into the yeast secretory vector with the appropriate leader sequence, the following sense and antisense primers (*Bam*HI sites underlined), respectively,

5'CGCGGATCCTGTCTTTGGATAAGAGAAGTACAAGTGCTGGACCTAC3' (SEQ ID NO: 61) and

5'CGCGGATCCTTATCCTATCTCATAGCCTT3' (SEQ ID NO: 62 ) were used for PCR with pba83multi#5 as template. The PCR conditions were as described above using PCR SUPERMIX HIGH FIDELITY (cat # 10790-020)(INVITROGEN®, Carlsbad, CA). The *Bam*HI fragment was isolated as described above and cloned into pCR2.1TOPO (INVITROGEN, Carlsbad, CA) according to the manufacturer's recommendation. Subsequently, the *Bam*HI fragment was gel-isolated again and ligated into pKH4α2 that had been digested with *Bam*HI and treated with alkaline phosphatase. The correct orientation and sequence was confirmed by DNA sequencing of plasmid pba63pKH4α2#11.

The plasmid pba63pKH4α2#11 was used to transform *S. cerevisiae* strain #1849 as in Examples 2 and 4. Leu<sup>+</sup> transformants obtained with pba63pKH4α2, pAGT1 (codon-optimized PA63, Example 4), and pKH4α2 (vector control) were fermented in complex medium YEHDG as described in Examples 2 and 4. Supernatants of cultures of twenty-four independent Leu<sup>+</sup> transformants obtained with pba63pKH4α2 were screened for the production of secreted PA63 as described in Example 4. No PA63 was detected from any of the transformants containing the authentic native sequence, even after prolonged exposure of the blot. Secreted PA63 was however, detected from transformants containing the yeast codon-optimized sequence (data not shown).

We had previously found both secreted and intracellular PA63 produced by transformants containing the plasmid pAGT1, designed to secrete codon-optimized PA63 (Example 4). To ensure that PA63 was not produced inside the cell from a transformant containing "authentic native" PA63 sequence, we evaluated selected transformants for both intracellular and extracellular production of PA63. Fermentations and assessment of PA63 production were conducted as described in Examples 2 and 4. The amount of PA63 produced in yeast from the authentic native bacterial sequence was compared to that of the "codon-optimized" gene by Western blot analysis as shown in FIG. 12. PA63 was detected in both the medium supernatants and cell lysates of transformants containing the codon-optimized gene as shown in lanes 6, 7 and 11, 12, respectively. In both cases, the PA63 detected was larger than 63 kDa. It was also larger than PA63 produced from a transformant constructed to produce PA63 intracellularly (see Example 2) as shown in lane 1 and described in Example 4. In contrast, PA63 was not detected in either cell lysates (lanes 9 and 10) or medium supernatants (lanes 4 and 5) from transformants containing the "native" construct, even after a very long exposure of the blot. No protein was detected in either supernatants (lane 3) or cell lysates (lane 8) of the vector control transformant.

#### EXAMPLE 9:

Intracellular Expression of Uncleavable PA83 with Altered Furin Cleavage Site in *S. cerevisiae*

The DNA encoding the PA83 protein with codons optimized for yeast expression was amplified from the final corrected clone (lacking the Furin cleavage site) as carried in the pGEM3Zf+ vector described in Example 6 using the following sense and antisense primers, respectively,

5'CGCGGATCCCACAAAACAAAATGGAAGTTAAGCAAGAAAACAGA 3' (SEQ ID NO: 63) and

5'CGCGGATCCTTAACCAATTTTCGTAACCCTTCTTAGAGAA3' (SEQ ID NO: 29) containing a *Bam*HI restriction site and TAA as a stop codon. The *Bam*HI fragment was subcloned in the proper orientation into a yeast vector (pGAL110, FIG. 4) to construct PA83pGAL10#24. The sequence of the insert was verified by DNA sequencing. The plasmid was used to transform *S. cerevisiae* strains #1260 (*MATa*, *leu2-2, 112*, *mn9*, *ura3Δ*, *can1*, *his3Δ::GAL10p-GAL4-URA3*, *prb1Δ::HIS3*, *circ*), #1558 (*MATa*, *leu2-04*, *prb1Δ::HIS3*, *mn9::ura3*, *ade1*, *his3::URA3*, *circ*) and #1849 (*MATa*, *leu2-04*, *prb1Δ::HIS3*, *mn9::ura3*, *ade1*, *his3::GAL10p-GAL4-URA3*, *circ*) to leucine prototrophy (*Leu*<sup>+</sup>) as described in Examples 2 and 4.

For screening multiple transformants of strains 1849 and 1558, small-scale trial fermentations were conducted in complex YEHDG medium and evaluated for expression of PA83 by Western blot as described in Example 2. A major protein that co-migrated with the *E. coli* PA83 standard was detected by Western blotting in cell lysates of transformants of both strains 1849 and 1558. No proteins were detected in lysates of vector control transformants. The best internal producer of PA83 was a transformant of 1558, strain Q-3, with a volumetric productivity of 12.0 μg PA83 produced per mL of culture medium with PA83 comprising 7.0 % of the total cell protein. Production of internal PA83 was greater in complex than in a defined medium. Media compositions were described in Example 2.

Production of uncleavable PA83 was evaluated from strain Q-3 and several transformants of strain 1260, 9-1 through 9-8, that were fermented in 50 mL of medium in 250-mL shake flasks. Inoculum development began by thawing the frozen vials and transferring 1.0 mL inoculum to 50 mL of medium contained in a 250-mL flask. Strain Q-3 was transferred into 5X minus leucine + 4% Dextrose medium and strains 9-1 through 9-8 were transferred into 5X minus leucine minus adenine + 4% Dextrose medium. The composition of 5X minus leucine medium was described in Example 2. The flasks were incubated at 28° C and agitated at 250 rpm. For each strain, samples were removed aseptically after ~ 24 h to determine the glucose concentration and OD<sub>600</sub>.

When the glucose in the 250-mL flask reached between 5 and 25 g/L, 1.0 mL of culture was transferred to another 250-mL Erlenmeyer flask containing YEHDG medium. YEHDG medium was described in Example 2. Again, the flasks were incubated at 28° C and agitated at 250 rpm. For each strain, samples were removed aseptically after 48 h and 72 h to determine the glucose and galactose concentration and OD<sub>600</sub>.

The flasks were harvested after 72 h and pellets corresponding to 25 OD<sub>600</sub> units were collected for each strain. The cell-pellets were broken with 0.5 g of 0.45 mm acid washed glass beads in 0.3 mL of 0.2 M HEPES, pH 7.3 containing 0.5 mg/mL Pefabloc (ROCHE DIAGNOSTICS, Mannheim,

Germany), 1x Complete Protease Inhibitor Cocktail (Roche), 3.5  $\mu$ g/mL pepstatin (ROCHE), 20 mM benzamidine (SIGMA, St. Louis MO), 5 mM EDTA, and 5 mM EGTA. Breakage was performed at 4° C using a vortex mixer for 15 minutes. Cellular debris and beads were collected by centrifugation in a microcentrifuge and the supernatant was transferred to a second microcentrifuge tube that was again centrifuged to remove debris. Aliquots were removed and assayed for total protein using the BCA assay (PIERCE, Rockford, Illinois). Four  $\mu$ g of each lysate were then loaded on a 4-12 % NUPAGE BIS TRIS gel and subjected to electrophoresis in MOPS SDS running buffer (INVITROGEN, Carlsbad, CA). The gel was transferred to PVDF membrane (INVITROGEN, Carlsbad, CA) for Western blotting using MAb 86613M (BIODESIGN INTERNATIONAL, Saco, ME) as primary antibody and goat anti-mouse-IgG peroxidase conjugate (PERKIN ELMER, Boston, MA) as secondary antibody. Detection was performed using CN/DAB peroxidase substrate (PIERCE, Rockford, Illinois). Purified recombinant *E. coli* PA83 (see Examples 2 and 4) was used as standard.

The results are shown in FIG. 13. Transformant 9-1 of *S. cerevisiae* strain 1260 (lane 1) was one of the best producers of internally-produced rPA83 and was chosen for large-scale fermentation.

#### EXAMPLE 10:

Intracellular Expression of PA83 with Intact Furin Cleavage Site (cleavable PA83) in *S. cerevisiae*

The DNA encoding the PA83 protein with a mutated Furin cleavage site (Example 6) and with codons optimized for yeast expression was subcloned into pCR4-TOPO (INVITROGEN, Carlsbad, CA). The PA83 coding sequence was altered to encode an arginine at amino acid 167 of the cleavage site using the QUICKCHANGE Site-directed mutagenesis kit (STRATAGENE, La Jolla, CA). The primers used for mutating the site were:

Sense 5' CAACTCCAGAAAGAAGAGATCCACCTCCGCTGGTC - SEQ ID NO: 64 and antisense 5' GACCAGCGGAGGTGGATCTCTTCTTTCTGGAGTTG - SEQ ID NO: 65

The sequence of the modified plasmid was verified by DNA sequencing. The DNA for the cleavable construct was amplified from pCR4-TOPO as a *Bam*HI fragment using the sense primer described in the previous example,

5'CGCGGATCCCACAAAACAAAATGGAAGTTAAGCAAGAAAACAGA (SEQ ID NO: 63), and the antisense primer described in Examples 1 and 2.

5'CGCGGATCCTTAACCAATTCGTAACCCTTCTTAGAGAA3' (SEQ ID NO: 29) The *Bam*HI fragment was subcloned in the proper orientation into a yeast expression vector (pGAL110, FIG. 4) to construct pPA83clGAL10#6. The sequence of the insert was verified by DNA sequencing. The plasmid was used to transform *S. cerevisiae* strain 1260 to leucine prototrophy as described in Examples 2 and 4. Production of cleavable PA83 was evaluated from several transformants of strain 1260 and uncleavable PA83 was produced from transformant 9-1 in small-scale fermentations conducted in YEHDG medium as described in Examples 2 and 4. Cell-pellets corresponding to 10 OD<sub>600</sub> units were broken in the



presence of 0.5 g of 0.45 mm glass beads and 0.5 mL of breaking buffer (20 mM HEPES, pH 8.2, 5 mM EDTA, 1x "Complete" protease inhibitor cocktail (ROCHE DIAGNOSTICS, Mannheim, Germany) by continuous vortexing at high speed at 4° C for 10 minutes. Cellular debris and glass beads were collected by centrifugation in a microcentrifuge at 4° C for 10 minutes. The clarified supernatants were transferred to new tubes and assayed for total protein using the BCA assay (Pierce, Rockford, Illinois). Two and one half µg of each sample was loaded onto a 4-12 % NUPAGE BIS TRIS gel and run in MOPS SDS running buffer (INVITROGEN, Carlsbad, CA). The gel was transferred to PVDF membrane (INVITROGEN, Carlsbad, CA) and Western blotted using Mab 86613M (BIODESIGN, Saco, ME) as primary antibody and goat anti-mouse-IgG peroxidase conjugate (PERKIN ELMER, Boston, MA) as secondary antibody. Detection was performed using CN/DAB peroxidase substrate (PIERCE, Rockford, IL). Purified recombinant *E. coli* PA83 (see Examples 2 and 4) was used as standard. No detection was obtained with a cell lysate containing the vector control. Cleavable PA83 was detected in all three yeast transformants tested and co-migrated with uncleavable PA83 produced in *S. cerevisiae*. Transformant 5C was chosen as one of the best producers of cleavable PA83.

Subsequently, production of uncleavable PA83 by yeast strain 9-1 and cleavable PA83 produced by strain 5-C, fermented in shake flasks in YEHDG medium, was assessed. Strain 5-C was also fermented in YEHDG in a culture tube. The tube fermentations were conducted as described in Examples 2 and 4. The shake-flask fermentations were conducted as described in Example 2, except that the galactose induction was conducted in 50 mL YEHDG medium in a 250-mL flask with inocula scaled-up proportionately. Cell lysates were prepared and evaluated by Western blot as described in Example 2. The results are shown in FIG. 14. Purified recombinant *E. coli* PA83 (lane 1) was used as standard. The additional protein detected below rPA83 is a degradation product that is sometimes observed. No detection was obtained with a cell lysate containing the vector control (lane 2). Production of uncleavable PA83 was greater than cleavable PA83 (compares lanes 3 and 4 to 5 and 6). Production of cleavable PA83 was greater in culture tube (5-mL volume) than in a shake flask (compare lanes 7 and 8 to 5 and 6).

#### EXAMPLE 11:

##### Fermentation and Purification of Internally-Expressed PA63

Frozen seed stock of yeast strain 8-3 (strain 1260 transformed with plasmid p63GAL10#2) was used for large-scale fermentation and purification. The vial of seed stock was thawed and 1.0 mL was used to inoculate a 250-mL Erlenmeyer flask containing 50 mL of a leucine-free selective medium (5X Leu<sup>-</sup> medium. Bayne et al., 1988.) containing 4 % dextrose. The flask was incubated at 28° C, 250 rpm on a rotary shaker. After 24 hours (residual glucose 22.3 g/L), a culture volume of 11 mL was added to a 2-L flask containing 877 mL of the same medium. Again, the flask was incubated at 28° C and agitated at 250 rpm. After 24.5 hours (residual glucose 12.9 g/L), the contents of the 2-L flask were used to

inoculate a 20-L reactor containing a chemically defined medium (Oura, E., 1974) optimized for our strains. This medium contained 20 g/L glucose followed by 40 g/L galactose for induction. The reactor was operated at 28° C, 4.7 L/min, 15 psig, and 300 rpm. Under these conditions, dissolved oxygen levels were maintained at greater than 30 % of saturation. Cellular growth was monitored by glucose  
5 consumption, optical density (A600 nm, 1-cm cuvettes), dry cell weight, galactose utilization and ethanol production. Cultivation continued for 90 h reaching an OD<sub>600</sub> of 35 and a dry cell weight of 19.7 g/L.

The culture was harvested via hollow fiber tangential flow filtration (AMICON H5MP01-43 cartridge) using an AMICON DC-10 harvest skid (MILLIPORE, Billerica, MA). The permeate was discarded and the cells were concentrated down to 1.35 L. Cells were then diafiltered with PBS, and  
10 collected by centrifugation at 8000 rpm, 4° C for 20 minutes using a Sorvall Evolution RC (SLA-3000 rotor). Cells were stored at -70° C.

To evaluate production of PA63 by strain 8-3 in large-scale fermentation, cell lysates were prepared from 10 OD<sub>600</sub> units of the harvested culture and evaluated as detailed in Examples 2 and 3. Production of PA63 from a small-scale culture tube fermentation (72 h, complex YEHDG medium) was  
15 also assessed. The results of a Western blot are shown in FIG. 15. It can be seen that the protein produced from the large-scale fermentation, lanes 5 and 6, comigrated with PA63 produced in a tube fermentation, lanes 7, and 8 and with the control PA63 shown in lanes 1, 2, 11 and 12. It is apparent that the yield of PA63 from the large-scale fermentation is greater than that of the tube fermentation. The titer of PA63 from the large-scale fermentation was estimated to be 220 µg per mL and the % total  
20 protein, 12 %, compared to 65 µg/mL and 8.0 % of the total protein for the tube fermentation (using the semi-quantitative Western method described in Example 3).

The quantitation of expression in the large-scale fermentation was confirmed by ELISA as described in Example 3. Volumetric titers of 360 and 80 µg per mL were determined for the large-scale and tube fermentations, respectively. The enhanced yields from the large-scale fermentation can  
25 probably be attributed to both decoupling of cell growth from induction of PA63 expression, and selective pressure for plasmid maintenance.

The purification process for PA63 from yeast is presented in FIG. 16. Frozen yeast cells were thawed in a cold-water bath for several hours. The cells were resuspended in five times the volume of cold breaking buffer (0.2 M HEPES, pH 7.4, 2 mM MgCl<sub>2</sub>, 0.5 mg/mL PEFABLOC (Roche Applied  
30 Science, Indianapolis, IN), 1x "complete" EDTA free protease inhibitor mix (ROCHE APPLIED SCIENCE, Indianapolis, IN), 3.5 µg/mL pepstatin (ROCHE APPLIED SCIENCE, Indianapolis, IN), 20 mM benzamidine (SIGMA, St. Louis, MO), and 1 µL benzonase (EM INDUSTRIES, Hawthorne, NY) per gram of cells.

The yeast cells were ruptured by 4 sequential passes through a microfluidizer apparatus (Model  
35 110S, MICROFLUIDICS, Newton, MA) at a pressure of 18,000 psi. The temperature of the lysate was

maintained at <15° C throughout the procedure by cooling between passes in an ice water bath. The pH of the lysate remained at 7.4 throughout the procedure.

Following the cell breakage, EDTA and EGTA were added to the lysate at final concentrations of 5 mM each. Insoluble material was removed from the lysate by low speed centrifugation (10,000 x g) in a Sorvall RC-5C refrigerated centrifuge with a GS3 rotor for 20 minutes at 4° C.

The supernatant of the low speed spin was clarified by filtration through a series of 47 mm diameter filters (AP15, AP25, and 5 µM (DURAPORE White Hydrophilic Disc SVLP, MILLIPORE, Billerica, MA). The clarified lysate was divided into aliquots and stored at -70° C.

Preliminary attempts were made to purify PA63 under non-denaturing conditions using a variety of column chemistries. None of the chemistries were able to resolve a single defined PA63 peak. In all cases investigated, the PA63 bled slowly off of the columns across the entire elution gradient. We believe this may be due in part to the active nature of PA63, which is designed to self-assemble into heptamers. This activity may be responsible for the formation of multimeric PA63 structures or PA63-yeast protein aggregates in the lysate, which prevents isolation of a single enriched PA63 fraction under non-denaturing conditions.

Therefore, further processing of the lysate was performed under denaturing conditions because the PA63 was not amenable to purification under non-denaturing conditions. Non-ionic denaturants are preferred because ionic denaturants would not be compatible with the chromatography resins employed in subsequent steps. Specifically, the lysate was made 6 M in urea and was applied to a 1 L POROS 50HS column (APPLIED BIOSYSTEMS, Foster City, CA) equilibrated in 6 M urea/20 mM HEPES, pH 7.3 at a flow rate of 35 mL/min using a WATERS 650 Prep system with a Linear UV/VIS detector (WATERS, Milford, MA). Proteins were eluted from the column using a 0-1 M NaCl gradient in 6 M urea/HEPES buffer.

Total protein in column fractions was determined using a commercial bicinchoninic acid (BCA) assay (PIERCE CHEMICAL, Rockford, IL) and SDS-PAGE with Western blotting. The PA63-containing fractions were pooled and concentrated over a 10-kDa tangential flow membrane (PREPSCALE TFF, MILLIPORE, Billerica, MA). The concentrated pool was diluted with 6 M urea-containing 20 mM HEPES buffer and then applied to a 50 mL SOURCE Q (AMERSHAM BIOSCIENCES, Piscataway, NJ) anion exchange column equilibrated in 6 M urea/HEPES and again purified with a 0-1 M NaCl gradient in the presence of 6 M urea. The PA63 containing fractions were pooled and dialyzed extensively against 20 mM HEPES, pH 7.3 containing 0.15 M NaCl and 16 µM CaCl<sub>2</sub>. The product of the Source Q step was >90 % pure PA63 by SDS-PAGE analysis. The pooled product was filtered at 0.2 µm and stored in aliquots at -70° C.

FIG. 17 presents the results of SDS-PAGE analysis by Coomassie staining and Western blotting for the final product and intermediate process retains. Table 2 summarizes the material balance of protein through the process.

Table 2. Material balance and protein recovery at research-scale

Process Retain	Volume (mL)	Protein Concentration ( $\mu\text{g/mL}$ )	Total Protein (mg)
Clarified Lysate	320	13200	4224
50HS Pool	420	1000	420
Source Q Pool (product)	240	589	141

## EXAMPLE 12:

## Immunogenicity of Recombinant PA63

5 An aspect of this invention indicates that the purified yeast recombinant PA63 protein (purified as described in Example 11) can induce in mammals a robust immune response that is cross-reactive to PA83 (the precursor form of PA63). Mice (five per group) were vaccinated on days 0, 7 and 21 with antigens formulated on Merck aluminum adjuvant (MAA), *E. coli* recombinant PA83, or yeast recombinant PA63. One group of mice received MAA alone. Mice were bled on day 29 to measure  
 10 antibody titers to recombinant antigens (Table 3). Titers were measured by coating 96 well plates with 0.1  $\mu\text{g/well}$  of either rPA63 or rPA83. The secondary antibody was goat anti-mouse IgG-HRP (SOUTHERN BIOTECHNOLOGY, Birmingham, AL) used at 1:6000 dilution. The plate was developed with TMB (PIERCE CHEMICALS, Rockford, IL) and read at OD<sub>450</sub>.

15 Table 3. Mouse end point titers to recombinant proteins, GMT of five mice per group

<u>Group</u>	<u>GMT to rPA63</u>	<u>GMT to rPA83</u>
50 $\mu\text{g}$ rPA83	1,350,519	3,103,372
50 $\mu\text{g}$ rPA63	588,128	588,128
20 MAA	<100	<100

Rabbits (ten per group) were vaccinated on days 0, 1 month, 2 months, and 3 months with recombinant yeast PA63 formulated on MAA. One group of rabbits received adjuvant alone, and one group of five rabbits received two 125  $\mu\text{L}$  doses of the currently licensed vaccine Anthrax Vaccine  
 25 Adsorbed (AVA) (BIOPORT CORP., Lansing, MI). All rabbits were bled at 2 weeks post last vaccination to measure antibody titers to recombinant PA83 (Table 4). Titers were measured as described above but the secondary antibody was goat anti-rabbit IgG-HRP (SOUTHERN BIOTECHNOLOGY, Birmingham, AL) used at 1:6000.

Table 4. Rabbit end point titers to recombinant PA83, GMT of ten rabbits per group, except for the AVA group in which there were five rabbits

	<u>Group</u>	<u>GMT to rPA83</u>
5	0.5 $\mu$ g rPA63	166,491
	5.0 $\mu$ g rPA63	455,795
	50 $\mu$ g rPA63	649,507
	AVA	799,882
	MAA	<100

10

Monkeys (three per group) were vaccinated on days 0, 2 months, and 6 months with recombinant yeast PA63 formulated on MAA. One group of monkeys received adjuvant alone, and one group of monkeys received three human doses (500  $\mu$ L) of the currently licensed AVA vaccine. Monkeys were bled at two weeks post dose three to measure antibody titers to recombinant PA83 (Table 5). End point titers were measured as described above except that the secondary antibody was goat anti-monkey IgG-HRP (SOUTHERN BIOTECHNOLOGY, Birmingham, AL) used at 1:5000 dilution.

15

Table 5. Monkey end point titers to recombinant PA83, GMT of three monkeys per group

	<u>Group</u>	<u>GMT to rPA83</u>
20	5 $\mu$ g rPA63	63,496
	50 $\mu$ g rPA63	100,793
	AVA	100,793
	MAA	1,000

25

#### EXAMPLE 13:

Protection against exposure to B. anthracis by yeast recombinant PA63

The immune response induced by the vaccine formulated with recombinant PA63 produced in yeast confers protection against a lethal aerosol exposure of the deadly B. anthracis. Rabbits were vaccinated as described above and exposed to a lethal aerosol challenge of B. anthracis Ames strain. Spores of the B. anthracis Ames strain were grown in Leighton and Doi medium (Leighton, T. J. and Doi, R. H., 1971), purified by centrifugation through 58% HYPAQUE-76 (NYCODED, INC., Princeton, NJ) and resuspended in sterile water containing 1% phenol, and stored at 2-8° C until used. Immediately before aerosol challenge, the spores were diluted in sterile water for injection to 2.2-2.8 X 10<sup>9</sup> CFU/ml and heat-shocked at 60° C for 45 min. After respiratory minute volumes were measured, animals were exposed in a head-only chamber to a spore aerosol generated by a three-jet collision

30

35

nebulizer. For each animal, the concentration of spores in the aerosol inhaled dose (expressed as LD<sub>50</sub>) was determined by plating a sample from an all glass impinger onto tryptic soy agar plates (DIFCO, Detroit, MI). Animals were observed for a period of two weeks and deaths from anthrax recorded (Table 6).

5

Table 6. Rabbit survival data after lethal challenge of *B. anthracis* Ames strain

	<u>Group</u>	<u>% Mortality</u>	<u>Spore Dose (LD<sub>50</sub>)</u>
	0.5 µg rPA63, 10 animals	50	733
10	5 µg rPA63, 9 animals	11	673
	50 µg rPA63, 10 animals	40	611
	AVA, 5 animals	0	591
15	MAA, 10 animals	100	624

Monkeys were vaccinated as described above, and given a booster dose of either 5 µg or 50 µg or MAA alone, and exposed to a lethal aerosol challenge of *B. anthracis* Ames strain, as described above, two weeks after the booster injection. The challenge dose was approximately 1000 LD<sub>50</sub> per animal. Animals were observed for a period of four weeks and deaths from anthrax recorded (Table 7).

20

Table 7. Monkey survival data after lethal challenge of *B. anthracis* Ames strain

	<u>Group (groups of 3)</u>	<u>% Mortality</u>
25	5 µg rPA63	0
	50 µg rPA63	30
	AVA	30
	MAA	100

30

The results from these single monkey and rabbit protection studies indicate that yeast-expressed rPA63 is a very promising candidate for a component of an anthrax vaccine. The data also suggest that rPA63 has the potential to be as effective as AVA, the current vaccine.

## REFERENCES

- 5 Baillie, L. (2001) The development of new vaccines against *Bacillus anthracis*. *J Appl Microbiol*, **91**, 609-13.
- Baillie, L., Moir, A. and Manchee, R. (1998a) The expression of the protective antigen of *Bacillus anthracis* in *Bacillus subtilis*. *J Appl Microbiol*, **84**, 741-6.
- Baillie, L.W., Moore, P. and McBride, B.W. (1998b) A heat-inducible *Bacillus subtilis* bacteriophage phi 105 expression system for the production of the protective antigen of *Bacillus anthracis*. *FEMS Microbiol Lett*, **163**, 43-7.
- 10 Bayne, M.L., Applebaum, J. Chicchi, G.G., Hayes, N.S., Green, B.G., and Cascieri, M.A. (1988) Expression, purification and characterization of recombinant human insulin-like growth factor I in yeast. *Gene*, **66**, 235-244.
- Beauregard, K.E., Collier, R.J. and Swanson, J.A. (2000) Proteolytic activation of receptor-bound 15 anthrax protective antigen on macrophages promotes its internalization. *Cell. Microbiol.* **2**, 251-258.
- Chauhan, V., Singh, A., Waheed, S.M., Singh, S. and Bhatnagar, R. (2001) Constitutive expression of protective antigen gene of *Bacillus anthracis* in *Escherichia coli*. *Biochem Biophys Res Commun*, **283**, 308-15.
- Cohen, S., Mendelson, I., Altboum, Z., Kobiler, D., Elhanany, E., Bino, T., Leitner, M., Inbar, I., 20 Rosenberg, H., Gozes, Y., Barak, R., Fisher, M., Kronman, C., Velan, B. and Shafferman, A. (2000) Attenuated nontoxigenic and nonencapsulated recombinant *Bacillus anthracis* spore vaccines protect against anthrax. *Infect Immun*, **68**, 4549-58.
- Coulson, N.M., Fulop, M. and Titball, R.W. (1994) *Bacillus anthracis* protective antigen, expressed in 25 *Salmonella typhimurium* SL 3261, affords protection against anthrax spore challenge. *Vaccine*, **12**, 1395-401.
- Fellows, P.F., Linscott, M.K., Ivins, B.E., Pitt, M.L., Rossi, C.A., Gibbs, P.H. and Friedlander, A.M. (2001) Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by *Bacillus anthracis* isolates of diverse geographical origin. *Vaccine*, **19**, 3241-7.
- Flick-Smith, H.C., Walker, N.J., Gibson, P., Bullifent, H., Hayward, S., Miller, J., Titball, R.W. and 30 Williamson, E.D. (2002) A recombinant carboxy-terminal domain of the protective antigen of *Bacillus anthracis* protects mice against anthrax infection. *Infect Immun*, **70**, 1653-6.
- Friedlander, A.M. (2000) Anthrax: clinical features, pathogenesis, and potential biological warfare threat. *Curr Clin Top Infect Dis*, **20**, 335-49.
- Gu, M.L., Leppla, S.H. and Klinman, D.M. (1999) Protection against anthrax toxin by vaccination with a 35 DNA plasmid encoding anthrax protective antigen. *Vaccine*, **17**, 340-4.

- Gupta, P., Waheed, S.M. and Bhatnagar, R. (1999) Expression and purification of the recombinant protective antigen of *Bacillus anthracis*. *Protein Expr Purif*, **16**, 369-76.
- Hinnen, A., Hicks, J.B. and Fink, G.R. (1978) Transformation of yeast. *Proc Natl Acad Sci U S A*, **75**, 1929-33.
- 5 Iacono-Connors, L.C., Schmaljohn, C.S. and Dalrymple, J.M. (1990) Expression of the *Bacillus anthracis* protective antigen gene by baculovirus and vaccinia virus recombinants. *Infect Immun*, **58**, 366-72.
- Ibrahim, K.H., Brown, G., Wright, D.H. and Rotschafer, J.C. (1999) *Bacillus anthracis*: medical issues of biologic warfare. *Pharmacotherapy*, **19**, 690-701.
- Ivins, B.E., Pitt, M.L., Fellows, P.F., Farchaus, J.W., Benner, G.E., Waag, D.M., Little, S.F., Anderson, G.W., Jr., Gibbs, P.H. and Friedlander, A.M. (1998) Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. *Vaccine*, **16**, 1141-8.
- 10 Ivins, B.E. and Welkos, S.L. (1986) Cloning and expression of the *Bacillus anthracis* protective antigen gene in *Bacillus subtilis*. *Infect Immun*, **54**, 537-42.
- Lathe. (1985) Synthetic oligonucleotide probes deduced from Amino Acid Sequence Data: Theoretical and Practical Considerations. *J. Molec. Biol.*, **183**, 1-12.
- 15 Leighton, T.J. and Doi, R.H. The stability of messenger ribonucleic acid during sporulation in *Bacillus subtilis*. *J. Biol. Chem.* 1971, 246, 3189-3195.
- Leppa, S.H.(2000) Anthrax Toxin, in: *Bacterial Protein Toxins*, eds. K. Aktories and I. Just, Springer, Berlin, pp. 445-472.
- 20 Leppa, S.H. (1988) Production and purification of anthrax toxin. *Methods Enzymol*, **165**, 103-16.
- Little, S.F. and Ivins, B.E. (1999) Molecular pathogenesis of *Bacillus anthracis* infection. *Microbes Infect*, **1**, 131-9.
- Miller, C.J., Elliott, J.L. and Collier, R.J. (1999) Anthrax protective antigen: prepore-to-pore conversion. *Biochemistry*, **38**, 10432-41.
- 25 Mock, M. and Fouet, A. (2001) Anthrax. *Annu Rev Microbiol*, **55**, 647-71.
- Oura, E. (1974) Effect of aeration intensity on the biochemical composition of baker's yeast. I. Factors affecting the type of metabolism. *Biotechnol. Bioengineer.* **16**, 1197-1212.
- Puziss, M., Wright, G.G. (1962) Gel-adsorbed protective antigen for immunization of man. *J. Bacteriol.*, **85**, 230-236.
- 30 Puziss, M., Manning, L.C. , Lynch, L.W., Barclay, E., Abelow, I. and Wright, G.G. (1963) Large-scale production of protective antigen of *B. anthracis* anaerobic cultures. *Appl. Microbiol.*, **11**, 330-334.
- Reuveny, S., White, M.D., Adar, Y.Y., Kafri, Y., Altboum, Z., Gozes, Y., Kobiler, D., Shafferman, A. and Velan, B. (2001) Search for correlates of protective immunity conferred by anthrax vaccine. *Infect Immun*, **69**, 2888-93.



Roberts, J.E., Watters, J.W., Ballard, J.D. and Dietrich, W.F. (1998) Ltx1, a mouse locus that influences the susceptibility of macrophages to cytolysis caused by intoxication with *Bacillus anthracis* lethal factor, maps to chromosome 11. *Mol Microbiol*, **29**, 581-91.

Sharma, M., Swain, P.K., Chopra, A.P., Chaudhary, V.K. and Singh, Y. (1996) Expression and  
5 purification of anthrax toxin protective antigen from *Escherichia coli*. *Protein Expr Purif*, **7**, 33-8.

Sharp, P.M. and Cowe, E. (1991) Synonymous codon usage in *Saccharomyces cerevisiae*. *Yeast*, **7**, 657-78.

Singh, Y., Klimpel, K.R., Quinn, C.P., Chaudhary, V.K. and Leppla, S.H. (1991) The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity. *J Biol Chem*, **266**,  
10 15493-7.

Turnbull, P.C., Leppla, S.H., Broster, M.G., Quinn, C.P. and Melling, J. (1988) Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. *Med Microbiol Immunol*, **177**, 293-303.

Vitale, G., Pellizzari, R., Recchi, C., Napolitani, G., Mock, M. and Montecucco, C. (1999) Anthrax lethal  
15 factor cleaves the N-terminus of MAPKKS and induces tyrosine/threonine phosphorylation of MAPKS in cultured macrophages. *J Appl Microbiol*, **87**, 288.

Zegers, N.D., Kluter, E., van Der Stap, H., van Dura, E., van Dalen, P., Shaw, M. and Baillie, L. (1999) Expression of the protective antigen of *Bacillus anthracis* by *Lactobacillus casei*: towards the development of an oral vaccine against anthrax. *J Appl Microbiol*, **87**, 309-14.

## WHAT IS CLAIMED IS:

1. A method for the production of recombinant Bacillus anthracis Protective Antigen protein, comprising:

5 a) providing an expression vector including a polynucleotide comprising a nucleotide sequence encoding a Bacillus anthracis Protective Antigen protein, said nucleotide sequence being codon-optimized for expression in yeast,

b) transforming a yeast with the vector,

10 c) fermenting the transformed yeast under conditions appropriate for the expression of the Protective Antigen protein, and

d) isolating the Protective Antigen protein.

2. The method according to Claim 1 wherein the Protective Antigen protein is PA63.

15 3. The method according to Claim 1 wherein the Protective Antigen protein is PA83.

4. The method according to Claim wherein the Protective Antigen protein encompasses a portion of the protein that, upon introduction into a patient, stimulates an immunoprotective response against Bacillus anthracis.

20 5. The method according to Claim 1 wherein the yeast is selected from the group consisting of Pichia pastoris, Hansenula sp., Candidia sp., Saccharomyces cerevisiae, Saccharomyces carlsbergensis and Kluyveromyces lactis.

25 6. The process according to Claim 1 wherein the yeast host comprises at least one genetic alteration selected from the group comprising alterations to prevent proteolysis, improve removal of the secretory leader and to promote proper glycosylation.

30 7. The process according to Claim 2 wherein the PA83 protein is modified to prevent protease cleavage of the PA83 at the cleavage site recognized by furin.

8. A synthetic polynucleotide comprising a sequence encoding a Bacillus anthracis Protective Antigen protein, the amino acid sequence of said Protective Antigen protein maintaining wild-type Protective Antigen protein immunogenicity, wherein said polynucleotide sequence encoding the  
35 Protective Antigen protein is comprised of codons optimal for expression in a yeast host.

9. A polynucleotide according to Claim 8 wherein the protein is selected from the group consisting of a PA63 protein having a wild type amino acid sequence, a PA83 protein having a wild type amino acid sequence and a PA83 protein modified to prevent protease cleavage of the PA83 at the cleavage site recognized by furin and/or other mammalian processing enzymes.

5

10. A polynucleotide according to Claim 8 which is DNA.

11. A polynucleotide according to Claim 8 which comprises a sequence selected from the group consisting of SEQ ID NOs: 49, 51, 55 and 57.

10

12. A yeast expression vector comprising a polynucleotide according to Claim 8.

13. The vector of Claim 12 wherein the polynucleotide is operably associated with at least one regulatory sequence recognized by a yeast host cell.

15

14. The vector according to Claim 13 wherein the regulatory sequences comprise a GAL10 promoter and a yeast transcriptional terminator.

15. The vector according to Claim 13 wherein the regulatory sequences comprise a GAL1 promoter and a yeast transcriptional terminator.

20

16. A yeast host cell harboring a vector according to Claim 12.

17. A yeast host cell harboring a vector according selected from the group consisting of the vectors of Claim 14 and Claim 15.

25

18. A vaccine comprising a recombinant Bacillus anthracis Protective Antigen protein wherein said Protective Antigen protein was produced in yeast by expression of a yeast codon-optimized nucleotide sequence.

30

19. A method of vaccination of a patient against Bacillus anthracis comprising administering of a vaccine of Claim 18 to the patient.

20. The method of Claim 19 wherein the patient is a human.

35

21. The method of Claim 19 wherein the patient is selected from the group consisting of domesticated animals and livestock.

22. The method of Claim 19 wherein the vaccine is administered by injection.


23. The method of Claim 1 wherein the Protective Antigen protein is secreted from the yeast.

24. The method of Claim 1 wherein the Protective Antigen protein is isolated from the cytoplasm of the yeast.

25. The expression vector of Claim 12 wherein a polynucleotide encoding a secretion signal recognized by a yeast is operably linked to the polynucleotide encoding the Protective Antigen protein.

26. A process of isolating the 63 kilodalton form of Protective Antigen from a culture of yeast cells expressing a recombinant PA63 gene comprising,  
disrupting the yeast cells to create a suspension and clarifying the suspension,  
adding a denaturant to the suspension,  
applying the suspension to a column containing a cation exchange resin in a denaturing buffer,  
eluting the PA63 from the cation exchange resin with a salt gradient in the denaturing buffer,  
applying the PA63 to a column containing an anion exchange resin in a denaturing buffer,  
eluting the PA63 from the anion exchange resin with a salt gradient in the denaturing buffer, and  
dialyzing the PA63 to remove the denaturant.

27. The process of Claim 26 wherein the denaturant and denaturing buffer contains a sufficient amount of urea to denature the PA63.



BACPAG  
4235 bp

FIGURE 1A

**Bacterial sequence (PA63)**

agtacaagtgctggacctacggttccagaccgtgacaatgatggaatccctga  
ttcatttagaggtagaaggatatacggttgatgtcaaaaataaaaagaacttttc  
tttcacccatggattttctaataattcatgaaaagaaaggattaaccaaataataa  
tcattctcctgaaaaatggagcacggcttctgatccgtacagtgatttcgaaaa  
ggttacaggacggattgataagaatgtatcaccagaggcaagacaccccccttg  
tggcagcttatccgattgtacatgtagatatggagaatattattctctcaaaa  
aatgaggatcaatccacacagaatactgatagtgaacgagaaacaataagtaa  
aaatacttctacaagtaggacacatactagtgaagtacatggaaatgcagaag  
tgcatgcgctcgttcttttgatattgggtgggagtgatctgcaggatttagtaat  
tcgaattcaagtacggtcgcaattgatcattcactatctcttagcaggggaaag  
aacttgggctgaaacaatgggttttaataaccgctgatacagcaagattaaatg  
ccaatattagatatgtaaatactgggacggctccaatctacaacgtgttacca  
acgacttcgttagtggttaggaaaaaatcaaacactcgcgacaattaaagctaa  
ggaaaaccaattaagtcaaatacttgcacctaataattattatccttctaaaa  
acttggcgccaatcgcattaaatgcacaagacgatttccagttctactccaatt  
acaatgaattacaatcaattttcttgagttagaaaaaacgaaacaattaagatt  
agatacggatcaagtatatgggaatatagcaacatacaattttgaaaatggaa  
gagtgaggggtggatacaggctcgaactggagtgaaagtgttaccgcaaattcaa  
gaaacaactgcacgtatcattttttaatggaaaagatttaaactctggtagaaag  
gcggatagcggcggttaatcctagtgatccattagaaacgactaaaccggata  
tgacattaaaagaagcccttaaaatagcatttgggatttaacgaaccgaatgga  
aacttacaatatcaagggaagacataaccgaaatttgatttttaatttcgatca  
acaaacatctcaaaatatcaagaatcagttagcgggaattaaacgcaactaaca  
tatatactgtattagataaaatcaaattaaatgcaaaaatgaatattttaata  
agagataaacgttttccattatgatagaaataacatagcagttggggcggtatga  
gtcagtagttaaggaggctcatagagaagtaattaatcgtcaacagagggat  
tattgttaaatattgataaggatataagaaaaatattatcaggttatattgta  
gaaattgaagatactgaagggtttaaagaagttataaatgacagatatgatat  
gttgaaatatttctagtttacggcaagatggaaaaacatttatagattttaaaa  
aatataatgataaattaccgttatatataagtaatcccaattataaggtaaat  
gtatatgctgttactaaagaaaacactattattaatcctagtgagaatgggga  
tactagtaccaacgggatcaagaaaattttaatcttttctaaaaaaggctatg  
agatagga

**Translation**

STSAGPTVPDRDNDGIPDSLEVEGYTVDVKNKR'TFLSPWISNIHEKKGLTKYK  
SSPEKWSTASDPYSDFEKVTGRIDKNVSPEARHPLVAAYPIVHVDMENIILSK  
NEDQSTQNTDSETRTISKNTSTSRHTHSEVHGNAEVHASFFDIGGSVSAGFSN  
FIGSNSSTVAIDHSLSLAGERTWAETMGLNTAD'TARLNANIRYVNTGTAPIYN  
VLPTTSLVLGKNQTLATIKAKENQLSQILAPNNYYPSKNLAPIALNAQDDFSS  
TPITMNYNQFLELEKTKQLRLDTDQVYGNIAITYNFENGVRVVDTGSNWSEVLP  
QIQETTARIIFNGKDLNLVERRIAAVNPSDPLE'TTKPDMTLKEALKIAFGFNE  
PNGNLQYQGKDITEFDNFDDQOTSQNIKNQLAELNATNIYTVLDKIKLNAKMN  
ILIRDKRFHYDRNNIAVGADESVVKEAHREVINSSTEGLLLLNIDKDIRKILSG  
YIVEIEDTEGLKEVINDRYDMLNISSLRQDGKTFIDFKKYNDKLPLYISNPNY  
KVNVAVTKENTIINPSENGDTSTNGIKKILIFSKKGYEIG

**FIGURE 1B**

## PA63 Yeast codon optimized

TCCACCTCCGCTGGTCCAACCTGTTCCAGACAGAGACAACGACGGTATTCAGAG  
 CTCCCTTGGAAGTCGAAGGTACACCGTCGACGTCAAGAACAAGAGAACCTTCT  
 TGTCTCCATGGATCTCCAACATTCACGAAAAGAAGGGTTTGACCAAGTACAAG  
 TCTTCCCCAGAAAAGTGGTCTACTGCTTCCGACCCATACTCCGACTTCGAAAA  
 GGTCACCGGTAGAATCGACAAGAAGCTCTCCCCAGAAAGCTAGACACCCATTGG  
 TTGCTGCTTACCCAATTGTCCACGTTGACATGGAAAACATCATTTTGTCCAAG  
 AACGAAGACCAATCCACCCAAAACACGGACTCCGAAACCAGAACTATCTCTAA  
 GAACACCTCCACTTCTAGAACCCACACTTCCGAAGTCCACGGTAACGCTGAAG  
 TTCACGCTTCTTTCTTCGACATTGGTGGTTCCGTCTCTGCTGGTTTCTCCAAC  
 TCCAACCTCCTCCACCGTCGCTATCGACCACTCTTTGTCTTGGCTGGTGAAAG  
 AACTTGGGCTGAAACCATGGGTTTGAACACTGCTGACACCGCTAGATTGAACG  
 CTAACATTAGATACGTCAACACTGGTACCGCTCCAATCTACAACGTCTTGCCA  
 ACCACCTCCTTGGTCTTGGGTAAGAACCACCTTGGCTACTATCAAGGCTAA  
 GGAAAACCAATTGTCCCAAATCTTGGCTCCAAACAACTACTACCCATCCAAGA  
 ACTTGGCTCCAATCGCTTTGAACGCTCAAGACGACTTCTCTCTACTCCAATC  
 ACCATGAACCTACAACCAATTCTTGGAAATTGGAAAAGACTAAGCAATTGCGTTT  
 GGACACCGACCAAGTTTACGGTAACATTGCTACTTACAACCTTCGAAAACGGTA  
 GAGTCAGAGTCGACACCGGTTCCAACCTGGTCTGAAGTCTTGCCACAAATCCAA  
 GAAACCACCGCTAGAATCATCTTCAACGGTAAGGACTTGAACCTTGGTTGAAAG  
 AAGAATTGCTGCTGTCAACCCATCCGACCCATTTGGAAACCACCAAGCCAGACA  
 TGACCTTGAAGGAAGCTTTGAAGATCGCTTTCGGTTTCAACGAACCAACGGT  
 AACTTGCAATACCAAGGTAAGGACATCACCGAATTCGACTTCAACTTCGACCA  
 ACAACCTCTCAAAACATCAAGAACCAATTGGCTGAATTGAACGCTACCAACA  
 TTTACACTGTTTTTGGACAAGATCAAGTTGAACGCCAAGATGAACATCTTGATC  
 AGAGACAAGAGATTCCACTACGACAGAAACAACATTGCTGTCCGGTGCTGACGA  
 ATCCGTTGTCAAGGAAGCCACAGAGAAGTCATCAACTCCTCCACCGAAGGTT  
 TGTGTTGAACATCGACAAGGACATCAGAAAGATCTTGTCCGGTTACATCGTC  
 GAAATTGAAGACACCGAAGGTTTGAAGGAAGTCATCAACGACAGATACGACAT  
 GTTGAACATTTCTCTTTGAGACAAGACGGTAAGACCTTCATCGACTTCAAGA  
 AGTACAACGACAAGTTGCCATTGTACATTTCCAACCCAACTACAAGGTCAAC  
 GTTTACGCTGTCACTAAGGAAAACACCATCATCAACCCATCCGAAAACGGTGA  
 CACTTCCACCAACGGTATCAAGAAGATTTTGATCTTCTCTAAGAAGGGTTACG  
 AAATTGGT

## Translation

STSAGPTVPDRDNDGIPDSLEVEGYTVDVKNKRTFLSPWISNIHEKKGLTKYK  
 SSPEKWSTASDPYSDFEKVTGRIDKNVSPEARHPLVAAYPIVHVDMENIILSK  
 NEDQSTQNTDSETRTISKNTSTSRHTTSEVHGNAEVHASFFDIGGSVSAGFSN  
 SNSSTVAIDHSLSLAGERTWAETMGLNTADTARLNANIRYVNTGTAPIYNVLP  
 TTSLVLGKNQTLATIKAKENQLSQILAPNNYYPSKNLAPIALNAQDDFSSTPI  
 TMNYNQFLELEKTKQLRLDTDQVYGNIAATYNFENGRVRVDTGSNWSEVLPQIQ  
 ETTARIIFNGKDLNLVERRIAAVNPSDPLETTKPDMTLKEALKIAFGFNEPNG  
 NLQYQGDITEFDNFDDQOTSQNIKNQLAELNATNIYTVLDKIKLNAKMNILI  
 RDKRFHYDRNNIAVGADESUVKEAHREVINSSTEGLLLNIDKDIRKILSGYIV  
 EIEDTEGLKEVINDRYDMLNISSLRQDGKTFIDFKKYNDKLPLYISNPYKVN  
 VYAVTKENTIINPSENGDTSTNGIKKILIFSKKGYEIG

FIGURE 2




FIGURE 3A






FIGURE 3B

pGAL110




FIGURE 4

7 / 24




FIGURE 5

8 / 24




FIGURE 6




FIGURE 7

gaagttaaacaggagaaccggttattaaatgaatcagaatcaagttcccaggggttactag  
gatactatTTTTtagtgatttgaatttttcaagcaccatggtgggttacctcttctactacagg  
ggatttatctattcctagttctgagttagaaaatattccatcggaaaaccaatattttcaa  
tctgctatttggtcaggatttatcaaagttaagaagagtgatgaatatacatatttgctactt  
ccgctgataatcatgtaacaatgtgggttagatgaccaagaagtgattaataaagcttctaa  
ttctaacaaaatcagattagaaaaaggaagattatatcaaataaaaattcaatatcaacga  
gaaaatcctactgaaaaaggattggatttcaagttgtactggaccgattctcaaaataaaa  
agaagtgatttcttagtgataacttacaattgccagaattaaaaaCaaaaatcttcgaactc  
aagaaaaaagcgaagtacaagtgcctggacctacggttccagaccgtgacaatgatggaatc  
cctgattcattagaggtagaaggatatacgggttgatgtcaaaaaataaaagaacttttcttt  
caccatggatttctaatattcatgaaaagaaaggattaaccaaatataaatcatctcctga  
aaaatggagcacggcttctgatccgtacagtgatttcgaaaagggttacaggacggattgat  
agaatgtatcaccagaggcaagacaccccccttgtggcagcttatccgattgtacatgtag  
atatggagaatattatttctctcaaaaaatgaggatcaatccacaCagaatactgatagtga  
acgagaacaataagtaaaaaatacttctacaagtaggacacatactagtgaagtacatgga  
aatgcagaagtgcattgcgtcgttctttgatattgggtgggagtgtatctgcaggatttagta  
attcgaattcaagtacggctcgcaattgatcattcactatctcttagcaggggaaagaacttg  
ggctgaaacaatgggttttaaataccgctgatacagcaagattaaatgccaatattagatat  
gtaaatactgggacggctccaatctacaacgtgttaccaacgacttcgttagtgttaggaa  
aaaatcaaacactcgcgacaattaaagctaaggaaaaccaattaagtcaaatacttgcacc  
taataattattatccttctaaaaaacttggcgccaatcgcatataatgcacaagacgatttc  
agttctactccaattacaatgaattacaatcaatttcttgagttagaaaaaacgaaacaat  
taagattagatacggatcaagtatatgggaatatagcaacatacaaatTTTtgaaaatggaag  
agtgaggggtggatacaggctcgaactggagtgaagtgttaccgcaaatcaagaaacaact  
gcacgtatcattttttaatggaaaagatttaaactctggtagaaaggcggatagcggcgggtta  
atcctagtgatccattagaaacgactaaaccggatatgacattaaagaagcccttaaaat  
agcatttggatttaacgaaccgaatggaaacttacaatatcaagggaagacataaccgaa  
tttgatttttaatttcgatcaacaaacatctcaaaatatcaagaatcagtttagcggaaattaa  
acgcaactaacatatatactgtattagataaaatcaaattaaatgcaaaaaat  
gaatatTTTtaataagagataaacgTTTTcattatgatagaaataacatagcagttggggcg  
gatgagtcagtagttaaggaggctcatagagaagtaattaattcgtcaacagagggattat  
tgttaaatattgataaggatataagaaaaatattatcaggttataattgtagaaattgaaga  
tactgaagggttaagaagttataaatgacagatatgatattgtgaatatttctagttta  
cggcaagatggaaaaacatttatagatttttaaaaaatataatgataaattaccgttatata  
taagtaatcccaattataaggtaaatgtatatgctgttactaaagaaaacactattattaa  
tcctagtgagaatggggatactagtagccaacgggatcaagaaaatTTTaatcttttctaaa  
aaaggctatgagatagga

FIGURE 8A

## Translation with Domain 4 underlined

1	EVKQENRLLN	ESESSSQGLL	GYFSDLNFQ	APMVVTSSTT	GDLSIPSSEL
51	ENIPSENQYF	QSAIWSGFIK	VKKSDEYTFA	TSADNHVTMW	VDDQEVINKA
101	SNSNKIRLEK	GRLYQIKIQY	QRENPTKGL	DFKLYWTD SQ	NKKEVISSDN
151	LQLPELKQKS	SNSRKKRSTS	AGPTVPDRDN	DGIPDSLEVE	GYTVDVKNKR
201	TFLSPWISNI	HEKKGLTKYK	SSPEKWSTAS	DPYSDFEKVT	GRIDKNVSPE
251	ARHPLVAAYP	IVHVDMENII	LSKNEDQSTQ	NTDSETRTIS	KNTSTSRTH T
301	SEVHGNAEVH	ASFFDIGGSV	SAGFSNSNSS	TVAIDHSLSL	AGERTWAETM
351	GLNTADTARL	NANIRYVNTG	TAPIYNVLP T	TSLVLGKNQT	LATIKAKENQ
401	LSQILAPNNY	YPSKNLAPIA	LNAQDDFSST	PITMNYNQFL	ELEKTKQLRL
451	DTDQVYGNIA	TYNFENGRVR	VDTGSNWSEV	LPQIQETTAR	IIFNGKDLNL
501	VERRIAAVNP	SDPLETTKPD	MTLKEALKIA	FGFNEPNGNL	QYQGKDITEF
551	DFNFDQQT SQ	NIKNQLAELN	ATNIYTVLDK	IKLNAKMNIL	IRDKRFHYDR
601	NNIAVGADES	VVKEAHREVI	NSSTEGLLLN	IDKDIRKILS	GYIVEIEDTE
651	GLKEVINDRY	DMLNISSLRQ	DGKTFIDFKK	YNDKLPLYIS	NPNYKVN VYA
701	VTKENTIINP	SENGDTSTNG	IKKILIFS KK	GYEIG	

FIGURE 8B

**Domain 4 - Yeast codon optimized DNA sequence without bacterial signal**

ttccactacgacagaaacaacattgctgtcgggtgctgacgaatccgttgt caaggaagccc  
acagagaagtcacatcaactcctccaccgaagggttggtggtgaacatcgac aaggacatcag  
aaagatccttgtccgggttacatcgtcgaaattgaagacaccgaagggttgga aggaagtcac  
aacgacagatacgacatggttgaaacatttcctccttgagacaagacggtaa gaccttcacg  
acttcaagaagtacaacgacaagttgccattgtacattttccaacccaaac tacaagggtcaa  
cgtttacgctgtcactaaggaaaacaccatcatcaacccatccgaaaacggtgacacttcc  
accaacggtatcaagaagattttgatcttctctaagaagggttacgaaat tggt

**Domain 4- Translated protein without signal sequence**

FHYDRNNIAVGADESVVKEAHREVINSSTEGLLLNIDKDIRKILSGYIVEIED  
TEGLKEVINDRYDMLNISSLRQDGKTFIDFKKYNDKLPLYISNPNYKVNRYAV  
TKENTIINPSENGDTSTNGIKKILIFSKKGYEIG



# DNA sequence and amino acid translation product of yeast codon-optimized *B. anthracis* PA83 gene

## DNA sequence

1	GAAGTTAAGC	AAGAAAACAG	ATTGTTGAAC	GAATCTGAAT	CCTCTTCCCA	AGGTTTGTG
	CTTCAATTCTG	TTCTTTTGTG	TAACAACCTG	CTTAGACTTA	GGAGAAGGGT	TCCAAACAAC
61	GGTTACTACT	TCTCCGACTT	GAACCTTCAA	GCTCCAATGG	TCGTCACC TC	CTCTACTACC
	CCAATGATGA	AGAGGCTGAA	CTTGAAGGTT	CGAGGTTACC	AGCAGTGGAG	GAGATGATGG
121	GGTGACTTGT	CCATCCCATC	CTCCGAATTA	GAGAACATCC	CATCCGAAAA	CCAATACTTC
	CCACTGAACA	GGTAGGGTAG	GAGGCTTAAT	CTCTTGTAGG	GTAGGCTTTT	GGTTATGAAG
181	CAATCCGCTA	TCTGGTCCGG	CTTCATCAAG	GTCAAGAAGT	CCGACGAATA	CACCTTCGCT
	GTTAGGCGAT	AGACCAGGCC	GAAGTAGTTC	CAGTTCTTCA	GGCTGCTTAT	GTGAAAGCGA
241	ACCTCCGCTG	ACAACCACGT	TACTATGTGG	GTCGACGACC	AAGAAGTCAT	CAACAAGGCT
	TGGAGGCGAC	TGTTGGTGCA	ATGATACACC	CAGCTGCTGG	TTCTTCAGTA	GTTGTTCCGA
301	TCCAACCTCCA	ACAAGATCAG	ATTGGAAAAAG	GGTAGATTGT	ACCAAATTAA	GATCCAATAC
	AGGTTGAGGT	TGTTCTAGTC	TAACCTTTTC	CCATCTAACA	TGGTTTAATT	CTAGGTTATG
361	CAAAAGAGAA	ACCCAACCGA	AAAGGGTTTG	GACTTCAAGT	TGTAAGTGAC	GCAGTCCCAA
	GTTTCTCTTT	TGGGTTGGCT	TTTCCCAAAAC	CTGAAGTTCA	ACATGACCTG	GCTGAGGGTT
421	AACAAGAAGG	AAGTCATCTC	CTCTGACAAC	TTGCAATTGC	CAGAATTGAA	GCAAAAGTCC
	TTGTTCTTCC	TTCAGTAGAG	GAGACTGTTG	AACGTTAACG	GTCTTAACCT	CGTTTTCAGG
481	TCCAACCTCCA	GAAAGAAGAG	ATCCACCTCC	GCTGGTCCAA	CTGTTCCAGA	CAGAGACAAC
	AGGTTGAGGT	CTTCTTCTTT	CAGGTGGAGG	CGACCAGGTT	GACAAGGTTCT	GTCTCTGTTG
541	GACGGTATTC	CAGACTCCTT	GGAAGTCGAA	GGTTACACCG	TCGACGTCAA	GAACAAGAGA
	CTGCCATAAG	GTCTGAGGAA	CCTTCAGCTT	CCAATGTGGC	AGCTGCAGTT	TTTGTCTCTC
601	ACCTTCTTGT	CTCCATGGAT	CTCCAACATT	CACGAAAAGA	AGGGTTTGAC	CAAGTACAAG
	TGGAAGAACA	GAGGTACCTA	GAGGTTGTAA	GTGCTTTTCT	TCCCAAAC TG	GTTTCATGTT
661	TCTTCCCCAG	AAAAGTGGTC	TACTGCTTCC	GACCCATACT	CCGACTTCGA	AAAGGTCACC
	AGAAGGGGTC	TTTTCACCAG	ATGACGAAGG	CTGGGTATGA	GGCTGAAGCT	TTTCCAGTGG
721	GGTAGAATCG	ACAAGAACGT	CTCCCCAGAA	CTAGACACCC	CATTGGTTGG	CATTATCCCA
	CCATCTTAGC	TGTTCTTGCA	GAGGGGTCTT	CGATCTGTGG	GTAACCAACG	ACGAATGGGT
781	ATTGTCCACG	TTGACATGGA	AAACATCATT	TTGTCCAAGA	ACGAAGACCA	ATCCACCCAA
	TAACAGGTGC	AACTGTACCT	TTTGTAGTAA	AACAGGTTCT	TGCTTCTGGT	TAGGTGGGTT
841	AACACGGACT	CCGAAACCAG	AACATATCTC	AAGAACACCT	CCACTTCTAG	AACCCACACT
	TTGTGCCTGA	GGCTTTGGTC	TTGATAGAGA	TTCTTGTGGA	GGTGAAGATC	TTGGGTGTGA
901	TCCGAAGTCC	ACGGTAACGC	TGAAGTTCAC	GCTTCTTTCT	TCGACATTGG	TGGTTCCGTC
	AGGCTTCAGG	TGCCATTGCG	ACTTCAAGTG	CGAAGAAAAG	AGCTGTAACC	ACCAAGGCAG
961	TCTGCTGGTT	TCTCCAACCT	CAACTCCTCC	ACCGTCGCTA	TCGACCACCT	TTTGTCCCTG
	AGACGACCAG	AGAGGTTGAG	GTTGAGGAGG	TGGCAGCGAT	AGCTGGTGAG	AAACAGGAAC
1021	GCTGGTGAAA	GAAC TTGGGC	TGAAACCATG	GGTTTGAACA	CTGCTGACAC	CGCTAGATTG
	CGACCAC TTT	CTTGAACCCG	ACTTTGGTAC	CCAAACTTGT	GACGACTGTG	GCGATCTAAC
1081	AACGCTAACA	TTAGATACGT	CAACACTGGT	ACCGCTCCAA	TCTACAACGT	CTTGCCAACC
	TTGCGATTGT	AATCTATGCA	GTTGTGACCA	TGGCGAGGTT	AGATGTTGCA	GAACGGTTGG
1141	ACCTCCTTGG	TCTTGGGTAA	GAACCAAACC	TTGGCTACTA	TCAAGGCTAA	GGAAAACCAA
	TGGAGGAACC	AGAACCATT	CTTGGTTTGG	AACCGATGAT	AGTTCCGATT	CCTTTTGGTT
1201	TTGTCCCAAA	TC TTGGCTCC	AAACAAC TAC	TACCCATCCA	AGAACTTGGC	TCCAATCGCT
	AACAGGGTTT	AGAACCGAGG	TTTGTGTGAT	ATGGGTAGGT	TCTTGAACCG	AGGTTAGCGA
1261	TTGAACGCTC	AAGACGACTT	CTCCTCTACT	CCAATCACCA	TGAAC TACAA	CCAATTCTTG
	AACTTGCGAG	TTCTGCTGAA	GAGGAGATGA	GGTTAGTGGT	ACTTGATGTT	GGTTAAGAAC
1321	GAATTGGAAG	AGACTAAGCA	ATTGCGTTTG	GACACCGACC	AAGTTTACGG	TAACATTGCT
	CTTAACCTTT	TCTGATTCGT	TAACGCAAAAC	CTGTGGCTGG	TTCAAATGCC	ATTGTAACGA
1381	ACTTACAAC	TCGAAAACGG	TAGAGTCAGA	GTCGACACCG	GTTCCAAC TG	GTCTGAAGTC
	TGAATGTTGA	AGCTTTTGCC	ATCTCAGTCT	CAGCTGTGGC	CAAGGTTGAC	CAGACTTCAG
1441	TTGCCACAAA	TCCAAGAAAC	CACCGCTAGA	ATCATCTTCA	ACGGTAAGGA	CTTGAAC T TG
	AACGGTGTTT	AGGTTCTTTG	GTGGCGATCT	TAGTAGAAGT	TGCCATTCTT	GAAC TTGAAC
1501	GTTGAAAGAA	GAATTGCTGC	TGTCAACCCA	TCCGACCCAT	TGGAACCCAC	CAAGCCAGAC
	CAACTTTCTT	CTTAACGACG	ACAGTTGGGT	AGGCTGGGTA	ACCTTTGGTG	GTTCCGGTCTG
1561	ATGACCTTGA	AGGAAGCTTT	GAAGATCGCT	TTCCGGTTTCA	ACGAACCAAA	CGGTAAC T TG
	TACTGGAAC	TCCTTCGAAA	CTTCTAGCGA	AAGCCAAAGT	TGCTTGGTTT	GCCATTGAAC

FIGURE 10A – 1

```

1621  CAATACCAAG GTAAGGACAT CACCGAATTC GACTTCAACT TCGACCAACA AACC'TCTCAA
      GTTATGGTTC CATTCCTGTA GTGGCTTAAG CTGAAGTTGA AGCTGGTTGT TTGGAGAGTT
1681  AACATCAAGA ACCAATTGGC TGAATTGAAC GCTACCAACA TTTACTACTGT TTTGGACAAG
      TTGTAGTTCT TGGTTAACCG ACTTAACTTG CGATGGTTGT AAATGTGACA AAACCTGTTC
1741  ATCAAGTTGA ACGCCAAGAT GAACATCTTG ATCAGAGACA AGAGATTCCA CTACGACAGA
      TAGTTCAACT TGCGGTTCTA CTTGTAGAAC TAGTCTCTGT TCTCTAAGGT GATGCTGTCT
1801  AACAACATTG CTGTCGGTGC TGACGAATCC GTTGTCAAGG AAGCCACAG AGAAGTCATC
      TTGTTGTAAAC GACAGCCACG ACTGCTTAGG CAACAGTTCC TTCGGGTGTC TCTTCAGTAG
1861  AACTCCTCCA CCGAAGGTTT GTTGTGAAC ATCGACAAGG ACATCAGAAA GATCTTGTC
      TTGAGGAGGT GGCTTCCAAA CAACAACCTG TAGCTGTTCC TGTAGTCTTT CTAGAACAGG
1921  GGTTACATCG TCGAAATTGA AGACACCGAA GGTTTGAAGG AAGTCATCAA CGACAGATAC
      CCAATGTAGC AGCTTTAACT TCTGTGGCTT CCAAAC'TTCC TTCAGTAGTT GCTGTCTATG
1981  GACATGTTGA ACATTTCTC TTTGAGACAA GACGGTAAGA CCTTCATCGA CTTCAGAAG
      CTGTACAAC'T TGTAAGGAG AAAC'TCTGTT CTGCCATTCT GGAAGTAGCT GAAGTTCTTC
2041  TACAACGACA AGTTGCCATT GTACATTTC AACC'CAAAC ACAAGGTCAA CGTTTACGCT
      ATGTTGCTGT TCAACGGTAA CATGTAAAGG TTGGGTTTGA TGTTCCAGTT GCAAATGCGA
2101  GTCACTAAGG AAAACACCAT CATCAACCCA TCCGAAAACG GTGACACTTC CACC'AACGGT
      CAGTGATTCC TTTTGTGGTA GTAGTTGGGT AGGCTTTTGC CACTGTGAAG GTGGTTGCCA
2161  ATCAAGAAGA TTTTGATCTT CTCTAAGAAG GGTACGAAA TTGGT

```

# Translation of Yeast codon optimized DNA sequence without leader

1	EVKQENRLLN	ESESSSQGLL	GYFSDLNQ	APMVVTSSTT	GDLSIPSSEL
51	ENIPSENQYF	QSAIWSGFIK	VKKSDEYTFA	TSADNHVTMW	VDDQEVINKA
101	SNSNKIRLEK	GRLYQIKIQY	QRENPTKGL	DFKLYWTDQ	NKKEVISSDN
151	LQLPELKQKS	SNSRKKRSTS	AGPTVPDRDN	DGIPDSLEVE	GYTVDVKNKR
201	TFLSPWISNI	HEKKGLTKYK	SSPEKWSTAS	DPYSDFEKVT	GRIDKNVSPE
251	ARHPLVAAYP	IVHVDMENII	LSKNEDQSTQ	NTDSETRTIS	KNTSTSRTHT
301	SEVHGNAEVH	ASFFDIGGSV	SAGFSNSNSS	TVAIDHSLSL	AGERTWAETM
351	GLNTADTARL	NANIRYVNTG	TAPIYNVLPT	TSLVLGKNQT	LATIKAKENQ
401	LSQILAPNNY	YPSKNLAPIA	LNAQDDFSST	PITMNYNQFL	ELEKTKQLRL
451	DTDQVYGNIA	TYNFENGRVR	VDTGSNWSEV	LPQIQETAR	IIFNGKDLNL
501	VERRIAAVNP	SDPLETTKPD	MTLKEALKIA	FGFNEPNGNL	QYQGKDI TEF
551	DFNFDQQTQ	NIKNQLAELN	ATNIYTVLDK	IKLNAKMNIL	IRDKRFHYDR
601	NNIAVGADDES	VVKEAHREVI	NSSTEGLLLN	IDKDIRKILS	GYIVEIEDTE
651	GLKEVINDRY	DMLNISSLRQ	DGKTFIDFKK	YNDKLPLYIS	NPYKVNVA
701	VTKENTIINP	SENGDTSTNG	IKKILIFSCK	GYEIG	

**FIGURE 10B**

DNA sequence and amino acid translation product of yeast codon-optimized B. anthracis PA83 gene with modified furin cleavage site

DNA sequence

1	GAAGTTAAGC	AAGAAAACAG	ATTGTTGAAC	GAATCTGAAT	CCTCTTCCCA	AGGTTTGTGTG
	CTTCAATTCTG	TTCTTTTGTG	TAACAACCTTG	CTTAGACTTA	GGAGAAGGGT	TCCAAACAAC
61	GGTTACTACT	TCTCCGACTT	GAACCTCCAA	GCTCCAATGG	TCGTCACCTC	CTCTACTACC
	CCAATGATGA	AGAGGCTGAA	CTTGAAGGTT	CGAGGTTACC	AGCAGTGGAG	GAGATGATGG
121	GGTGACTTGT	CCATCCCATC	CTCCGAATTA	GAGAACATCC	CATCCGAAAA	CCAATACTTC
	CCACTGAACA	GGTAGGGTAG	GAGGCTTAAT	CTCTTGTAGG	GTAGGCTTTT	GGTTATGAAG
181	CAATCCGCTA	TCTGGTCCGG	CTTCATCAAG	GTCAAGAAGT	CCGACGAATA	CACTTTCGCT
	GTTAGGCGAT	AGACCAGGCC	GAAGTAGTTC	CAGTTCCTCA	GGCTGCTTAT	GTGAAAGCGA
241	ACCTCCGCTG	ACAACCACGT	TACTATGTGG	GTGACGACC	AAGAAGTCAT	CAACAAGGCT
	TGGAGGCGAC	TGTTGGTGCA	ATGATACACC	CAGCTGCTGG	TTCTTCAGTA	GTTGTCCGA
301	TCCAACCTCA	ACAAGATCAG	ATTGGAAAAG	GGTAGATTGT	ACCAAATTAA	GATCCAATAC
	AGGTTGAGGT	TGTTCTAGTC	TAACCTTTTC	CCATCTAACA	TGGTTTAATT	CTAGGTTATG
361	CAAAGAGAAA	ACCCAACCGA	AAAGGGTTTG	GACTTCAAGT	TGTACTGGAC	CGACTCCCAA
	GTTTCTCTTT	TGGGTTGGCT	TTTCCCAAAC	CTGAAGTTCA	ACATGACCTG	GCTGAGGGTT
421	AACAAGAAGG	AAGTCATCTC	CTCTGACAAC	TTGCAATTGC	CAGAATTGAA	GCAAAAGTCC
	TTGTTCTTCC	TTCAGTAGAG	GAGACTGTTG	AACGTTAACG	GTCTTAACCT	CGTTTTCAGG
481	TCCAACCTCA	GAAAGAAGAA	GTCCACCTCC	GCTGGTCCAA	CTGTTCCAGA	CAGAGACAAC
	AGGTTGAGGT	CTTTCTTCTT	CAGGTGGAGG	CGACCAGGTT	GACAAGGTCT	GTCTCTGTGG
541	GACGGTATTC	CAGACTCCTT	GGAAAGTCGAA	GGTTACACCG	TCGACGTCAA	GAACAAGAGA
	CTGCCATAAG	GTCTGAGGAA	CCTTCAGCTT	CCAATGTGGC	AGCTGCAGTT	CTTGTCTCT
601	ACCTTCTTGT	CTCCATGGAT	CTCCAACATT	CACGAAAAGA	AGGGTTTGAC	CAAGTACAAG
	TGGAAGAACA	GAGGTACCTA	GAGGTTGTAA	GTGCTTTTCT	TCCCAAACCTG	GTTTCTGTTT
661	TCTTCCCCAG	AAAAGTGGTC	TACTGCTTCC	GACCCATACT	CCGACTTCGA	AAAGGTCACC
	AGAAGGGGTC	TTTTACACAG	ATGACGAAGG	CTGGGTATGA	GGCTGAAGCT	TTTCCAGTGG
721	GGTAGAATCG	ACAAGAACGT	CTCCCCAGAA	GCTAGACACC	CATTGGTTGC	TGCTTACCCA
	CCATCTTAGC	TGTTCTTGCA	GAGGGGTCCT	CGATCTGTGG	GTAACCAACG	ACGAAATGGGT
781	ATTGTCCACG	TTGACATGGA	AAACATCATT	TTGTCCAAGA	ACGAAGACCA	ATGCCACCAA
	TAACAGGTGC	AACTGTACCT	TTTGTAGTAA	AACAGGTTCT	TGCTTCTGGT	TAGGTGGGTT
841	AACACGGACT	CCGAAACCAG	AACTATCTCT	AAGAACACCT	CCACTTCTAG	AACCCACACT
	TTGTGCCTGA	GGCTTTGGTC	TTGATAGAGA	TTCTTGTGGA	GGTGAAGATC	TTGGGTGTGA
901	TCCGAAGTCC	ACGGTAACGC	TGAAGTTTAC	GCTTCTTTCT	TCGACATTGG	TGGTTCGGTC
	AGGCTTCAGG	TGCCATTGCG	ACTTCAAGTG	CGAAGAAAGA	AGCTGTAACC	ACCAAGGCAG
961	TCTGCTGGTT	TCTCCAACCT	CAACTCCTCC	ACCGTCGCTA	TCGACCACCT	TTTGTCTTTG
	AGACGACCAA	AGAGGTTGAG	GTTGAGGAGG	TGGCAGCGAT	AGCTGGTGAG	AAACAGGAAC
1021	GCTGGTGAAA	GAACCTGGGC	TGAAACCATG	GGTTTGAACA	CTGCTGACAC	CGCTAGATTG
	CGACCACTTT	CTTGAACCCG	ACTTTGGTAC	CCAAACTTGT	GACGACTGTG	GCGATCTAAC
1081	AACGCTAACA	TTAGATACGT	CAACACTGGT	ACCGCTCCAA	TCTACAACGT	CTTGCCAACC
	TTGCGATTGT	AATCTATGCA	GTTGTGACCA	TGGCGAGGTT	AGATGTTGCA	GAACGGTTGG
1141	ACCTCCTTGG	TCTTGGGTAA	GAACCAAACC	TTGGCTACTA	TCAAGGCTAA	GGAAAACCAA
	TGGAGGAACC	AGAACCCATT	CTTGGTTTGG	AACCGATGAT	AGTTCCGATT	CCTTTTGGTT
1201	TTGTCCCAAA	TCTTGGCTCC	AAACAACCTAC	TACCCATCCA	AGAACTTGGC	TCCAATCGCT
	AACAGGGTTT	AGAACCGAGG	TTTGTTGATG	ATGGGTAGGT	TCTTGAACCG	AGGTTAGCGA
1261	TTGAACGCTC	AAGACGACTT	CTCCTCTACT	CCAATCACCA	TGAACACAA	CCAATCTCTG
	AACTTGCGAG	TTCTGCTGAA	GAGGAGATGA	GGTTAGTGGT	ACTTGATGTT	GGTTAAGAAC
1321	GAATTGGAAA	AGACTAAGCA	ATTGCGTTTG	GACACCGACC	AAGTTTACGG	TAAATTTGCT
	CTTAACCTTT	TCTGATTCTG	TAACGCAAAAC	CTGTGGCTGG	TTCAAATGCC	ATTGTAACGA
1381	ACTTACAAC	TCGAAAACGG	TAGAGTCAGA	GTGACACCG	GTTCCAACCTG	GTCTGAAGTC
	TGAATGTTGA	AGCTTTTGCC	ATCTCAGTCT	CAGCTGTGGC	CAAGGTTGAC	CAGACTTCAG
1441	TTGCCACAAA	TCCAAGAAAC	CACCGCTAGA	ATCATCTTCA	ACGGTAAGGA	CTTGAACCTG
	AACGGTGTTT	AGGTTCTTTG	GTGGCGTACT	TAGTAGAAGT	TGCCATTCCCT	GTCTTGAAC
1501	GTTGAAAGAA	GAATTGCTGC	TGTCAACCCA	TCCGACCCAT	TGGAAACCAC	CAAGCCAGAC
	CAACTTTCTT	CTTAACGACG	ACAGTTGGGT	AGGCTGGGTA	ACCTTTGGTG	GTTCCGCTCTG

FIGURE 11A – 1

1561	ATGACCTTGA	AGGAAGCTTT	GAAGATCGCT	TTCGGTTTCA	ACGAACCAAA	CGGTAACTTG
	TACTGGAACT	TCCTTCGAAA	CTTCTAGCGA	AAGCCAAAAGT	TGCTTGGTTT	GCCATTGAAC
1621	CAATACCAAG	GTAAGGACAT	CACCGAATTC	GACTTCAACT	TCGACCAACA	AACCTCTCAA
	GTTATGGTTC	CATTCCCTGTA	GTGGCTTAAG	CTGAAAGTTGA	AGCTGGTTGT	TTGGAGAGTT
1681	AACATCAAGA	ACCAATTGGC	TGAATTGAAC	GCTACCAACA	TTTACACTGT	TTTGGACAAG
	TTGTAGTTCT	TGGTTAACCG	ACTTAACTTG	CGATGGTTGT	AAATGTGACA	AAACCTGTTC
1741	ATCAAGTTGA	ACGCCAAGAT	GAACATCTTG	ATCAGAGACA	AGAGATTCCA	CTACGACAGA
	TAGTTCAACT	TGCGGTTCCTA	CTTGTAGAAC	TAGTCTCTGT	TCTCTAAGGT	GATGCTGTCT
1801	AACAACATTG	CTGTCGGTGC	TGACGAATCC	GTTGTCAAGG	AAGCCCACAG	AGAAGTCATC
	TTGTTGTAAC	GACAGCCACG	ACTGCTTAGG	CAACAGTTCC	TTCGGGTGTC	TCTTCAGTAG
1861	AACTCCTCCA	CCGAAGGTTT	GTTGTTGAAC	ATCGACAAGG	ACATCAGAAA	GATCTTGTC
	TTGAGGAGGT	GGCTTCCAAA	CAACAACCTG	TAGCTGTTCC	TGTAGTCTTT	CTAGAACAGG
1921	GGTTACATCG	TCGAAATTGA	AGACACCGAA	GGTTTGAAGG	AAGTCATCAA	CGACAGATAC
	CCAATGTAGC	AGCTTTAACT	TCTGTGGCTT	CCAAACTTCC	TTCAGTAGTT	GCTGTCTATG
1981	GACATGTTGA	ACATTTCCCTC	TTTGAGACAA	GACGTAAGA	CCTTCATCGA	CTTCAAGAAG
	CTGTACAAC	TGTAAAGGAG	AAACTCTGTT	CTGCCATTCT	GGAAGTAGCT	GAAGTTCTTC
2041	TACAACGACA	AGTTGCCATT	GTACATTTCC	AACCCAAACT	ACAAGGTCAA	CGTTTACGCT
	ATGTTGCTGT	TCAACGGTAA	CATGTAAAGG	TTGGGTTTGA	TGTTCCAGTT	GCAAATGCGA
2101	GTCACTAAGG	AAAACACCAT	CATCAACCCA	TCCGAAAACG	GTGACACTTC	CACCAACGGT
	CAGTGATTCC	TTTTGTGGTA	GTAGTTGGGT	AGGCTTTTGC	CACTGTGAAG	GTGGTTGCCA
2161	ATCAAGAAGA	TTTTGATCTT	CTCTAAGAAG	GGTACGAAA	TTGGT	

FIGURE 11A – 2

## Translated

```

1   EVKQENRLLN  ESESSSQGLL  GYYFSDLNFQ  APMVVTSTTT  GDLSIPSEL
51  ENIPSENQYF  QSAIWSGFIK  VKKSDEYTFA  TSADNHVTMW  VDDQEVINKA
101 SNSNKIRLEK  GRLYQIKIQY  QRENPTKGL  DFKLYWTDSD  NKKEVISSDN
151 LQLPELKQKS  SNSRKKKSTS  AGPTVPDRDN  DGIPDSLEVE  GYTVDVKNKR
201 TFLSPWISNI  HEKKGLTKYK  SSPEKWSTAS  DPYSDFEKVT  GRIDKNVSPE
251 ARHPLVAAYP  IVHVDMENII  LSKNEDQSTQ  NTDSETRTIS  KNTSTSRTHT
301 SEVHGNAEVH  ASFFDIGGSV  SAGFSNSNSS  TVAIDHSLSL  AGERTWAETM
351 GLNTADTARL  NANIRYVNTG  TAPIYNVLP  TSLVLGKNQT  LATIKAKENQ
401 LSQILAPNNY  YPSKNLAPIA  LNAQDDFSST  PITMNYNQFL  ELEKTKQLRL
451 DTDQVYGNIA  TYNFENGVR  VDTGSNWSEV  LPQIQETAR  IIFNGKDLNL
501 VERRIAAVNP  SDPLETTKPD  MTLKEALKIA  FGFNEPNGNL  QYQGKDITEF
551 DFNFDQQTST  NIKNQLAELN  ATNIYTVLDK  IKLNAKMNIL  IRDKRFHYDR
601 NNIAVGADES  VVKEAHREVI  NSSTEGLLLN  IDKDIRKILS  GYIVEIEDTE
651 GLKEVINDRY  DMLNISSLRQ  DGKTFIDFKK  YNDKLPLYIS  NPNYKVNVA
701 VTKENTIINP  SENGDTSTNG  IKKILIFSKK  GYEIG

```

FIGURE 11B




FIGURE 12




FIGURE 13






FIGURE 14




FIGURE 15




FIGURE 16

## A. SDS PAGE Analysis of 50HS Chromatography




FIGURE 17A

## B. SDS PAGE Analysis of Source Q Chromatography




FIGURE 17B

## SEQUENCE LISTING

<110> Merck & Co., Inc.

<120> ANTHRAX VACCINE

<130> PCT 21112Y

<150> 60/470,563

<151> 2003-05-14

<160> 65

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 87

<212> DNA

<213> Bacillus anthracis

<400> 1

gacgtcgacg gtgtaacctt cgacttccaa ggagtctgga ataccgtcgt tgtctctgtc 60  
tggaacagtt ggaccagcgg aggtgga 87

<210> 2

<211> 98

<212> DNA

<213> Bacillus anthracis

<400> 2

ccttggaagt cgaaggttac accgtcgacg tcaagaacaa gagaaccttc ttgtctccat 60  
ggatctccaa cattcacgaa aagaagggtt tgaccaag 98

<210> 3

<211> 101

<212> DNA

<213> Bacillus anthracis

<400> 3

cggtgacctt ttcgaagtcg gagtatgggt cggaagcagt agaccacttt tctggggaag 60  
acttgacttt ggtcaaacc ttcttttcgt gaatgttga g 101

<210> 4

<211> 103

<212> DNA

<213> Bacillus anthracis

<400> 4

ccgacccata ctccgacttc gaaaagggtca ccggtagaat cgacaagaac gtctccccag 60  
aagctagaca cccattgggt gctgcttacc caattgtcca cgt 103

<210> 5

<211> 101

<212> DNA

<213> Bacillus anthracis

<400> 5  
ctgggtttcgg agtccgtggt ttgggtggat tggctctcgt tcttggacaa aatgatgttt 60  
tccatgtcaa cgtggacaat tgggtaagca gcaaccaatg g 101

<210> 6  
<211> 102  
<212> DNA  
<213> Bacillus anthracis

<400> 6  
atccacccaa aacacggact ccgaaaccag aactatctct aagaacacct ccacttctag 60  
aaccacact tccgaagtc acggtaacgc tgaagttcac gc 102

<210> 7  
<211> 101  
<212> DNA  
<213> Bacillus anthracis

<400> 7  
cgatagcgac ggtggaggag ttggagtgg agaaaccagc agagacggaa ccaccaatgt 60  
cgaagaaaga agcgtgaact tcagcgttac cgtggacttc g 101

<210> 8  
<211> 102  
<212> DNA  
<213> Bacillus anthracis

<400> 8  
ctccaactcc aactcctcca ccgtcgctat cgaccactct ttgtccttgg ctggtgaaag 60  
aacttgggct gaaaccatgg gtttgaacac tgctgacacc gc 102

<210> 9  
<211> 101  
<212> DNA  
<213> Bacillus anthracis

<400> 9  
ggaggtggtt ggcaagacgt tgtagattgg agcggtagca gtgttgacgt atctaattgt 60  
agcgttcaat ctacgggtgt cagcagtgtt caaacccatg g 101

<210> 10  
<211> 103  
<212> DNA  
<213> Bacillus anthracis

<400> 10  
ctccaatcta caacgtcttg ccaaccacct ccttggctctt gggtaagaac caaaccttgg 60  
ctactatcaa ggctaaggaa aaccaattgt cccaaatctt ggc 103

<210> 11  
<211> 100  
<212> DNA  
<213> Bacillus anthracis

<400> 11  
ggagaagtcg tcttgagcgt tcaaagcgat tggagccaag ttcttggatg ggtagtagtt 60  
gtttggagcc aagatttggg acaattgggtt ttccttagcc 100

<210> 12  
<211> 105  
<212> DNA  
<213> Bacillus anthracis

<400> 12  
ccaatcgctt tgaacgctca agacgacttc tcctctactc caatcaccat gaactacaac 60  
caattcttgg aattggaaaa gactaagcaa ttgcgtttgg acacc 105

<210> 13  
<211> 100  
<212> DNA  
<213> Bacillus anthracis

<400> 13  
ccggtgtcga ctctgactct accgttttctg aagttgtaag tagcaatgtt accgtaaact 60  
tggtcgggtg ccaaacgcaa ttgcttagtc ttttccaatt 100

<210> 14  
<211> 106  
<212> DNA  
<213> Bacillus anthracis

<400> 14  
cttcgaaaaac ggtagagtca gagtcgacac cggttccaac tgggtctgaag tcttgccaca 60  
aatccaagaa accaccgcta gaatcatctt caacggtaag gacttg 106

<210> 15  
<211> 101  
<212> DNA  
<213> Bacillus anthracis

<400> 15  
gtctggccttg gtggtttcca atggggtcgga tggggtgaca gcagcaattc ttctttcaac 60  
caagttcaag tccttaccgt tgaagatgat tctagcggtg g 101

<210> 16  
<211> 105  
<212> DNA  
<213> Bacillus anthracis

<400> 16  
ccgacccatt ggaaaccacc aagccagaca tgaccttgaa ggaagctttg aagatcgctt 60  
tcggttttcaa cgaaccaaac ggtaacttgc aataccaagg taagg 105

<210> 17  
<211> 99  
<212> DNA  
<213> Bacillus anthracis

<400> 17  
gccaatgggt tcttgatggt ttgagagggt tgttggtcga agttgaagtc gaattcgggtg 60  
atgtccttac ctggtattg caagttaccg tttggttcg 99

<210> 18  
<211> 115  
<212> DNA  
<213> Bacillus anthracis

<400> 18  
ccaacaaacc tctcaaaaca tcaagaacca attggctgaa ttgaacgcta ccaacattta 60  
cactgttttg gacaagatca agttgaacgc caagatgaac atcttgatca gagac 115

<210> 19  
<211> 104  
<212> DNA  
<213> Bacillus anthracis

<400> 19  
gggcttcctt gacaacggat tcgtcagcac cgacagcaat gttgtttctg tcgtagtgga 60  
atctctgtgc tctgatcaag atgttcatct tggcgttcaa ctg 104

<210> 20  
<211> 104  
<212> DNA  
<213> Bacillus anthracis

<400> 20  
gctgacgaat ccgttgtcaa ggaagccac agagaagtca tcaactcctc caccgaaggt 60  
ttgttgttga acatcgacaa ggacatcaga aagatcttgt ccgg 104

<210> 21  
<211> 111  
<212> DNA  
<213> Bacillus anthracis

<400> 21  
gaggaaatgt tcaacatgtc gtatctgtcg ttgatgactt ctttcaaacc ttcgggtgtct 60  
tcaatttcga cgatgtaacc ggacaagatc tttctgatgt cttgtcgat g 111

<210> 22  
<211> 95  
<212> DNA  
<213> Bacillus anthracis

<400> 22  
gtcatcaacg acagatacga catgttgaac atttcctctt tgagacaaga cggtaaagacc 60  
ttcatcgact tcaagaagta caacgacaag ttgcc 95

<210> 23  
<211> 109  
<212> DNA  
<213> Bacillus anthracis



<400> 23  
gggttgatga tgggtgttttc cttagtgaca gcgtaaacgt tgaccttgta gtttggggtg 60  
gaaatgtaca atggcaactt gtcgttgtag ttcttgaagt cgatgaagg 109

<210> 24  
<211> 109  
<212> DNA  
<213> Bacillus Anthracis

<400> 24  
cgctgtcact aaggaaaaca ccatacatcaa cccatccgaa aacggtgaca cttccaccaa 60  
cggatcaag aagattttga tcttctctaa gaagggttac gaaattggt 109

<210> 25  
<211> 39  
<212> DNA  
<213> Bacillus anthracis

<400> 25  
cgcggtatcct taaccaattt cgtaaccctt cttagagaa 39

<210> 26  
<211> 28  
<212> DNA  
<213> Bacillus anthracis

<400> 26  
gtcacggatc ctgtcttttg ataagaga 28

<210> 27  
<211> 7  
<212> PRT  
<213> Bacillus anthracis

<400> 27  
Ile Leu Ser Leu Asp Lys Arg  
1 5

<210> 28  
<211> 49  
<212> DNA  
<213> Bacillus anthracis

<400> 28  
cgcggtatccc acaaaacaaa atgtccacct ccgctgggtcc aactgttcc 49

<210> 29  
<211> 39  
<212> DNA  
<213> Bacillus anthracis

<400> 29  
cgcggtatcct taaccaattt cgtaaccctt cttagagaa 39

<210> 30  
 <211> 7  
 <212> PRT  
 <213> Bacillus anthracis  
  
 <400> 30  
 Ile Leu Ser Leu Asp Lys Arg  
 1 5  
  
 <210> 31  
 <211> 52  
 <212> DNA  
 <213> Baccillus anthracis  
  
 <400> 31  
 gtcacggatc ctgtctttgg ataagagatt ccactacgac agaaacaaca tt 52  
  
 <210> 32  
 <211> 39  
 <212> DNA  
 <213> Bacillus anthracis  
  
 <400> 32  
 cgcggtatcct taaccaatct cgtaaccctt cttagagaa 39  
  
 <210> 33  
 <211> 4  
 <212> PRT  
 <213> Bacillus anthracis  
  
 <400> 33  
 Arg Lys Lys Lys  
 1  
  
 <210> 34  
 <211> 4  
 <212> PRT  
 <213> Bacillus anthracis  
  
 <400> 34  
 Arg Lys Lys Arg  
 1  
  
 <210> 35  
 <211> 108  
 <212> DNA  
 <213> Bacillus anthracis  
  
 <400> 35  
 gaagttaagc aagaaaacag attgttgaac gaatctgaat cctcttccca aggtttgttg 60  
 ggttactact tctccgactt gaacttccaa gtcctaatgg tcgtcacc 108  
  
 <210> 36  
 <211> 93  
 <212> DNA

<213> Bacillus anthracis

<400> 36

cggatgggat gttcttctaatt tcggaggatg ggatggacaa gtcaccggta gtagaggagg 60  
tgacgaccat tggagcttgg aagttcaagt cgg 93

<210> 37

<211> 93

<212> DNA

<213> Bacillus anthracis

<400> 37

tcccatcctc cgaattagag aacatcccat ccgaaaacca atacttccaa tccgctatct 60  
ggtccggctt catcaaggtc aagaagtccg acg 93

<210> 38

<211> 107

<212> DNA

<213> Bacillus anthracis

<400> 38

ggaagccttg ttgatgactt cttgggtcgtc gaccacata gtaacgtggg tgtcagcgga 60  
ggtagcgaaa gtgtattcgt cggacttctt gaccttgatg aagccgg 107

<210> 39

<211> 111

<212> DNA

<213> Bacillus anthracis

<400> 39

gggtcgacga ccaagaagtc atcaacaagg cttccaactc caacaagatc agattggaaa 60  
agggtagatt gtaccaaatt aagatccaat accaaagaga aaaccaacc g 111

<210> 40

<211> 99

<212> DNA

<213> Bacillus anthracis

<400> 40

gagatgactt ctttcttgtt ttgggagtcg gtccagtaca acttgaagtc caaacctttt 60  
tcggttgggt tttctctttg gtattggatc ttaatttgg 99

<210> 41

<211> 109

<212> DNA

<213> Bacillus anthracis

<400> 41

ggaccgactc ccaaaacaag aaggaagtca tctcytctga caacttgcaa ttgccagaat 60  
tgaagcaaaa gtcytcacac tccagaaaga agaagtccac ctccgctgg 109

<210> 42

<211> 107

<212> DNA

<213> Bacillus anthracis

<400> 42

gacgtcgacg gtgtaacctt cgacttccaa ggagtctgga ataccgtcgt tgtctctgtc 60  
tggaacagtt ggaccagcgg aggtggactt cttctttctg gagttgg 107

<210> 43

<211> 98

<212> DNA

<213> Bacillus anthracis

<400> 43

ccttggaagt cgaaggttac accgtcgacg tcaagaacaa gagaaccttc ttgtctccat 60  
ggatctccaa cattcacgaa aagaagggtt tgaccaag 98

<210> 44

<211> 101

<212> DNA

<213> Bacillus anthracis

<400> 44

cggtgacctt ttcgaagtcg gagtatgggt cggaagcagt agaccacttt tctggggaag 60  
acttgacttt ggtcaaacc ttcttttctg gaatgttggg g 101

<210> 45

<211> 103

<212> DNA

<213> Bacillus anthracis

<400> 45

ccgacccata ctccgacttc gaaaagggtca ccggtagaat cgacaagaac gtctccccag 60  
aagctagaca cccattgggt gctgcttacc caattgtcca cgt 103

<210> 46

<211> 101

<212> DNA

<213> Bacillus anthracis

<400> 46

ctggtttctcg agtccgtggt ttgggtggat tgggtcttcgt tcttggacaa aatgatgttt 60  
tccatgtcaa cgtggacaat tgggtaagca gcaaccaatg g 101

<210> 47

<211> 1704

<212> DNA

<213> Bacillus anthracis

<400> 47

agtacaagtg ctggacctac ggttccagac cgtgacaatg atggaatccc tgattcatta 60  
gaggtagaag gatatacggg tgatgtcaaa aataaaagaa cttttctttc accatggatt 120  
tctaataattc atgaaaagaa aggattaacc aaatataaat catctcctga aaaatggagc 180  
acggcttctg atccgtacag tgatttcgaa aagggttacag gacggattga taagaatgta 240  
tcaccagagg caagacaccc ccttgtggca gcttatccga ttgtacatgt agatatggag 300  
aatattattc tctcaaaaaa tgaggatcaa tccacacaga atactgatag tgaaacgaga 360  
acaataagta aaaatacttc tacaagtagg acacatacta gtgaagtaca tggaaatgca 420

```

gaagtgcattg cgctcgttctt tgatatttggg gggagtgtat ctgcaggatt tagtaattcgc 480
aattcaagta cggtcgcaat tgatcattca ctatctcttag caggggaaag aacttgggct 540
gaaacaatgg gtttaaatac cgctgataca gcaagattaa atgccaatat tagatatgta 600
aatactggga cggctccaat ctacaacgtg ttaccaacga cttcgttagt gttaggaaaa 660
aatcaaacac tcgcgacaat taaagctaag gaaaaccaat taagtcaaata acttgcacct 720
aataattatt atccttctaa aaacttggcg ccaatcgcat taaatgcaca agacgatttc 780
agttctactc caattacaat gaattacaat caatttcttg agttagaaaa aacgaaacaa 840
ttaagattag atacggatca agtatatggg aatatagcaa catacaattt tgaaaatgga 900
agagtgaggg tggatacagg ctcgaaactgg agtgaagtgt taccgcaaat tcaagaaaca 960
actgcacgta tcatttttaa tggaaaagat ttaaatctgg tagaaaggcg gatagcggcg 1020
gttaatccta gtgatccatt agaaacgact aaaccggata tgacattaaa agaagccctt 1080
aaaatagcat ttggatttaa cgaaccgaat ggaaacttac aatatcaagg gaaagacata 1140
accgaatttg attttaattt cgatcaacaa acatctcaaa atatcaagaa tcagtttagcg 1200
gaattaaacg caactaacat atatactgta ttagataaaa tcaaattaaa tgcaaaaatg 1260
aatattttta taagagataa acgttttcat tatgatagaa ataacatagc agttggggcg 1320
gatgagtcag tagttaagga ggctcataga gaagtaatta attcgtcaac agagggatta 1380
ttgttaaata ttgataagga tataagaaaa atattatcag gttatattgt agaaattgaa 1440
gatactgaag ggcttaaaga agttataaat gacagatatg atatgttgaa tatttctagt 1500
ttacggcaag atggaaaaac attttagatg tttaaaaaat ataatagataa attaccgtta 1560
tatataagta atcccaatta taaggtaaat gtatatgctg ttactaaaga aaacactatt 1620
attaatccta gtgagaatgg ggatactagt accaacggga tcaagaaaat tttaatcttt 1680
tctaaaaaag gctatgatag agga 1704

```

&lt;210&gt; 48

&lt;211&gt; 571

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 48

```

Ser Thr Ser Ala Gly Pro Thr Val Pro Asp Arg Asp Asn Asp Gly Ile
1      5      10      15
Pro Asp Ser Leu Glu Val Glu Gly Tyr Thr Val Asp Val Lys Asn Lys
20     25     30
Arg Thr Phe Leu Ser Pro Trp Ile Ser Asn Ile His Glu Lys Lys Gly
35     40     45
Leu Thr Lys Tyr Lys Ser Ser Pro Glu Lys Trp Ser Thr Ala Ser Asp
50     55     60
Pro Tyr Ser Asp Phe Glu Lys Val Thr Gly Arg Ile Asp Lys Asn Val
65     70     75     80
Ser Pro Glu Ala Arg His Pro Leu Val Ala Ala Tyr Pro Ile Val His
85     90     95
Val Asp Met Glu Asn Ile Ile Leu Ser Lys Asn Glu Asp Gln Ser Thr
100    105    110
Gln Asn Thr Asp Ser Glu Thr Arg Thr Ile Ser Lys Asn Thr Ser Thr
115    120    125
Ser Arg Thr His Thr Ser Glu Val His Gly Asn Ala Glu Val His Ala
130    135    140
Ser Phe Phe Asp Ile Gly Gly Ser Val Ser Ala Gly Phe Ser Asn Phe
145    150    155    160
Ile Gly Ser Asn Ser Ser Thr Val Ala Ile Asp His Ser Leu Ser Leu
165    170    175
Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu Asn Thr Ala Asp
180    185    190
Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn Thr Gly Thr Ala
195    200    205

```

Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val Leu Gly Lys Asn  
 210 215 220  
 Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln Leu Ser Gln Ile  
 225 230 235 240  
 Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu Ala Pro Ile Ala  
 245 250 255  
 Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile Thr Met Asn Tyr  
 260 265 270  
 Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu Arg Leu Asp Thr  
 275 280 285  
 Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe Glu Asn Gly Arg  
 290 295 300  
 Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val Leu Pro Gln Ile  
 305 310 315 320  
 Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys Asp Leu Asn Leu  
 325 330 335  
 Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp Pro Leu Glu Thr  
 340 345 350  
 Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys Ile Ala Phe Gly  
 355 360 365  
 Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly Lys Asp Ile Thr  
 370 375 380  
 Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln Asn Ile Lys Asn  
 385 390 395 400  
 Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr Val Leu Asp Lys  
 405 410 415  
 Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg Asp Lys Arg Phe  
 420 425 430  
 His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val Val  
 435 440 445  
 Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu Leu  
 450 455 460  
 Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile Val  
 465 470 475 480  
 Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg Tyr  
 485 490 495  
 Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe Ile  
 500 505 510  
 Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro  
 515 520 525  
 Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile Ile  
 530 535 540  
 Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys Ile  
 545 550 555 560  
 Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly  
 565 570

<210> 49  
 <211> 1704  
 <212> DNA  
 <213> Bacillus anthracis

<400> 49  
 tccacctccg ctggtccaac tgttccagac agagacaacg acggtattcc agactccttg 60  
 gaagtcgaag gttacaccgt cgacgtcaag aacaagagaa ccttcttgtc tccatggatc 120

```

tccaacattc acgaaaagaa gggtttgacc aagtacaagt cttccccaga aaagtgggtct 180
actgcttccg acccatactc cgacttcgaa aagggtcaccg gtagaatcga caagaacgtc 240
tccccagaag ctagacaccc attgggttgct gcttacccaa ttgtccacgt tgacatggaa 300
aacatcattt tgtccaagaa cgaagaccaa tccacccaaa acacggactc cgaaaccaga 360
actatctcta agaacacctc cactttctaga acccacactt ccgaagtcca cggtaacgct 420
gaagttcacg cttcttttctt cgacattggg ggttccgtct ctgctgggtt ctccaactcc 480
aactcctcca ccgtcgtat cgaccactct ttgtccttgg ctgggtgaaag aacttgggct 540
gaaaccatgg gtttgaacac tgctgacacc gctagattga acgctaacat tagatacgtc 600
aacactggta ccgtcctaat ctacaacgct ttgccaacca cctccttggg cttgggtaag 660
aaccaaacct tggctactat caaggctaag gaaaaccaat tgtcccaaat cttgggtcca 720
aacaactact acccatccaa gaacttgggt ccaatcgctt tgaacgctca agacgacttc 780
tcctctactc caatcaccat gaactacaac caattcttgg aattggaaaa gactaagcaa 840
ttgcgtttgg acaccgacca agtttacggg aacattgcta cttacaactt cgaaaacggg 900
agagtcagag tcgacaccgg ttccaactgg tctgaagtct tgccacaaat ccaagaaacc 960
accgctagaa tcatcttcaa cggttaaggac ttgaacttgg ttgaaagaag aattgctgct 1020
gtcaacccat ccgaccatt ggaaaccacc aagccagaca tgaccttgaa ggaagctttg 1080
aagatcgctt tcggtttcaa cgaaccaaac ggtaacttgc aataccaagg taaggacatc 1140
accgaattcg acttcaactt cgaccaacaa acctctcaaa acatcaagaa ccaattgggt 1200
gaattgaacg ctaccaacat ttacactgtt ttggacaaga tcaagttgaa cgccaagatg 1260
aacatcttga tcagagacaa gagattccac tacgacagaa acaacattgc tgtcgggtgct 1320
gacgaatccg ttgtcaagga agcccacaga gaagtcacat actcctccac cgaaggtttg 1380
ttgttgaaca tcgacaagga catcagaaag atcttgtccg gttacatcgt cgaaattgaa 1440
gacaccgaag gtttgaagga agtcatcaac gacagatacg acatgttgaa catttcctct 1500
ttgagacaag acggttaagac cttcatcgac ttcaagaagt acaacgacaa gttgccattg 1560
tacatttcca acccaaacta caaggtcaac gtttacgctg tcactaagga aaacaccatc 1620
atcaacccat ccgaaaacgg tgacacttcc accaacggta tcaagaagat tttgatcttc 1680
tctaagaagg gttacgaaat tggt 1704

```

&lt;210&gt; 50

&lt;211&gt; 568

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 50

```

Ser Thr Ser Ala Gly Pro Thr Val Pro Asp Arg Asp Asn Asp Gly Ile
1          5          10          15
Pro Asp Ser Leu Glu Val Glu Gly Tyr Thr Val Asp Val Lys Asn Lys
20          25          30
Arg Thr Phe Leu Ser Pro Trp Ile Ser Asn Ile His Glu Lys Lys Gly
35          40          45
Leu Thr Lys Tyr Lys Ser Ser Pro Glu Lys Trp Ser Thr Ala Ser Asp
50          55          60
Pro Tyr Ser Asp Phe Glu Lys Val Thr Gly Arg Ile Asp Lys Asn Val
65          70          75          80
Ser Pro Glu Ala Arg His Pro Leu Val Ala Ala Tyr Pro Ile Val His
85          90          95
Val Asp Met Glu Asn Ile Ile Leu Ser Lys Asn Glu Asp Gln Ser Thr
100         105         110
Gln Asn Thr Asp Ser Glu Thr Arg Thr Ile Ser Lys Asn Thr Ser Thr
115         120         125
Ser Arg Thr His Thr Ser Glu Val His Gly Asn Ala Glu Val His Ala
130         135         140
Ser Phe Phe Asp Ile Gly Gly Ser Val Ser Ala Gly Phe Ser Asn Ser
145         150         155         160

```

```

Asn Ser Ser Thr Val Ala Ile Asp His Ser Leu Ser Leu Ala Gly Glu
      165      170      175
Arg Thr Trp Ala Glu Thr Met Gly Leu Asn Thr Ala Asp Thr Ala Arg
      180      185      190
Leu Asn Ala Asn Ile Arg Tyr Val Asn Thr Gly Thr Ala Pro Ile Tyr
      195      200      205
Asn Val Leu Pro Thr Thr Ser Leu Val Leu Gly Lys Asn Gln Thr Leu
      210      215      220
Ala Thr Ile Lys Ala Lys Glu Asn Gln Leu Ser Gln Ile Leu Ala Pro
      225      230      235      240
Asn Asn Tyr Tyr Pro Ser Lys Asn Leu Ala Pro Ile Ala Leu Asn Ala
      245      250      255
Gln Asp Asp Phe Ser Ser Thr Pro Ile Thr Met Asn Tyr Asn Gln Phe
      260      265      270
Leu Glu Leu Glu Lys Thr Lys Gln Leu Arg Leu Asp Thr Asp Gln Val
      275      280      285
Tyr Gly Asn Ile Ala Thr Tyr Asn Phe Glu Asn Gly Arg Val Arg Val
      290      295      300
Asp Thr Gly Ser Asn Trp Ser Glu Val Leu Pro Gln Ile Gln Glu Thr
      305      310      315      320
Thr Ala Arg Ile Ile Phe Asn Gly Lys Asp Leu Asn Leu Val Glu Arg
      325      330      335
Arg Ile Ala Ala Val Asn Pro Ser Asp Pro Leu Glu Thr Thr Lys Pro
      340      345      350
Asp Met Thr Leu Lys Glu Ala Leu Lys Ile Ala Phe Gly Phe Asn Glu
      355      360      365
Pro Asn Gly Asn Leu Gln Tyr Gln Gly Lys Asp Ile Thr Glu Phe Asp
      370      375      380
Phe Asn Phe Asp Gln Gln Thr Ser Gln Asn Ile Lys Asn Gln Leu Ala
      385      390      395      400
Glu Leu Asn Ala Thr Asn Ile Tyr Thr Val Leu Asp Lys Ile Lys Leu
      405      410      415
Asn Ala Lys Met Asn Ile Leu Ile Arg Asp Lys Arg Phe His Tyr Asp
      420      425      430
Arg Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val Val Lys Glu Ala
      435      440      445
His Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu Leu Leu Asn Ile
      450      455      460
Asp Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile Val Glu Ile Glu
      465      470      475      480
Asp Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg Tyr Asp Met Leu
      485      490      495
Asn Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe Ile Asp Phe Lys
      500      505      510
Lys Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro Asn Tyr Lys
      515      520      525
Val Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile Ile Asn Pro Ser
      530      535      540
Glu Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys Ile Leu Ile Phe
      545      550      555      560
Ser Lys Lys Gly Tyr Glu Ile Gly
      565

```

&lt;210&gt; 51

&lt;211&gt; 420



&lt;212&gt; DNA

<213> *Bacillus anthracis*

&lt;400&gt; 51

```

ttccactacg acagaaacaa cattgctgtc ggtgctgacg aatccgttgt caaggaagcc 60
cacagagaag tcatcaactc ctccaccgaa ggtttgttgt tgaacatcga caaggacatc 120
agaaagatct tgtccggtta catcgtcgaa attgaagaca ccgaagggtt gaaggaagtc 180
atcaacgaca gatacgacat gttgaacatt tcctctttga gacaagacgg taagaccttc 240
atcgacttca agaagtacaa cgacaagttg ccattgtaca tttccaaccc aaactacaag 300
gtcaacgttt acgctgtcac taaggaaaac accatcatca acccatccga aaacggtgac 360
acttccacca acggtatcaa gaagattttg atcttctcta agaagggtta cgaaattggt 420

```

&lt;210&gt; 52

&lt;211&gt; 140

&lt;212&gt; PRT

<213> *Bacillus anthracis*

&lt;400&gt; 52

```

Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val
 1              5              10              15
Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu
      20              25              30
Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile
      35              40              45
Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg
      50              55              60
Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe
      65              70              75              80
Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn
      85              90              95
Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile
      100             105             110
Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys
      115             120             125
Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly
      130             135             140

```

&lt;210&gt; 53

&lt;211&gt; 2205

&lt;212&gt; DNA

<213> *Bacillus anthracis*

&lt;400&gt; 53

```

gaagttaaac aggagaaccg gttattaaat gaatcagaat caagttccca ggggttacta 60
ggatactatt ttagtgattt gaattttcaa gcacccatgg tggttacctc ttctactaca 120
ggggatttat ctattcctag ttctgagtta gaaaatattc catcgaaaaa ccaatatattt 180
caatctgcta tttggtcagg atttatcaaaa gttaagaaga gtgatgaata tacatttgct 240
acttccgctg ataatcatgt aacaatgtgg gtagatgacc aagaagtgat taataaagct 300
tctaattcta acaaaatcag attagaaaaa ggaagattat atcaaataaa aattcaatat 360
caacgagaaa atcctactga aaaaggattg gatttcaagt tgtactggac cgattctcaa 420
aataaaaaag aagtgatttc tagtgataac ttacaattgc cagaattaaa acaaaaatct 480
tcgaactcaa gaaaaaagcg aagtacaagt gctggaccta cggttccaga ccgtgacaat 540
gatggaatcc ctgattcatt agaggtagaa ggatatacgg ttgatgtcaa aaataaaaga 600
acttttcttt caccatggat ttctaataat catgaaaaga aaggattaac caaatataaa 660

```

```

tcattctcctg aaaaatggag caccgcttct gatccgtaca gtgatttcga aaagggttaca 720
ggacggattg ataagaatgt atcaccagag gcaagacacc cccttggtgc agcttatccg 780
attgtacatg tagatatgga gaattattatt ctctcaaaaa atgaggatca atccacacag 840
aatactgata gtgaaacgag aacaataagt aaaaataactt ctacaagtag gacacatact 900
agtgaagtac atggaaatgc agaagtgcac gcgtcgttct ttgatattgg tgggagtgta 960
tctgcaggat ttagtaattc gaattcaagt acggtcgcaa ttgatcattc actatctcta 1020
gcaggggaaa gaacttgggc tgaaacaatg ggtttaaata ccgctgatac agcaagatta 1080
aatgccaaata ttagatatgt aaatactggg acggctccaa tctacaacgt gttaccaacg 1140
acttcgttag tgttaggaaa aaatcaaaca ctgcgcgaca ttaaagctaa ggaaaaccaa 1200
ttaagtcaaa tacttgcacc taataattat tatecttcta aaaacttggc gccaatcgca 1260
ttaaatgcac aagacgattt cagttctact ccaattacaa tgaattacaa tcaatttctt 1320
gagttagaaa aaacgaaaca attaagatta gatcaggatc aagtatatgg gaatatagca 1380
acatacaatt ttgaaaatgg aagagtggag gtggatacag gctcgaactg gagtgaagtg 1440
ttaccgcaaa ttcaagaaac aactgcacgt atcattttta atggaaaaga tttaaatctg 1500
gtagaaaggc ggatagcggc ggttaatcct agtgatccat tagaaacgac taaaccggat 1560
atgacattaa aagaagccct taaaatagca tttggattta acgaaccgaa tggaaactta 1620
caatatcaag ggaaagacat aaccgaattt gatttttaatt tcgatcaaca aacatctcaa 1680
aatatcaaga atcagttagc ggaattaaac gcaactaaca tatatactgt attagataaa 1740
atcaaattaa atgcaaaaat gaataatttt ataagagata aacgttttca ttatgataga 1800
aataacatag cagttggggc ggatgagtc gtagttaagg aggtcatag agaagtaatt 1860
aattcgtcaa cagagggatt attgttaaatt attgataagg atataagaaa aatattatca 1920
ggttatattg tagaaattga agatactgaa gggcttaaaag aagttataaa tgacagatat 1980
gatatgttga atatttctag ttacggtcaa gatggaaaaa catttataga ttttaaaaaa 2040
tataatgata aattaccgtt atatataagt aatcccaatt ataaggtaaa tgtatatgct 2100
gttactaaag aaaacactat tattaatcct agtgagaatg gggatactag taccaacggg 2160
atcaagaaaa ttttaattct ttctaaaaaa ggctatgaga tagga 2205

```

&lt;210&gt; 54

&lt;211&gt; 735

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 54

```

Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
1          5          10          15
Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
20          25          30
Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
35          40          45
Glu Leu Glu Asn Ile Pro Ser Glu Asn Gln Tyr Phe Gln Ser Ala Ile
50          55          60
Trp Ser Gly Phe Ile Lys Val Lys Lys Ser Asp Glu Tyr Thr Phe Ala
65          70          75          80
Thr Ser Ala Asp Asn His Val Thr Met Trp Val Asp Asp Gln Glu Val
85          90          95
Ile Asn Lys Ala Ser Asn Ser Asn Lys Ile Arg Leu Glu Lys Gly Arg
100          105          110
Leu Tyr Gln Ile Lys Ile Gln Tyr Gln Arg Glu Asn Pro Thr Glu Lys
115          120          125
Gly Leu Asp Phe Lys Leu Tyr Trp Thr Asp Ser Gln Asn Lys Lys Glu
130          135          140
Val Ile Ser Ser Asp Asn Leu Gln Leu Pro Glu Leu Lys Gln Lys Ser
145          150          155          160
Ser Asn Ser Arg Lys Lys Arg Ser Thr Ser Ala Gly Pro Thr Val Pro
165          170          175

```

Asp	Arg	Asp	Asn	Asp	Gly	Ile	Pro	Asp	Ser	Leu	Glu	Val	Glu	Gly	Tyr	
			180					185					190			
Thr	Val	Asp	Val	Lys	Asn	Lys	Arg	Thr	Phe	Leu	Ser	Pro	Trp	Ile	Ser	
		195					200					205				
Asn	Ile	His	Glu	Lys	Lys	Gly	Leu	Thr	Lys	Tyr	Lys	Ser	Ser	Pro	Glu	
	210					215					220					
Lys	Trp	Ser	Thr	Ala	Ser	Asp	Pro	Tyr	Ser	Asp	Phe	Glu	Lys	Val	Thr	
225					230					235					240	
Gly	Arg	Ile	Asp	Lys	Asn	Val	Ser	Pro	Glu	Ala	Arg	His	Pro	Leu	Val	
				245					250					255		
Ala	Ala	Tyr	Pro	Ile	Val	His	Val	Asp	Met	Glu	Asn	Ile	Ile	Leu	Ser	
			260					265					270			
Lys	Asn	Glu	Asp	Gln	Ser	Thr	Gln	Asn	Thr	Asp	Ser	Glu	Thr	Arg	Thr	
		275					280					285				
Ile	Ser	Lys	Asn	Thr	Ser	Thr	Ser	Arg	Thr	His	Thr	Ser	Glu	Val	His	
	290					295					300					
Gly	Asn	Ala	Glu	Val	His	Ala	Ser	Phe	Phe	Asp	Ile	Gly	Gly	Ser	Val	
305					310					315					320	
Ser	Ala	Gly	Phe	Ser	Asn	Ser	Asn	Ser	Ser	Thr	Val	Ala	Ile	Asp	His	
				325					330					335		
Ser	Leu	Ser	Leu	Ala	Gly	Glu	Arg	Thr	Trp	Ala	Glu	Thr	Met	Gly	Leu	
			340					345					350			
Asn	Thr	Ala	Asp	Thr	Ala	Arg	Leu	Asn	Ala	Asn	Ile	Arg	Tyr	Val	Asn	
		355					360					365				
Thr	Gly	Thr	Ala	Pro	Ile	Tyr	Asn	Val	Leu	Pro	Thr	Thr	Ser	Leu	Val	
	370					375					380					
Leu	Gly	Lys	Asn	Gln	Thr	Leu	Ala	Thr	Ile	Lys	Ala	Lys	Glu	Asn	Gln	
385				390						395					400	
Leu	Ser	Gln	Ile	Leu	Ala	Pro	Asn	Asn	Tyr	Tyr	Pro	Ser	Lys	Asn	Leu	
			405						410					415		
Ala	Pro	Ile	Ala	Leu	Asn	Ala	Gln	Asp	Asp	Phe	Ser	Ser	Thr	Pro	Ile	
			420					425					430			
Thr	Met	Asn	Tyr	Asn	Gln	Phe	Leu	Glu	Leu	Glu	Lys	Thr	Lys	Gln	Leu	
		435					440					445				
Arg	Leu	Asp	Thr	Asp	Gln	Val	Tyr	Gly	Asn	Ile	Ala	Thr	Tyr	Asn	Phe	
	450				455					460						
Glu	Asn	Gly	Arg	Val	Arg	Val	Asp	Thr	Gly	Ser	Asn	Trp	Ser	Glu	Val	
465				470						475					480	
Leu	Pro	Gln	Ile	Gln	Glu	Thr	Thr	Ala	Arg	Ile	Ile	Phe	Asn	Gly	Lys	
			485					490						495		
Asp	Leu	Asn	Leu	Val	Glu	Arg	Arg	Ile	Ala	Ala	Val	Asn	Pro	Ser	Asp	
		500						505					510			
Pro	Leu	Glu	Thr	Thr	Lys	Pro	Asp	Met	Thr	Leu	Lys	Glu	Ala	Leu	Lys	
		515					520					525				
Ile	Ala	Phe	Gly	Phe	Asn	Glu	Pro	Asn	Gly	Asn	Leu	Gln	Tyr	Gln	Gly	
	530					535					540					
Lys	Asp	Ile	Thr	Glu	Phe	Asp	Phe	Asn	Phe	Asp	Gln	Gln	Thr	Ser	Gln	
545				550						555					560	
Asn	Ile	Lys	Asn	Gln	Leu	Ala	Glu	Leu	Asn	Ala	Thr	Asn	Ile	Tyr	Thr	
			565					570						575		
Val	Leu	Asp	Lys	Ile	Lys	Leu	Asn	Ala	Lys	Met	Asn	Ile	Leu	Ile	Arg	
		580					585						590			
Asp	Lys	Arg	Phe	His	Tyr	Asp	Arg	Asn	Asn	Ile	Ala	Val	Gly	Ala	Asp	
		595					600					605				

Glu	Ser	Val	Val	Lys	Glu	Ala	His	Arg	Glu	Val	Ile	Asn	Ser	Ser	Thr
610						615					620				
Glu	Gly	Leu	Leu	Leu	Asn	Ile	Asp	Lys	Asp	Ile	Arg	Lys	Ile	Leu	Ser
625					630					635					640
Gly	Tyr	Ile	Val	Glu	Ile	Glu	Asp	Thr	Glu	Gly	Leu	Lys	Glu	Val	Ile
				645					650					655	
Asn	Asp	Arg	Tyr	Asp	Met	Leu	Asn	Ile	Ser	Ser	Leu	Arg	Gln	Asp	Gly
			660					665					670		
Lys	Thr	Phe	Ile	Asp	Phe	Lys	Lys	Tyr	Asn	Asp	Lys	Leu	Pro	Leu	Tyr
		675					680					685			
Ile	Ser	Asn	Pro	Asn	Tyr	Lys	Val	Asn	Val	Tyr	Ala	Val	Thr	Lys	Glu
	690					695					700				
Asn	Thr	Ile	Ile	Asn	Pro	Ser	Glu	Asn	Gly	Asp	Thr	Ser	Thr	Asn	Gly
705					710				715						720
Ile	Lys	Lys	Ile	Leu	Ile	Phe	Ser	Lys	Lys	Gly	Tyr	Glu	Ile	Gly	
				725					730					735	

&lt;210&gt; 55

&lt;211&gt; 4365

&lt;212&gt; DNA

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 55

```

gaagttaagc aagaaaacag attggtgaac gaatctgaat cctcttccca aggtttgttg 60
cttcaattcg ttcttttgtc taacaacttg cttagactta ggagaagggt tccaaacaac 120
ggttactact tctccgactt gaacttccaa gctccaatgg tcgtcacctc ctctactacc 180
ccaatgatga agaggctgaa cttgaagggt cgagggttacc agcagtggag gagatgatgg 240
ggtgacttgt ccattcccatc ctccgaatta gagaacatcc catccgaaaa ccaatacttc 300
ccactgaaca ggtagggttag gaggttaaat ctctttagg gtaggctttt ggttatgaag 360
caatccgcta tctggtccgg cttcatcaag gtcaagaagt cgcacgaata cactttcgct 420
gttaggcgat agaccaggcc gaagtagttc cagttcttca ggctgcttat gtgaaagcga 480
acctccgctg acaaccacgt tactatgtgg gtcgacgacc aagaagtcac caacaaggct 540
tgaggcgac tgttggtgca atgatacacc cagctgctgg ttcttcagta gttgttccga 600
tccaactcca acaagatcag attggaaaag ggtagattgt accaaattaa gatccaatac 660
aggttgaggt tgttctagtc taaccttttc ccatctaaca tggtttaatt ctaggttatg 720
caaagagaaa acccaaccga aaagggtttg gacttcaagt tgtactggac cgactcccaa 780
gtttctcttt tgggttggct ttccccaaac ctgaagtcca acatgacctg gctgagggtt 840
aacaagaagg aagtcatttc ctctgacaac ttgcaattgc cagaattgaa gcaaaagtcc 900
ttgttcttcc ttcagtagag gagactgttg aacgttaacg gtcttaactt cgttttcagg 960
tccaactcca gaaagaagag atccacctcc gctggtccaa ctgttccaga cagagacaac 1020
aggttgaggt ctttcttctt cagggtggag cgaccagggt gacaaggctc gtctctgttg 1080
gacggtatcc cagactcctt ggaagtcgaa ggttacaccg tcgacgtcaa gaacaagaga 1140
ctgccataag gtctgaggaa ccttcagctt ccaatgtggc agctgcagtt cttgttctct 1200
accttcttgt ctccatggat ctccaacatt caccgaaaaga agggtttgac caagtacaag 1260
tggaagaaca gaggtaccta gaggttgtaa gtgcttttct tcccaaactg gttcatgttc 1320
tcttccccag aaaagtggct tactgcttcc gaccatact ccgacttcga aaaggctacc 1380
agaagggttc ttttcaccag atgacgaagg ctgggtatga ggctgaagct tttccagtgg 1440
ggtagaatcg acaagaacgt ctccccagaa gctagacacc cattgggttg tgcttaccga 1500
ccatcttagc tgttcttgca gaggggtctt cgatctgtgg gtaaccaacg acgaatgggt 1560
attgtccacg ttgacatgga aaacatcatt ttgtccaaga acgaagacca atccaccca 1620
taacagggtc aactgtacct tttgtagtaa aacagggtct tgcttctggg taggtgggtt 1680
aacacggact ccgaaaccag aactatctct aagaacacct ccacttctag aaccacact 1740
ttgtgcctga ggctttggct ttgatagaga ttcttgtgga ggtgaagatc ttgggtgtga 1800
tccgaagtc acggtaacgc tgaagttcac gcttcttctc tcgacattgg tggttccgtc 1860
aggcttcagg tgccattgag acttcaagtg cgaagaaaga agctgtaacc accaaggcag 1920

```

```

tctgctggtt tctccaactc caactcctcc accgtcgcta tcgaccactc tttgtccttg 1980
agacgaccaa agagggttgag gttgaggagg tggcagcgat agctggtgag aaacaggaac 2040
cgtggtgaaa gaacttgggc tgaaccatg gggttgaaca ctgctgacac cgctagattg 2100
cgaccacttt cttgaaccgg actttggtac ccaaacttgt gacgactgtg gcgatctaac 2160
aacgctaaca ttagatacgt caacactggt accgctccaa tctacaacgt cttgccaac 2220
ttgcgattgt aatctatgca gttgtgacca tggcgagggt agatggttga gaacggttgg 2280
acctccttgg tcttgggtaa gaaccaaacc ttggctacta tcaaggctaa ggaaaaccaa 2340
tggaggaacc agaaccatt cttgggttgg aaccgatgat agtccgatt ccttttgggt 2400
ttgtcccaaa tcttgggtcc aaacaactac taccatcca agaacttggc tccaatcgct 2460
aacaggggtt agaaccgagg tttgttgatg atgggtagggt tcttgaaccg aggttagcga 2520
ttgaacgctc aagacgactt ctctctact ccaatcacca tgaactacaa ccaattcctg 2580
aacttgcgag ttctgctgaa gaggagatg ggtagtggt acttgatgtt ggtaagaag 2640
gaattggaaa agactaagca attgctgttg gacaccgacc aagtttacgg taacattgct 2700
cttaaccttt tctgattcgt taacgcaaac ctgtggctgg ttcaaatgcc attgtaacga 2760
acttacaact tcgaaaacgg tagagtcaga gtcgacaccg gttccaactg gtctgaagtc 2820
tgaatgttga agcttttggc atctcagtct cagctgtggc caaggttgac cagacttcag 2880
ttgccacaaa tccaagaaac caccgctaga atcatcttca acgtaagga cttgaacttg 2940
aacgggtgtt aggttctttg gtggcgatct tagtagaagt tgccattcct gaacttgaac 3000
gttgaaaaga gaattgctgc tgtcaaccca tccgaccat tggaaaccac caagccagac 3060
caactttctt cttaacgacg acagttgggt aggttgggtg acctttgggt gttcgggtctg 3120
atgaccttga aggaagcttt gaagatcgct ttcggtttca acgaaccaa cggttaactg 3180
tactggaaact tccttcgaaa cttctagcga aagccaaagt tgcttgggtt gccattgaac 3240
caataccaag gtaaggacat caccgaattc gacttcaact tcgaccaaca aacctctcaa 3300
gttatggttc cattcctgta gtggcttaag ctgaagttga agctggttgt ttggagagtt 3360
aacatcaaga accaattggc tgaattgaac gctaccaaca ttactactgt tttggacaag 3420
ttgtagttct tggttaaccg acttaacttg cgatggttgt aaatgtgaca aaacctgttc 3480
atcaagttga acgccaagat gaacatcttg atcagagaca agagattcca ctacgacaga 3540
tagttcaact tgcggttcta cttgtagaac tagtctctgt tctctaaggt gatgctgtct 3600
aacaacattg ctgtcgggtc tgacgaatcc gttgtcaagg aagccacag agaagtcac 3660
ttgttgtaac gacagccag actgcttagg caacagttcc ttcgggtgtc tcttcagtag 3720
aactcctcca ccgaagggtt gttgttgaa atcgacaagg acatcagaaa gatcttgtcc 3780
ttgaggagggt ggcttccaaa caacaacttg tagctgttcc tgtagtcttt ctagaacagg 3840
ggttacatcg tcgaaattga agacaccgaa gggttgaagg aagtcacaa cgacagatac 3900
ccaatgtagc agctttaact tctgtggctt ccaaacttcc ttcagtagtt gctgtctatg 3960
gacatgttga acatttcctc tttgagacaa gacggtaaga ccttcacga cttcaagaag 4020
ctgtacaact tgtaaaggag aaactctgtt ctgccattct ggaagtagct gaagttcttc 4080
tacaacgaca agttgccatt gtacatttcc aacccaaact acaaggtaac cgtttacgct 4140
atgttgctgt tcaacggtaa catgtaaagg ttgggttga tgttcagtt gcaaagtcga 4200
gtcactaagg aaaacacat catcaacca tccgaaaacg gtgacacttc caccaacgg 4260
cagtgattcc ttttgtggta gtagttgggt aggttttgc cactgtgaag gtggttgcca 4320
atcaagaaga ttttgcatt ctctaagaag ggttacgaaa ttggt 4365

```

&lt;210&gt; 56

&lt;211&gt; 735

&lt;212&gt; PRT

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 56

```

Glu Val Lys Gln Glu Asn Arg Leu Leu Asn Glu Ser Glu Ser Ser Ser
 1             5             10             15
Gln Gly Leu Leu Gly Tyr Tyr Phe Ser Asp Leu Asn Phe Gln Ala Pro
      20             25             30
Met Val Val Thr Ser Ser Thr Thr Gly Asp Leu Ser Ile Pro Ser Ser
      35             40             45

```

Glu	Leu	Glu	Asn	Ile	Pro	Ser	Glu	Asn	Gln	Tyr	Phe	Gln	Ser	Ala	Ile
50						55					60				
Trp	Ser	Gly	Phe	Ile	Lys	Val	Lys	Lys	Ser	Asp	Glu	Tyr	Thr	Phe	Ala
65					70					75					80
Thr	Ser	Ala	Asp	Asn	His	Val	Thr	Met	Trp	Val	Asp	Asp	Gln	Glu	Val
				85					90					95	
Ile	Asn	Lys	Ala	Ser	Asn	Ser	Asn	Lys	Ile	Arg	Leu	Glu	Lys	Gly	Arg
			100					105					110		
Leu	Tyr	Gln	Ile	Lys	Ile	Gln	Tyr	Gln	Arg	Glu	Asn	Pro	Thr	Glu	Lys
		115					120					125			
Gly	Leu	Asp	Phe	Lys	Leu	Tyr	Trp	Thr	Asp	Ser	Gln	Asn	Lys	Lys	Glu
130						135					140				
Val	Ile	Ser	Ser	Asp	Asn	Leu	Gln	Leu	Pro	Glu	Leu	Lys	Gln	Lys	Ser
145					150					155					160
Ser	Asn	Ser	Arg	Lys	Lys	Arg	Ser	Thr	Ser	Ala	Gly	Pro	Thr	Val	Pro
				165					170					175	
Asp	Arg	Asp	Asn	Asp	Gly	Ile	Pro	Asp	Ser	Leu	Glu	Val	Glu	Gly	Tyr
			180					185					190		
Thr	Val	Asp	Val	Lys	Asn	Lys	Arg	Thr	Phe	Leu	Ser	Pro	Trp	Ile	Ser
		195					200					205			
Asn	Ile	His	Glu	Lys	Lys	Gly	Leu	Thr	Lys	Tyr	Lys	Ser	Ser	Pro	Glu
210						215					220				
Lys	Trp	Ser	Thr	Ala	Ser	Asp	Pro	Tyr	Ser	Asp	Phe	Glu	Lys	Val	Thr
225					230					235					240
Gly	Arg	Ile	Asp	Lys	Asn	Val	Ser	Pro	Glu	Ala	Arg	His	Pro	Leu	Val
				245					250					255	
Ala	Ala	Tyr	Pro	Ile	Val	His	Val	Asp	Met	Glu	Asn	Ile	Ile	Leu	Ser
			260					265					270		
Lys	Asn	Glu	Asp	Gln	Ser	Thr	Gln	Asn	Thr	Asp	Ser	Glu	Thr	Arg	Thr
		275					280					285			
Ile	Ser	Lys	Asn	Thr	Ser	Thr	Ser	Arg	Thr	His	Thr	Ser	Glu	Val	His
290						295					300				
Gly	Asn	Ala	Glu	Val	His	Ala	Ser	Phe	Phe	Asp	Ile	Gly	Gly	Ser	Val
305					310					315					320
Ser	Ala	Gly	Phe	Ser	Asn	Ser	Asn	Ser	Ser	Thr	Val	Ala	Ile	Asp	His
				325					330					335	
Ser	Leu	Ser	Leu	Ala	Gly	Glu	Arg	Thr	Trp	Ala	Glu	Thr	Met	Gly	Leu
			340					345					350		
Asn	Thr	Ala	Asp	Thr	Ala	Arg	Leu	Asn	Ala	Asn	Ile	Arg	Tyr	Val	Asn
		355					360					365			
Thr	Gly	Thr	Ala	Pro	Ile	Tyr	Asn	Val	Leu	Pro	Thr	Thr	Ser	Leu	Val
370						375					380				
Leu	Gly	Lys	Asn	Gln	Thr	Leu	Ala	Thr	Ile	Lys	Ala	Lys	Glu	Asn	Gln
385					390					395					400
Leu	Ser	Gln	Ile	Leu	Ala	Pro	Asn	Asn	Tyr	Tyr	Pro	Ser	Lys	Asn	Leu
				405					410					415	
Ala	Pro	Ile	Ala	Leu	Asn	Ala	Gln	Asp	Phe	Ser	Ser	Thr	Pro	Ile	
			420					425				430			
Thr	Met	Asn	Tyr	Asn	Gln	Phe	Leu	Glu	Leu	Glu	Lys	Thr	Lys	Gln	Leu
		435					440					445			
Arg	Leu	Asp	Thr	Asp	Gln	Val	Tyr	Gly	Asn	Ile	Ala	Thr	Tyr	Asn	Phe
450						455					460				
Glu	Asn	Gly	Arg	Val	Arg	Val	Asp	Thr	Gly	Ser	Asn	Trp	Ser	Glu	Val
465						470				475					480

Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys  
 485 490 495  
 Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp  
 500 505 510  
 Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys  
 515 520 525  
 Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly  
 530 535 540  
 Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln  
 545 550 555 560  
 Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr  
 565 570 575  
 Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg  
 580 585 590  
 Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp  
 595 600 605  
 Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr  
 610 615 620  
 Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser  
 625 630 635 640  
 Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile  
 645 650 655  
 Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly  
 660 665 670  
 Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr  
 675 680 685  
 Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu  
 690 695 700  
 Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly  
 705 710 715 720  
 Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly  
 725 730 735

&lt;210&gt; 57

&lt;211&gt; 4365

&lt;212&gt; DNA

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 57

gaagttaagc aagaaaacag attggtgaac gaatctgaat cctcttccca aggtttgttg 60  
 cttcaattcg ttcttttgtc taacaacttg cttagactta ggagaagggt tccaaacaac 120  
 ggttactact tctccgactt gaacttccaa gctccaatgg tcgtcacctc ctctactacc 180  
 ccaatgatga agaggctgaa cttgaagggt cgagggttacc agcagtggag gagatgatgg 240  
 ggtgacttgt ccatcccatc ctccgaatta gagaacatcc catccgaaaa ccaatacttc 300  
 ccaactgaaca ggtagggttag gaggcttaat ctcttgttagg gtaggctttt ggttatgaag 360  
 caatccgcta tctggtccgg cttcatcaag gtcaagaagt ccgacgaata cactttcgct 420  
 gttaggcgat agaccaggcc gaagtagttc cagttcttca ggctgcttat gtgaaagcga 480  
 acctccgctg acaaccacgt tactatgtgg gtcgacgacc aagaagtcac caacaaggct 540  
 tggaggcgac tgttgggtgca atgatacacc cagctgctgg ttcttcagta gttgttccga 600  
 tccaactcca acaagatcag attggaaaag ggtagattgt accaaattaa gatccaatac 660  
 aggttgagggt tgttctagtc taaccttttc ccatctaaca tgggtttaatt ctaggttatg 720  
 caaagagaaa acccaaccga aaagggtttg gacttcaagt tgtactggac cgactcccaa 780  
 gtttctcttt tgggttggct tttcccaaac ctgaagttca acatgacctg gctgagggtt 840  
 aacaagaagg aagtcacatc ctctgacaac ttgcaattgc cagaattgaa gcaaaagtcc 900  
 ttgttcttcc ttcagtagag gagactgttg aacgttaacg gtcttaactt cgttttcagg 960

tccaactcca	gaaagaagaa	gtccacctcc	gctgggtccaa	ctgttccaga	cagagacaac	1020
agggtgaggt	ctttcttctt	caggtggagg	cgaccaggtt	gacaaggtct	gtctctgttg	1080
gacggtattc	cagactcctt	ggaagtcgaa	ggttacaccg	tcgacgtcaa	gaacaagaga	1140
ctgccataag	gtctgaggaa	ccttcagctt	ccaatgtggc	agctgcagtt	cttgttctct	1200
accttcttgt	ctccatggat	ctccaacatt	cacgaaaaga	agggtttgac	caagtacaag	1260
tggagaagaa	gaggtaccta	gaggttgtaa	gtgcttttct	tccaaaactg	gttcatgttc	1320
tcttccccag	aaaagtggtc	tactgcttcc	gaccatact	ccgacttcga	aaaggtcacc	1380
agaaggggtc	ttttcaccag	atgacgaagg	ctgggtatga	ggctgaagct	tttccagtgg	1440
ggtagaatcg	acaagaacgt	ctccccagaa	gctagacacc	cattggttgc	tgcttaccga	1500
ccatcttagc	tgttcttgca	gaggggtctt	cgatctgtgg	gtaaccaacg	acgaatgggt	1560
attgtccacg	ttgacatgga	aaacatcatt	ttgtccaaga	acgaagacca	atccacccaa	1620
taacagggtg	aactgtacct	ttttagtaga	aacaggttct	tgcttctggt	taggtgggtt	1680
aacacggact	ccgaaaccag	aactatctct	aagaacacct	ccacttctag	aaccacact	1740
ttgtgcctga	ggctttggtc	ttgatagaga	ttcttgtgga	ggtgaagatc	ttgggtgtga	1800
tccgaagtcc	acggtaacgc	tgaagttcac	gcttctttct	tcgacattgg	tggttccgtc	1860
aggcttcagg	tgccattgct	acttcaagt	cgaagaaaga	agctgtaacc	accaaggcag	1920
tctgctgggt	tctccaactc	caactcctcc	accgtcgcta	tcgaccactc	tttgccttg	1980
agacgaccaa	agaggttgag	gttgaggagg	tggcagcgat	agctgggtgag	aaacaggaac	2040
gctggtgaaa	gaacttgggc	tgaaaacatg	ggtttgaaca	ctgctgacac	cgctagattg	2100
cgaccacttt	cttgaaccgg	actttggtag	caaacttgt	gacgactgtg	gcgatctaac	2160
aacgctaaca	ttagatacgt	caacactgtc	accgtccaa	tctacaacgt	cttgccaacc	2220
ttgcgattgt	aatctatgca	gttgtgacca	tggcgagggt	agatgttgca	gaacggttgg	2280
acctccttgg	tcttgggtaa	gaaccaaacc	ttggctacta	tcaaggctaa	ggaaaaccaa	2340
tggaggaacc	agaaccatt	cttggtttgg	aaccgatgat	agttccgatt	ccttttgggt	2400
ttgtcccaaa	tcttggctcc	aaacaactac	tacccatcca	agaacttggc	tccaatcgct	2460
aacaggggtt	agaaccgagg	tttgttgatg	atgggttaggt	tcttgaaccg	agggttagcga	2520
ttgaacgctc	aagacgactt	ctcctctact	ccaatcacca	tgaactacaa	ccaattcttg	2580
aacttgcgag	ttctgctgaa	gaggagatga	ggttagtggg	acttgatggt	ggttaagaac	2640
gaattggaaa	agactaagca	attgcgtttg	gacaccgacc	aagtttacgg	taacatttgt	2700
cttaaccctt	tctgattcgt	taacgcaaac	ctgtggctgg	ttcaaattgcc	attgtaacga	2760
acttacaact	tcgaaaacgg	tagagtcaga	gtcgacaccg	gttccaactg	gtctgaagtc	2820
tgaatgttga	agcttttgcc	atctcagtct	cagctgtggc	caagggtgac	cagacttcag	2880
ttgccacaaa	tccaagaaac	caccgctaga	atcatcttca	acggtaagga	cttgaacttg	2940
aacgggtgtt	aggttctttg	gtggcgatct	tagtagaagt	tgccattcct	gaacttgaac	3000
gttgaagaaa	gaattgctgc	tgtcaaccca	tccgaccat	tggaaaccac	caagccagac	3060
caactttctt	cttaacgacg	acagttgggt	aggctgggta	acctttgggt	gttcgggtctg	3120
atgaccttga	aggaagcttt	gaagatcgct	ttcggtttca	acgaaccaa	cggtaacttg	3180
tactggaact	ctcttcgaaa	cttctagcga	aagccaaagt	tgcttgggtt	gccattgaac	3240
caataccaag	gtaaggacat	caccgaatc	gacttcaact	tcgaccaaca	aacctctcaa	3300
gttatgggtc	cattcctgta	gtggcttaag	ctgaagttga	agctggttgt	ttggagagtt	3360
aacatcaaga	accaattggc	tgaattgaac	gctaccaaca	tttactactg	tttggacaag	3420
ttgtagttct	tggttaaccg	acttaacttg	cgatgggtgt	aaatgtgaca	aaacctgttc	3480
atcaagttga	acgccaagat	gaacatcttg	atcagagaca	agagattcca	ctacgacaga	3540
tagttcaact	tgcggttcta	cttgtagaac	tagtctctgt	tctctaaggt	gatgctgtct	3600
aacaacattg	ctgtcgggtc	tgacgaatcc	gttgtcaagg	aagcccacag	agaagtcata	3660
ttgttgtaac	gacagccacg	actgcttagg	caacagttcc	ttcgggtgtc	tcttcagtag	3720
aactcctcca	ccgaagggtt	gttgttgaa	atcgacaagg	acatcagaaa	gatcttgtcc	3780
ttgaggaggt	ggcttccaaa	caacaacttg	tagctgttcc	tgtagtcttt	ctagaacagg	3840
ggttacatcg	tcgaaattga	agacaccgaa	ggtttgaagg	aagtcatcaa	cgacagatac	3900
ccaatgtagc	agctttaact	tctgtggctt	ccaaacttcc	ttcagtagtt	gctgtctatg	3960
gacatgttga	acatttcctc	tttgagacaa	gacggtaaga	ccttcacgca	cttcaagaag	4020
ctgtacaact	tgtaaaggag	aaactctgtt	ctgccattct	ggaagtagct	gaagttcttc	4080
tacaacgaca	agttgccatt	gtacatttcc	aacccaaact	acaaggtcaa	cgtttacgct	4140
atgttgctgt	tcaacggtaa	catgtaaagg	ttgggtttga	tgttccagtt	gcaaatgcga	4200
gtcactaagg	aaaacaccat	catcaaccca	tccgaaaacg	gtgacacttc	caccaacggt	4260



cagtgattcc ttttgtggta gtagttgggt aggcttttgc cactgtgaag gtgggttgcca 4320  
 atcaagaaga ttttgcattt ctctaagaag gggtacgaaa ttgggt 4365

<210> 58  
 <211> 735  
 <212> PRT  
 <213> Bacillus anthracis

<400> 58

Glu	Val	Lys	Gln	Glu	Asn	Arg	Leu	Leu	Asn	Glu	Ser	Glu	Ser	Ser	Ser
1				5					10					15	
Gln	Gly	Leu	Leu	Gly	Tyr	Tyr	Phe	Ser	Asp	Leu	Asn	Phe	Gln	Ala	Pro
		20						25					30		
Met	Val	Val	Thr	Ser	Ser	Thr	Thr	Gly	Asp	Leu	Ser	Ile	Pro	Ser	Ser
		35				40						45			
Glu	Leu	Glu	Asn	Ile	Pro	Ser	Glu	Asn	Gln	Tyr	Phe	Gln	Ser	Ala	Ile
	50				55						60				
Trp	Ser	Gly	Phe	Ile	Lys	Val	Lys	Lys	Ser	Asp	Glu	Tyr	Thr	Phe	Ala
65					70					75					80
Thr	Ser	Ala	Asp	Asn	His	Val	Thr	Met	Trp	Val	Asp	Asp	Gln	Glu	Val
				85					90					95	
Ile	Asn	Lys	Ala	Ser	Asn	Ser	Asn	Lys	Ile	Arg	Leu	Glu	Lys	Gly	Arg
			100					105					110		
Leu	Tyr	Gln	Ile	Lys	Ile	Gln	Tyr	Gln	Arg	Glu	Asn	Pro	Thr	Glu	Lys
		115				120						125			
Gly	Leu	Asp	Phe	Lys	Leu	Tyr	Trp	Thr	Asp	Ser	Gln	Asn	Lys	Lys	Glu
	130					135					140				
Val	Ile	Ser	Ser	Asp	Asn	Leu	Gln	Leu	Pro	Glu	Leu	Lys	Gln	Lys	Ser
145					150					155					160
Ser	Asn	Ser	Arg	Lys	Lys	Lys	Ser	Thr	Ser	Ala	Gly	Pro	Thr	Val	Pro
				165					170					175	
Asp	Arg	Asp	Asn	Asp	Gly	Ile	Pro	Asp	Ser	Leu	Glu	Val	Glu	Gly	Tyr
			180					185					190		
Thr	Val	Asp	Val	Lys	Asn	Lys	Arg	Thr	Phe	Leu	Ser	Pro	Trp	Ile	Ser
		195					200						205		
Asn	Ile	His	Glu	Lys	Lys	Gly	Leu	Thr	Lys	Tyr	Lys	Ser	Ser	Pro	Glu
	210					215					220				
Lys	Trp	Ser	Thr	Ala	Ser	Asp	Pro	Tyr	Ser	Asp	Phe	Glu	Lys	Val	Thr
225					230					235					240
Gly	Arg	Ile	Asp	Lys	Asn	Val	Ser	Pro	Glu	Ala	Arg	His	Pro	Leu	Val
				245					250					255	
Ala	Ala	Tyr	Pro	Ile	Val	His	Val	Asp	Met	Glu	Asn	Ile	Ile	Leu	Ser
			260					265					270		
Lys	Asn	Glu	Asp	Gln	Ser	Thr	Gln	Asn	Thr	Asp	Ser	Glu	Thr	Arg	Thr
		275					280					285			
Ile	Ser	Lys	Asn	Thr	Ser	Thr	Ser	Arg	Thr	His	Thr	Ser	Glu	Val	His
	290					295						300			
Gly	Asn	Ala	Glu	Val	His	Ala	Ser	Phe	Phe	Asp	Ile	Gly	Gly	Ser	Val
305					310					315					320
Ser	Ala	Gly	Phe	Ser	Asn	Ser	Asn	Ser	Ser	Thr	Val	Ala	Ile	Asp	His
				325					330					335	
Ser	Leu	Ser	Leu	Ala	Gly	Glu	Arg	Thr	Trp	Ala	Glu	Thr	Met	Gly	Leu
			340					345					350		
Asn	Thr	Ala	Asp	Thr	Ala	Arg	Leu	Asn	Ala	Asn	Ile	Arg	Tyr	Val	Asn
		355					360					365			

Thr Gly Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val  
 370 375 380  
 Leu Gly Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln  
 385 390 395 400  
 Leu Ser Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu  
 405 410 415  
 Ala Pro Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile  
 420 425 430  
 Thr Met Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu  
 435 440 445  
 Arg Leu Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe  
 450 455 460  
 Glu Asn Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val  
 465 470 475 480  
 Leu Pro Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys  
 485 490 495  
 Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp  
 500 505 510  
 Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys  
 515 520 525  
 Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly  
 530 535 540  
 Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln  
 545 550 555 560  
 Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr  
 565 570 575  
 Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg  
 580 585 590  
 Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp  
 595 600 605  
 Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr  
 610 615 620  
 Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser  
 625 630 635 640  
 Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile  
 645 650 655  
 Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly  
 660 665 670  
 Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr  
 675 680 685  
 Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu  
 690 695 700  
 Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly  
 705 710 715 720  
 Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly  
 725 730 735

&lt;210&gt; 59

&lt;211&gt; 29

&lt;212&gt; DNA

&lt;213&gt; Bacillus anthracis

&lt;400&gt; 59

cgcggtatccg aagttaaaca ggagaaccg

<210> 60  
<211> 29  
<212> DNA  
<213> Bacillus anthracis

<400> 60  
cgcggtatcct taccctatct catagcctt 29

<210> 61  
<211> 46  
<212> DNA  
<213> Bacillus anthracis

<400> 61  
cgcggtatcct gtcttttgat aagagaagta caagtgtctg acctac 46

<210> 62  
<211> 29  
<212> DNA  
<213> Bacillus anthracis

<400> 62  
cgcggtatcct taccctatct catagcctt 29

<210> 63  
<211> 44  
<212> DNA  
<213> Bacillus anthracis

<400> 63  
cgcggtatccc acaaaacaaa atggaagtta agcaagaaaa caga 44

<210> 64  
<211> 35  
<212> DNA  
<213> Bacillus anthracis

<400> 64  
caactccaga aagaagagat ccacctccgc tggtc 35

<210> 65  
<211> 35  
<212> DNA  
<213> Bacillus anthracis

<400> 65  
gaccagcgga ggtggatctc ttctttcttg agttg 35